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ABSTRACT 
    Increasing prevalence of the respiratory diseases are reporting both in 
developed and developing countries.  On comparing the symptoms of “Swasakasam” 
it can be correlated to “Bronchial asthma” in modern science.40 patients (20-out 
patients and 20-in patients) were selected for the study conducted in GSMC& H, 
Palayamkottai.Trial medicine Jaathipalathi Chooranam 30 mg/ kg /BW thrice a day, 
after food along with honey for 30 days was administrated for entire study period. 
Jaathipalathi Chooranam has the reference from Sarabendhra Vaithiya Muraikal- 
Kasa Swasa Roga Sikicha, Vasudevasasthri, and Venkadarajan,2006. 
Trial medicine was subjected to various pre-clinical studies like bio- chemical, 
phytochemical, pharmacological and microbiological analysis. Safety profile of the 
trial drug was evaluated and no morbidity and mortality was noted in experimental 
analysis. The biochemistry analysis showed, the presence of  Calcium, Starch, Ferrous 
iron, Tannic acid Unsaturated compound, Reducing sugar and aminoacid. The 
alkaloids, Carbohydrates, Glycosides, Phytosterols, Flavonoids, Tannin, Protien and 
Lignin were observed in Phytochemical analysis. Invivo and Invitro studies are 
showed the better results in  Antihistaminic and Anti anaphylactic, Antiinflammotary 
and Bronchodilator activity. The trial medicine was found to have high sensitivity in 
Staphylococcus aureus, Streptococcus mutans, Bacillus subtilis, Klebsiella 
pneumoniae and E.coli organism. At the end of the study majority of the cases were 
analysed with fixed clinical criterias and showed good clinical improvement. All the 
relevant reports were statistically analysed and found to be significant. 
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CHAPTER-1 
INTRODUCTION 
1.1.BACKGROUND: 
Siddha system is one among the traditional medical systems which evolved 
along Dravidian culture .It possess strong fundamentals based on ‘vatham’(Alchemy), 
‘vaithiyam’(Medicines), ‘yogam’(Steps for attaining perfection) & ‘gnanam(Arivu or 
Universal truth).So it  can be understood that Siddha system not only gives 
importance to mere physical body but also to the psychological , social , and spiritual 
well-being from the works complied by Spiritual scientist called Siddhars. They have 
mentioned all  the essentialities for a man’s carrier in life viz. According to Siddha 
system there is a close relation and intimate connection between the universe and the 
internal man. Man is the miniature of the world. Therefore his soul and mind are as 
much parts of his true constitution, as are the terrestrial elements of which his 
elementary body is made up.  
Only through a healthy body, ultimate aim of external bliss (perinbam)                                    
can be attained with the aid of vatham, vaithiyam, and yogam. One of the major 
obstacles in the path of salvation is manifestation of various diseases. Therefore 
Siddhars gave predominant consideration for curative and preventive aspects of 
disease. Siddhar Agathiyar had classified total diseases as 4448 in number and 
Siddhar Yugimuni had categorized diseases based on signs and symptoms. 
Siddha treatment principle is aimed at restoring balance between mukkutram 
(three vital humours), ezhu udal kattukal (Seven physical constituents), and 
panchabootham (Five elements). Envagai thervu is the specific set of diagnostic tools 
in Siddha for  arriving apt diagnosis. While treating patient, special concern will be 
paid to 96 thathuvams especially to criterias as Yakkai,Thinai, Paruvakaalam ,Naadi, 
Neerkuri and Neikuri for the analysis of prognosis. Swasakasam is a chronic 
inflammatory disorder of the airways associated with airway hyper-responsiveness 
that leads to recurrent episodes of wheezing ,breathlessness, chest tightness, and 
coughing  particularly at night or in the early morning. 
 Bronchial asthma is the most common chronic respiratory disease with an case 
burden of approximately 358.2 million in 2015. In 2015, about 0.40 million people 
died from asthma , a decrease of 26.7% from 1990, and the age- standardized  
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prevalence decreased by 17.7%.(GBD 2015). It has a higher prevalence in boys than 
in girls before puberty and a higher prevalence  in women than in men in 
adulthood.(Postma DS. 2007).  
My dissertation work is an attempt to provide relief for SWASAKASAM and 
keep the severity  of the disease under control . Swasakasam   was clearly explained 
with symptoms and signs in  NOI NAADAL; NOI MUTHAL NAADAL  part II book.This 
dissertation work is a systemic and scientific attempt to treat with a classical and bio-
safe drug “JAATHIPALATHI CHOORANAM’’ mentioned in the siddha text book 
(SarabendhraVaithiyaMuraikal- KasaSwasaRogaSikicha, Vasudevasasthri,  and 
Venkadarajan,2006).The ingredients of this trial drug were found to possess 
bronchodilator, anti-inflammatory, anti-histamine actions, expectorant, anti-
spasmodic, immunomodulatary actions. 
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1.2. AIM AND OBJECTIVES 
AIM             
To document the therapeutic efficacy of JAATHIPALATHI CHOORANAM  
(Internal)  in the treatment of  SWASAKASAM (BRONCHIAL ASTHMA). 
OBJECTIVES 
Primary Objective:- 
 To evaluate the clinical efficacy of JAATHIPALATHI CHOORANAM 
(Internal) in the treatment of  SWASA KASAM. 
Secondary objectives:- 
 To collect various literary evidence about swasakasam disease. 
 To evaluate bio – chemical and phytochemical analysis. 
 To evaluate anti-microbial analysis. 
 To evaluate pharmacological parameters such as anti-histamine,  
bronchodilator, anti –inflammatory, actions. 
 To evaluate acute and sub-acute toxicity activities of the trial medicine. 
 To collect the details about swasakasam with deep observation of 
etiology, clinical features, diagnosis and prognosis. 
 To confirm the diagnosis in Siddha system with the help of modern 
parameters. 
 To evaluate addition effects and Siddha parameters (Envagai 
Thervugal) changes in swasakasam. 
 To perform statistical analysis. 
  
JUSTIFICATION OF RESEARCH 
 
WHO estimates that about 235 million people currently suffer from asthma. 
338000 deaths were reported in 2015 & most death occurs in older adults.Asthma 
deaths will increase in the next 10 years if urgent action is not taken. Asthma cannot 
be cured, but proper diagnosis ,treatment and patient education can result in good 
asthma control and management.Asthma occurs in all countries regardless of level of 
development. Over 80% of asthma deaths occur in low and lower- middle income 
countries. For effective control, it is essential to make good quality medications 
affordable and available.Respiratory diseases are one among the four non-
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communicable diseases globally.For some people the symptoms become worse during 
physical activity or at night. Failure to recognize and avoid triggers that lead to a 
tightened airway can be life threating and may result in an asthma attack, respiratory 
distress and even death. Through appropriate treatment,the number of asthma 
exacerbation and asthma –related deaths can be reduced.It can be controlled through 
different prevention and treatment plans according to individual symptoms, leading to 
increased quality of life.  
The strongest risk factors for developing asthma are exposure to indoor 
allergens and outdoor allergens.Asthma triggers can include cold air, extreme 
emotional arousal such as anger or fear, and physical exercise.Asthma creates a 
substantial burden to individuals and families and possibly restricts individual’s 
activities for a lifetime. 
Considering the above facts I have selected the Siddha classical drug 
Jaathipalathi chooranam for the management of swasakasam. 
  
2.1  DRUG  REVIEW- IN JOURNALS:
 The poly herbal formulation 
nine drugs individually viz.
Piper nigrum Linn., Mesua naggesarium Linn., Symplocos  racemosa Roxb.,  
Illicium  verum Hook, Piper nigum Linn.,[Rt], 
Sacharum officinarum Linn.
TAXONOMY 
Myristica fragrans  Houtt
Kingdom   : Plantae
Subkingdom  : Tracheobionta
Superdivision:   Sperma
Division  :  Magnoliophyta
Class   :    Dicotyledons
Subclass  :   Magnoliidae
Order   :   Magnoliales
Family   : Myristicaceae
Genus  :   Myristica
Species  :   Myristica
  
Chemical constituents: 
 The essential oil isolated from the seeds of
(Nutmeg) was found to contain sabinene (49.09%), 
α-phellandrene (6.72%), and terpinen
by GC and GC-MS. (I.A. Ogunwande
Pharmacological  actions:
 Myristica fragrans 
against animal and plant pathogens , food poisoning , and spo
Bacillus subtilis, Escherichia coli, Saccharomyces cerevisiae, multi
Salmonella typhi and Helicobacter pylori 
aphrodisiac, antioxidant and hepatoprotective activities.
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CHAPTER.II 
REVIEW LITERATURE 
 
Jaathipalathi chooranam  (JPC) is composed of 
 Myristica fragrans Houtt, Syzygium aromaticum Li
Cinnamomum  camphor Linn., 
 
: 
 
  
tophyta  
  
 
 
 
  
 Gronov. 
 fragrans Houtt.   
 Myristica fragrans 
α-pinene (13.19%), 
-4-ol (6.43%) as major constituents on analysis 
 et al. 2013). 
 
Houtt. is known to exhibit strong antimicrobial activity 
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Syzygium aromaticum Linn., 
Kingdom        :           Plantae   
Subkingdom  :   Tracheobionta  
Superdivision :   Spermatophyta  
Division  :   Magnoliophyta  
Class   :   Dicotyledons 
Subclass  :   Rosidae 
Order   :   Myrtales 
Family  : Myrtaceae  
Genus  :    Syzygium 
Species  :  Syzygium aromaticum (L.)  
Chemical constituents: 
 Approximately 72-90% of the essential oil extracted from cloves contains 
Euginol. Other compounds are Acetyl euginol, Beta-caryhyllene ,Crategolic acid, 
tannins , gallotannic acid, methyl salicylate, Flavonoids- eugenin, kaempferol, 
rhamnetin, and eugenitin. 
Pharmacological  actions: 
 Clove is a natural antiviral, antimicrobial, antiseptic, and anti-fungal agent. It 
also holds aphrodisiac and circulation –stimulating  capacities.  The  oil of cloves has 
been used in  a variety of health conditions including  indigestion,  generalized stress, 
parasitic infestations, cough, toothache, and blood impurities.  Clove oil clears the 
respiratory passages , acting as an expectorant, for treating many upper- respiratory 
related diseases.(Debjit Bhowmik et al. 2012) 
Piper nigrum Linn(Seed and Root) 
Kingdom  :  Plantae 
Subkingdom  :   Tracheobionta 
Superdivision  :   Spermatophyta 
Division   :   Magnoliophyta 
Class   :   Dicotyledons 
Subclass           :   Magnoliidae 
Order               :    Piperales 
Family              :   Piperaceae 
Genus               :   Piper L. 
Species             :    Piper nigrum L.   
Figure 2.1.2Syzygium aromaticum 
     Figure 2.1.3  Piper nigrum (seed) 
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Chemical constituents: 
 Piperine is the active principle of black pepper . 
Piperine has anti- inflammatory and antioxidant properties. 
Pharmacological  actions: 
 Pepper have been used in the treatment of asthma and  
chronic bronchitis.  They are also  recommended for  
neurological , broncho-pulmonary and  
gastrointestinal disorders. ( Chopra et al.1959). 
 
Mesua naggesarium Linn., 
Kingdom  :  Plantae  
Subkingdom  :   Tracheobionta                 
Superdivision :   Spermatophyta  
Division  :   Magnoliophyta  
Class   :   Dicotyledons 
Subclass        :   Polypetalae 
Order             :    Guttiferales 
Family            :   Clusiaceae 
Genus             :   Mesua 
Species           :   Mesua  naggesarium 
 
Chemical constituents: 
 Flower parts of the plant have shown the presence of  various constituents 
such as glycosides, coumarins, flavonoids,  xanthones, triglycerides and resins. 
Specifically it contains alpha-copaene and germacrene D,  Mesuaferrone B, 
Mesuol etc.(Sahu Alakh et al.2014). 
Pharmacological  actions: 
        The crude extract of   Mesua naggesarium showed a strong cytotoxic activity 
towards T-lymphocyte leukemia cells. (Nordin K et al. 2004). 
 
 
 
 
Figure 2.1.5  Mesua naggesarium 
Figure 2.1.4 
Piper nigrum (root) 
8 
Symplocos  racemosa Roxb. 
Kingdom  :  Plantae 
Subkingdom  :   Tracheobionta 
Superdivision  :   Spermatophyta 
Division   :   Magnoliophyta 
Class   :   Dicotyledons 
Subclass           :   Dilleniidae 
Order               :    Ebenales 
Family              :   Symplocaceae 
Genus               :   Symplocos 
Species              :   Symplocos  racemosa 
Chemical constituents: 
Symplocos  racemosa was pure source of phytochemicals which include 
flavonoids, phenols, tannins, saponins and glycosides. It contains several flavonoid 
glucosides like symplocoside, symposide, leucopelargonidine-3 glucoside, ellagic 
acid, rhamnetin 3-digalactoside, triterpenoids like 19 α-hydroxy acetic acid3, 28-O-
bis- β-glucopyranosides, betulin, lino-leic acid, β-sitosterol . 
Pharmacological  actions: 
         The ethanolic extract of bark was used for the treatment of female disorders.  
Ethanolic bark  which help in the treatment of female reproductive disorder induced 
by cold resistant stress.(Thimmy Johnson et al.2018). 
Illicium  verum Hook 
 
Kingdom  :  Plantae 
Subkingdom  :   Tracheobionta 
Superdivision :   Spermatophyta 
Division  :   Magnoliophyta 
Class   :   Dicotyledons 
Order              :    Austrobaileyales 
Family             :   Illiciaceae 
Genus              :   Illicium 
Species             :   Illicium verumHook 
 
 
     Figure 2.1.6 Symplocos  racemosa 
Figure 2.1.7Illicium  verum 
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Chemical constituents: 
The fruit contain higher bitter principle, tannins and essential oil (9-10%), 
consisting of anethole (85-90%), α-pinene, limone, β-phellandrene, α-terpineol, 
farnesol and safrol. 
Pharmacological  actions: 
Swine flu is a respiratory disease caused by influenza viruses that infects the 
respiratory tract of pigs, results in nasal secretion, a barking like cough, decreased 
appetite, and listless behavior. Swine influenza is an infection of any of several types 
of swine influenza viruses. Shikmic acid is used for synthesis for potent antiflu drug 
tamiflu. 
 Antioxidant Activity : 
 The antioxygenic activity of star anise and their extracts were evaluated and 
found to have greater potential as natural oxidant (Divya Chouksey et al.2010). 
 
Cinnamomum  camphora. Linn 
Kingdom         :   Plantae 
Subkingdom   :   Tracheobionta 
Superdivision :   Spermatophyta 
Division          :   Magnoliophyta 
Class               :   Dicotyledons 
Subclass   :  Magnoliidae 
Order              :    Laurales 
Family            :   Lauraceae 
Genus             :  Cinnamomum 
Species           :  Cinnamomum  camphora. Linn 
Chemical constituents: 
The oil’s high eugenol content also makes it valuable as a source of this 
chemical for subsequent conversion into isoeugenol, another flavouring agent. Major 
oil constituent of C. camphora are camphor, linalool, borneol, camphene, dipentene, 
terpeneol, safrole and cineole. 
Pharmacological  actions: 
Immunoglobulin E-suppressing Activity 
 Identification of Dimethylmatairesinol as an Immunoglobulin E-suppressing 
component of the leaves of Cinnamomum camphora. Immunoglobulin E (IgE) plays 
Figure 2.1.8Cinnamomum  camphora 
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an important role in allergic diseases. The study shows that a methanol extract of 
leaves of the camphor tree Cinnamomum camphora reduced the amount of IgE 
secreted by human myeloma U266 cells.(Hiroki T et al. 2011). 
 
Sacharum officinarum Linn 
Kingdom          :   Plantae 
Subkingdom    :   Tracheobionta 
Superdivision  :   Spermatophyta 
Division          :   Magnoliophyta 
Class               :   Monocotyledons 
Subclass         :  Commelinidae 
Order            :   Cyperales 
Family       :  Poaceae – Grass family 
Genus         :   Saccharum  
Species        : Saccharum   officinarum 
Chemical constituents: 
Flavanoids                        :    Naringenin, Tricin, Apigenin and Luteolin  
Flavonoid  glucosides : Tricin Glucoside and Orientin from cane juice. 
Fatty acid      :   Palmittic, Linoleic, Policosanol. 
Pharmacological  actions: 
Tricin glucoside      :        Antioxidant 
Anthocyanin extract from peel        :        Anticancer 
Polyphenol rich fraction of plant     :          Immunomodulative 
Fatty acids     :        Anti-inflammatory 
2.2. SIDDHA LITERATURE 
According toWHO’s report around 65-85% of world population relies on 
traditional medicines of plant origin for their primary health care needs                
(Sahu Alakh N et al. 2014).  
The Jaathipalathi chooranam is an internal medicine comes under the 
chooranam types of medicine. It is mentioned in Sarabendhra Vaithiya Muraikal- 
Kasa Swasa Roga Sikicha, Vasudevasasthri, and Venkadarajan,2006 indicated for 
Agni mantham, kasa swasam, varatchi, gunmam, ullerivu (thegathin anathal) eral 
kulai erivu, peeliga katti, kabathinal undana vigarangal, kaluthu noigal 
  
Figure 2.1.9Sacharum officinarum 
11 
 
2.2.1. GUNAPADAM  ASPECT OF JPC: 
Table.2.2.1. Ingredients and therapeutic uses: 
S.NO INGREDIENTS PHARMACOLOGICAL 
ACTIONS 
THERAPEUTIC USES IN 
SIDDHA  
1 Myristica 
fragrans Houtt., 
Anti oxidant  
Antimicrobial  
Expectorant 
Anti inflammatory 
Headache,Bronchial 
Asthma, 
Cough,Oligospermia 
2 Syzygium 
aromaticum 
Linn., 
Antibacterial 
Antispasmodic 
Diarrhoea ,Otalgia 
Hemorrhoids 
3 Piper nigrum 
Linn., 
Antidote, Anti oxidant 
Antispasmodic 
 
Fever with rigor, 
Anaemia ,Diarrhoea  
Acid Peptic Disease, 
Ageusia,Cough , Otalgia 
4 Mesua 
naggesarium 
Linn., 
Antiseptic  
Anti-inflammatory 
Expectorant 
Leucorrhoea 
Cough 
Diarrhoea 
5 Symplocos  
racemosa Roxb., 
Antidote 
Refrigerant 
Mild astringent 
Poisoning, Tuberculosis, 
Ascites,  
Hoarseness of voice 
 
 
6 Illicium  verum 
Hook, 
Nutritive Fever , Anaemia 
Rheumatic diseases 
 
7 Piper nigum 
Linn.,[Rt] 
Antidote 
 
Fever with rigor, 
Anaemia ,Diarrhoea  
Acid Peptic Disease, 
Ageusia,Cough , Otalgia 
8 Cinnamomum  
camphor Linn., 
Analgesic, Antiseptic 
Expectorant 
Antidepressant 
Antiinflammatory 
 
Bronchial Asthma 
Myocardial Infarction 
Carbuncles, Diptheria 
 Rheumatic diseases 
 
9 Sacharum 
officinarum 
Linn. 
 
Analgesic 
Expectorant 
Antidepressant 
Antiinflammatory 
Antiseptic 
Common cold 
Chronic sinusitis 
 
. 
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2.3.SIDDHA   ASPECTS OF SWASAKASAM 
2.3.1. VERU PEYARGAL (SYNONYMS ) 
 Ezhuppu erumal 
 Swasa erumal 
2.3.2. EYAL (DEFINITION) 
 Swasakasam is characterized by paroxysmal dyspnoea associated with 
discomfort in the chest. There is difficulty in the process of respiration. Usually the 
respiration is associated with musical sounds. The patient may find it difficult to expel 
the sputum.( Siddha maruthuvam ,Noi naadal noi mudhal naadal thiratu- 2nd part ) 
2.3.3. NOI VARUM VAZHI (AETIOLOGY) 
 In Siddha system various causes of the disease were mentioned.  The 
following Siddha texts have described them in various aspects. 
 
1.ACCORDING TO (a)YOGI VAIDHYA CHINTHAMANI AND(b)NOI 
NAADAL NOI MUDHAL NAADAL THIRATU- 2ND PART 
“Ougqe<x!ukqglil<!HjgbqeiZl<!
lQXgqe<x!hi{k<kiz<!lqg<Gf<kiOe”!
“hi{k<kiz<!hvlig<gqeq!lqGg<jgbiZl<!
hivli!lilqsr<gt<!Hsqg<jgbiZl<!
ki{k<kix<!sR<sivf<!kuqv<g<jgbiZl<!
svqhmih<!hkiv<k<kr<gt<!Hsqk<kziZl<!
kQ{k<kix<!HsqbilzqVg<jgbiZl<!
!!!!!!!Osbqjpbiv<!Olzqe<hR<!sqjkukiZl<!
liek<kiz<!liKg<g!ljmukiZl<!
lkk<kiZl<!SuislK!lVUl<!giO{”!
)B,gq!juk<kqb!sqf<kil{q*!
• Chronic smoking 
• Excessive intake of cool drinks 
• More exposure to cold air 
• Starvation 
• Intake of unhygienic diet 
• Excessive non vegetarian diet 
• Anger and Sadness 
• Food allergy 
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2. ACCORDING TO SIDDHA MARUTHUVAM POTHU 
 Highly irregular, unsuitable diet. 
 Excessive intake of kaba promoting diets. 
 Various fumes, dust 
 Inhaling irritable smelling substances. 
3 .ACCORDING TO T.V.SAMBASIVAM PILLAI DICTIONARY  
 A disease caused by exposure to cold environment ,rainy season , drinking 
cold water  and intake of cold food stuffs. 
4. ACCORDING TO ANUBAVA VAITHIYA  DEVA RAGASIYAM 
• Excessive vatha and kapha 
• Pollution 
• Toxic anaemia 
• Persistent fever 
• Excessive cold  
5.ACCORDING TO  SARABENDHRA VAITHYA MURAIGAL: 
 Smoke exposure 
 Regurgitation of food  
 Increased exercise 
 Suppression of sneezing  
 Eating fastly causes swasakasam 
 
2.3.4. MURKURIKAL (PRELIMINARY SIGNS AND SYMPTOMS) 
1.NOI NAADAL NOI MUDHAL NAADAL THIRATU- 2ND PART 
   “-VlOziM!g{<mk<kqEm<!Hxl<!hx<xq!
! ! ! =jtuQp<f<kpz<!&s<skib<!
! ! ! -bz<hie!okieqlixqk<!oki{<jmg<!gm<migqOb!
! ! ! Wpqzgz!ofif<Kzi<f<K!
! ! ! uVlx<h!uif<kqBme<!oue<uqzi!uzq!ogi{<M!
! ! ! uiB{U!Ou{<mik<kib<!
! ! ! lieUmz<!ux<xqg<!gVk<Ok!Gtqv<f<K!
! ! ! lqg!uzq!ogi{<M!Kbvolb<kq!
! ! ! lVUxi!ouh<hOliM!kqlqvq!gjth<OhiMg{<!
! ! ! lR<stqk<kqm<M!LgLl<!
uimiK!uQg<glkib<!outqvqOb!bi{<jlbK!
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! ! ! lixq!lqG!ofM!fix<xlib<!
! ! ! ohiVU!jle<eqxLx<x!GVkq!OlOeig<gqh<!!!!!!!!!!!!
! ! ! ohiVf<KuK!gisole<eh<!
! ! ! HgZV!lqVlz<!Ofib<!Lx<Gxq!weh<!
! ! ! Hgz<uv<!HlqlQ!kxqf<K{v<juOb”!
!
The premonitory symptoms of  Swasakasam  mentioned  as per Siddha 
Literature Noi Naadal Noi Mudhal Naadal Thiratu cough with mild expectoration , 
hoarseness of voice , nausea and vomiting, intercostal pain , reduction in weight, 
tiredness.   
2. SIDDHA MARUTHUVAM POTHU  
 Swasakasam Patient will develop aura(Peculiar sensation) and that he may 
undergo an attack of Swasakasam on that day and to some extent he can assess the 
Severity of the attack. 
 The prominent feature are dyspnea, discomfort in the chest, flatulence, 
sweating in the forehead, wheezing which may gradually develop in severity of the 
disease.  
2.3.5. NOI ENN (CLASSIFICATION)  
 The types of Swasakasam  is clearly described by the following texts books 
they are, 
1.(a)NOI NAADAL NOI MUDHAL NAADAL THIRATU- 2ND PART  &  
    (b)YUGI VAITHYA CHINTHAMANI 
   Swasakasam is described as one of the twelve types of Kasam.   The twelve 
types are, 
1. Mandhara kasam 
2. Pakka Mandharakasam 
3. Sudar kasam 
4. Vadha Kasam 
5. Pitha Kasam 
6. Swasa Kasam 
7. Ratha Kasam 
8. Silethuma Kasam 
9. Peenisa Kasam 
10. Vathapitha Kasam 
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 11. Pitha silethuma Kasam 
12. Thontha Kasam 
2. SARABENTHIRAR VAIDHYA MURAIGAL 
Types -5 
1. Maha swasam 
2. Oothuva swasam 
3. Chinna swasam 
4. Thamakka swasam 
5. Soothira swasam 
3.  ANUBAVA VAIDHYA DEVA RAGASYAM 
There are five types. 
Those are, 
1. Arpa swasam 
2. Thamaraka swasam 
3. Vichchina swasam 
4. Maha swasam 
5. Orthuva swasam 
4.T.V. SAMBHASIVAM PILLAI   DICTIONARY 
There are 20 types. 
Those are, 
1. Swasakasam 
2. Manthara kasam 
3. Ratha kasam 
4. Neela kasam 
5. Silaethuma kasam 
6. Pitha kasam 
7. Vatha kasam 
8. Bala kasam 
9. Virana kasam 
10. Karpa kasam 
11. Elai kasam 
12. Thontha kasam 
13. Pakka kasam 
14. Pakka manthara kasam 
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15. Sudar kasam 
16. Peenisa kasam 
17. Naatha kasam 
18. Vali kasam 
19. Adaippu kasam 
20. Gunma kasam 
 
2.3.6. KURI GUNANGAL (SIGNS AND SYMPTOMS)  
 The signs and Symptoms of SWASAKASAM were described elaborately in 
various Siddha literatures. They are described here as follows  
 
1.(a)YUGI VAITHYA CHINTHAMANI  AND (b) NOI NAADAL NOI MUDHAL 
NAADAL THIRATTU –PART-2 
!
“u{<jlbib<g<!Ogijpgm<c!-Vlq!uQPl<!
lifigl<!OhizOu!uir<GR<!Suisl<!
kq{<jlbib<s<!osVlZ{<mi!lcg<g!cg<Gs<!
sQv{!lqzilOz!ubqX!&Kl<!
fe<jlbib<!fisqbK!k{z<Ohi!ziGl<!
fzqf<Kml<H!ux<xq!uVr<!GvZl<!gl<Ll<!
d{<jlbi!B{<{ig<!gqZiXr<!Og{q!
Bpf<KOl!Suisgi!sk<kqoeih<Oh”!
! ! ! ! )B,gq!juk<kqb!sqf<kil{q.*!
 
Characteristics of Swasakasam  according to Yugi Vaithya Chinthamani  And 
Noi Naadal Noi Mudhal Naadal Thirattu –Part-2 were severe cough with or without 
expectoration, expiration sound similar to  hiss of a serpent ,frequent humming, sense 
of heat in both nostrils,emaciation,hoarseness of voice, indigestion and  flatulence. 
The patient feels difficulty in breathing even in sleep. 
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2.ACCORDING TO T.V.SAMBHASIVAMPILLAI DICTIONARY 
 It is only an attack attended with great difficulty in breathing,and is of a 
spasmodic disorder ,occurring in paroxysms. This disease is said to be of two kinds 
viz. humid and dry according to the presence or absence of expectoration. Although 
the origin of this is traced to results of Karmic actions ,the medical science explains it 
as due to deranged condition of vital air (prana) combining with the other three 
humours,  thereby giving  rise to the following exciting causes viz. emotions such as 
anger or fright ,costive bowels, heavy supper, flatulence, and other forms of 
dyspepsia, gouty nature,emphysema of the lungs etc. More over, the disease is 
ascribed to the sudden spasmodic contraction of the wind-pipe or shock to the nervous 
system often ushering in attacks. 
 
2.3.7. MUKKUTRA VERUPADUGAL : 
According to Siddha system, the manifestation of all diseases are the result of 
derangement of three dhoshas i.e., vatha, pitha  and Kaba. The prime factor which 
involved in Swasakasam is Kabam, which is accompanied with vitiated vatham (or) 
Pitham and produces the clinical symptoms of Swasakasam. This is clearly indicated 
by Theriyar as, 
“ghk<kqjebe<xq!gis!Suisl<!gi{iK”!.!!OkjvbI!!
1. Excess of Kabam in the respiratory organs affect the Melnokkumkal and 
Uyirkal  and so, the air is not able to reach the terminal point of respiration, 
which produces gasping and labored breathing. 
2. Some authors says that Swasakasam is caused by deranged vatham. This 
thought is also acceptable, because the obstruction of air in the respiratory 
tract is abnormally present. 
3. Excessive intake of vatha promoting diet which  induces the pitha kutram. 
This type of pitham produces more heat and this heat goes upwards  to head 
resulting in running nose, heaviness of head , sneezing  and causes narrowing 
of air passage which leads to the onset of the disease. This is indicates 
“hqk<kOl!lqGf<kiz<!=jt!-VlZl<!hzk<K!fqx<Gl<”!
.!G{uigm!fic!!
So, the changes of diet and results increased vatha or kaba and  produces the 
clinical symptoms of Swasakasam.In Swasakasam, Piranan is the primary vayu 
affected, leadings to difficulty in breathing and involvement of uthanan leads to cough 
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and sneezing. Involvement of devathathan leads to tiredness and the involvement of 
sathaga pitham leads to Sluggishness. In Kabam derangement of avalambagam leads 
to dyspnoea ,cough and wheezing.  
 In seven udal thathus, Saram and Senneer are affected which leads to lethargy 
and depression. When the Oon and Kozhuppu are affected and it  produces the 
symptoms of emaciations and body pain. 
 
2.3.8. PINIYARI MURAIMAI (DIAGNOSIS)  
 The diagnosis is based on. 
 1. Poriyalarithal (Inspection)  
2. Pulanalarithal (Palpation)  
3. Vinathal ( interrogatioin) and  
4. Ennvagai Thervugal (Diagnostic Tools). 
 
1. PORIYALARITHAL (INSPECTION)  
 Poriyalarithal are perception of the five sense organs. They are nose, 
tongue, eyes, skin and ears. Poriyalarithal is examining the pori of the patient by 
pori of the physician. In Swasakasam ,it is as follows.  
Nose - Visible movements of alar  nasi, irritation of the nose, running Nose.  
Eyes - Redness, sometimes dusky and pale 
Tongue - Dry, pale and Coated 
Ear - normal  
Skin - Sweating all over the body, waxy 
2. PULANALARITHAL (PALPATION)  
 Pulangal are the five object of senses namely smell, taste, sight, sensation 
and sound.  
• Smell  - Altered or absent due to running nose and 
                                   inflammation of the nasal mucosa.  
• Taste  - Diminished or normal  
• Vision  - Normal  
• Sensation - Normal or cold due to sweating  
• Sound  - Diminished  
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3. VINATHAL (INTERROGATION)  
 By Vinathal, the physician knows about the patients name, age, occupation, 
native place (Thinai), Family History, Socio Economic status, diet habits prone to any 
allergens (e.g. Dust, Smoke).History of previous episode, frequency of attacks by 
change of season, relevant history of treatment and habits etc. 
1. KALAM (AGE DISTRIBUTION)  
 The period of human life is totally said to be 100 years. This is divided into 
three stages according to the domination of three humours as per this  
1. The first stage     - 1 to 33 years  - Vatha period  
2. Second stage  -34 to 66 years  - Pitha period  
3. Third stage  -67 to 100 years - Kaba period  
         In each of the stage the other humours were also involved. But a particular 
humor would be dominating more. According to this, Swasakasam comes under the 
types of Kaba disease. 
2. IVAGAI NILAM (LAND OR PLACE)  
 Study of five places is very important and useful, because there may be 
possibilities of respiratory disease in some areas. 
Five lands are : 
a. Kurinchi - Mountain and its surroundings  
b. Mullai - Forest and its surroundins  
c. Marutham - Fields and its surroundings  
d. Neithal - Sea and sea shore  
e. Palai - Desert and its surroundings  
a. KURINCHI  
“GxqR<sq!uVfqzk<kqz<!ogix<xL{<c!vk<kl<!!
dxqR<sq!!uV!SvL{<mil<!.!nxqRjvg<!!
jgbOl!kr<G!kvk<kijl!uz<jzBr<!gkqg<Gl<!!
JbOl!kr<G!lxq”!!!)hkiIk<k!G{!sqf<kil{q*.!
 
Person who live in Kurunchi Nilam are usually liable as developing fever that 
results in blood dyscariasis, disease of the spleen and liver and prevalence  of kaba 
disease is more in Kurinchi nilam.   
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b.MULLAI: 
“!Lz<jz!fqzk<kbOl!&iqfqjvOleqElu<!
ouz<jz!fqjzk<khqk<k!olr<GXr<gi{<!.uz<jzobeqe<!
uikolipq!bikk!E{<!le<E!lju!upqOfib<h<!
Ohkolipq!bikjxb!h<hqe<H”!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
)!hkiIk<k!G{!sqf<kil{q*.!
In  Mullai Nilam, is the place of cattles, it is the place of increasing Pitha, Vatha also 
joined to that Pitha due to these Kutrams many diseases occur. 
c.MARUTHAM 
Marutham the agricultural land is fertile with very good water which will 
drive out the diseases of all the three humors, so cures all the three Vatha, Pitha and 
Kaba diseases.  
d.NEITHAL:  
‘ofb<keqz!OlZh<jh!fQr<gi!KxqElK!!!
oub<keqz!Olkr<G!uQmiGl<!.!ofb<kz<!!!
!lVr<Gmjz!lqg<gig<Gl<!uz<ZXh<jh!uQg<Gl<!
gVr<Gmjzg<!gQpqxg<Gr<!gi{<”!!!!!!..!)hkiIk<k!G{!sqf<kil{q*.!
 Through Neithal nilam dominant taste of uvarppu (salt) , it is the place of pitha 
vayu.The people who dwell here are susceptible to odema due to Kaba, Silipatha 
Rogam (Filariasis), Kudalanda Viruthi (Hernia). 
e. PALAI  
“hijz!fqzl<Ohiz<!hmjv!hqxh<hqg<g!!
Oljz!fqzlQbiK!uqiqk<kx<G!.!Oujz!fqz!!
Lh<hq{qg<G!lqz<zil<!LjxOb!bux<xizil<!!
wh<hq{qg<G!lqz<zil0oke<”!!!!!!!!!!!)hkiIk<k!G{!sqf<kil{q*!!
 Persons who live in palai are liable to develop the disease of three dhoshas. 
 From Ivagai Nilangal we understood that kabha disease is predominant in 
kurinchi thinai. 
3. PARUVAKALAM (SEASON)  
“giOv!%kqi<!Le<heq!hqe<heq!!
sQiqt!Oueqz<!Oueqz<!we<xir<G!!
-V&e<X!kqxk<kK!okiqohVl<!ohiPOk” 
)sqk<k!lVk<Kuir<gs<!SVg<gl<*!.!
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With reference to the position of sun the year is divided into 6 seasons they are  
1. Karkalam (Avani and Purattasi)  - August and September  
2. Koothirkalam (Iyppasi and Karthigai) - October and November  
3. Munpani Kalam ( Markazhi and Thai) - December and January  
4. Pinpani Kalam (Masi and Panguni)  - February and March  
5. Elavenil Kalam (Chittirai and Vaigasi) - April and May  
6. Mudhuvenil Kalam (Aani and Aadi)  - June and July  
 
Swasakasam mainly occurs due to the vititation of kaba. Thannilai valarchi of 
kabam occurs  in pinpanikalam and vertunilai valarchi occurs is elavenilkalam and 
comes to thanilai in mudhuvenil kalam. So the pinpani and elavenil kalam are more 
precipitate of the Swasakasam. 
4. MUKKUTRA NILAIGAL  
A. VATHAM  
‘Ljxjlbil<!hqvi{Oeimhiee<!uqbiee<!!
&i<g<gli!&kieOeiM!slie!eige<!!
kqjxjlbir<!%i<lOeiM!gqVg!ve<xe<!!
Okukk<k!oeiMkeR<!sbE!liGl<’!
!!.!B,gq!juk<kqb!sqf<kil{q!911!
1. Piranan  
 It is responsible for respiration.  
In Swasakasam difficulty in breathing is due to the affection of this vayu.  
2. Abanan  
 It helps to excrete the urine and motion. 
In Swasakasam  some patients had constipation.  
3. Viyanan  
 Since it has the qualities of  Akayam it spreads through out the body. 
In Swasakasam this distribution is affected.  
4. Udhanan  
 It appears from Udarakkini.Udhana Vayu is called in tamil as Mel Nokku 
Kaal. In Swasakasam sneezing and cough  may present due to the derangement of this 
vayu.  
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5. Samanan  
 It helps  Sadarakkini in assimilating the food and liquids. 
  It helps in separating the essence and excretion.  
In Swasakasam  signs of dyspepsia may present. So this is also affect 
6. Nagan  
 This vayu maintains the opening and closure  of eye lids.  
In Swasakasam this vayu may be deranged.  
7. Koorman   
 This vayu is responsible for vision and yawning and is not affected in 
Swasakasam.  
8. Kirukaran  
It controls salivation, running nose, sneezing, cough.  
In Swasakasam this vayu may deranged with loss of appetite.  
9. Devathathan  
 It is responsible for tiredness and anger. It is affected in Swasakasam.  
10. Dhananjeyan  
 It produces swelling of the body after death and escapes,  
due to the separating of sutures of the skull after the third day.  
B. PITHAM  
“Ng<gez<!u{<{ouiq!bix<xzr<gq!obit<otitqk<kQ!!
Ofig<gpzil<!hqk<kjlf<k!F~keli!.!big<Golipq!!
Hisslq!vR<sgR<!sikgl<!visgli!!
Ozisg!ole<xqMOli!Ozi”!!!!!! ! )lVk<Ku!keqh<himz<*!
 According to its site and function, it is divided  into five kinds.  
1. Anala Pitham  
 This is residing in the stomach, and helps in digestion. 
 In Swasakasam loss of appetite may be present.  
2. Ranjaga Pitham 
 This is residing in stomach and regulates the quality of blood.  
In Swasakasam anemia may be present. 
3. Sathaga Pitham  
 It resides in heart and makes correct activities with the help of minds and 
brain. In this disease restlessness is present.  
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4. Aalosaga Pitham  
 It resides in both eyes and gives correct vision.  
5. Pirasaga Pitham  
 It resides in skin and gives complexion. 
C. KABHAM  
! ‘Nkv!uil<olb<g!guzl<!hklir<gq!!
! Ozkg!liR<Sjuh<!Ohk&{i<h<!.!Ohikglil<!!
! kx<hgliR<!sf<kqgtqx<!xr<GR<!sqOzmgli!!
! lx<hlqzis<!Osk<Kl!jlf<K”/!!!!!!!!!!!!!).!lVk<Ku!keqh<himz<*!
1. Avalambagam  
 This is considered to be support for other  ayyams. It occupies the lungs and 
the heart and helps  the other four by its natural quality of its spreading. Cough, 
Wheezing, dyspnoea are present in  Swasakasam.  
2. Kilethagam  
 It is present in the stomach and gives moisture to the food materials and also 
helps in digestion. In this disease loss of appetite is present.  
3. Pothagam  
 It is present in the tongue and reveals the taste.  
4. Tharpagam  
 It resides in the head and helps the eye to close.  
5. Santhigam   
 It resides in joints and helps for free movements.  
5. SEVEN UDAL KATTUKAL  
“ke<elil!vslqvk<kli!r<gqsL!Oljk!!
! ! !kjs!ls<jsobiM!Sg<zf<ki!Okpigq”!–)B,gq!juk<kqb!sqf<kil{q!911*!!
 They are the seven basic principles which constitute the entire body. These are 
otherwise called as udal thathukkal. They are, 
1. Saram (Chyle-essence of food):  
 This is the end product of the digestive process. It strengthens the body and 
mind. This is deranged due to loss of appetite in Swasakasam 
2. Senneer (Blood): 
 The rasam after absorption is converted into senneer. It is responsible for 
intelligence, skill,  and healthy complexion. So, this is deranged is Swasakasam.. 
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3. Oon (Muscles):  
 It  helps in growing of bones and establishes the parts of the body according to 
their functions. 
4. Kozhuppu (Fat):  
 When the organs of the body do their works this thathu helps for lubrication 
and facilitates their functions.  
5. Enbu (Bones):  
 It gives shape to the body and is responsible for protection of vital organs. It is 
the basis for the movementof the body. 
6. Moolai (Marrow): 
 It is present in the core of the bone which strengthens and maintains the 
normal conditions of the bones.  
7. Sukkilam/ Suronitha (Semen): 
 It is responsible for the reproduction. When the seven udal thathukkal may 
increases or decreases from the normal level, normal functioning of the body is 
affected.  
6. ENN VAGAI THERVUGAL  
 It is the basic diagnostic principle and the unique specialty of the siddha 
system of medicine. The following verses reveals this as followis, 
 “fic!hvqsl<!fi!fqxl<!olipq!uqpq!
! ! lzl<!&k<kqvlqju!lVk<KuviBkl<”!
.!Ofib<fimz<!< << << < Ofib<Lkeimz<!kqvm<M!Lkz<!higl<< < < < << < < < << < < < <!!
! ! “olb<g<Gxq!fqxf<okieq!uqpq!fiuqVlzl<!jgg<Gxq”!
.!OkvI!
 The diagnostic value of Enn vagai Thervugal is important one in siddha 
system and presumes the vitiated dhoshas in the patient. They are described in siddha 
maruthuvam as an essential one for the siddha physician. Enn vagai thervugal are,  
1. Naadi    (Pulse) 
2. Sparisam  (Palpation) 
3. Naa   (Tongue) 
4. Niram   (Colour of the Skin) 
5. Mozhi   ( Speech)  
6. Vizhi   (Eyes)  
7. Malam  (Motion) 
8. Moothiram  (Urine)  
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Enn Vagai Thervugal gives a definite idea to diagnose the Swasakasam. This is 
explaines as follows.  
1. NAADI  
 Naadi otherwise known as pulse is the very important helpful observation for 
diagnosis and prognosis. The Naadi which indicates the states of the Uyir thathukkal 
are whether they are normal or abnormal. The importance of naadi is clearly 
mentioned by Saint Thiruvalluvar by the following verse 
  “Neha;ehb Neha; KjdhbaJ jzpf;Fk;  
tha;ehb tha;g;gr; nray;”.- jpUts;StH;;;  
In Noi Nadal text is defined as, 
 “clypy; caph; jhpj;jpUg;gjw;Ff; fhuzkhd [Pt rf;jp vJNth mJNt 
jhJ my;yJ ehb vdg;gLk;”.  
Genesis of Naadi  
The three thathus are formed by the combination of three naadies with three vayus.  
Idakalai + Abanan   = Vatham  
Pinkalai + Piranan   = Pitham  
Suzhumunai + Samanan  = Kabam 
“,Ug;ghd ehb vOgNjhBuh  
apukhd Njfj;jpy; Vyg;ngUehb  
xf;f jrkj; njhopiy Cf;f jrthAf;fs;  
jf;fgb vd;Nw rhUk;.  
rhUe;jrehb jd;dpy; %yk; %d;W  
NrUkplk; gpq;fiyAk; gpd;dYld; khWk;  
ciuf;ftpuw; fhw;nwhl;Lzh;j;JNk ehrp  
tiu RopNah ikaj;jpy; te;J’ 
te;jfiy %d;wpy; thAthk ghdDld;  
je;j gpuhzd; rkhdDf;FQ; re;jkwf;  
$l;LwT Nufpj;jy; cWk; thjk; gpj;jk;  
ehl;Lq; gNkahk; ehL”- (fz;Zr;rhkpak;) ; ; ;; ; ;; ; ; - 
These naadies can be felt one inch below  the wrist on the radial side by means of 
palpation with the tips of index, middle and ring finger corresponding to vatha, pitha 
and kaba respectively.  
“fhpKfdbia tho;j;jpf; ifjdpy; ehb ghh;f;fpy;  
ngUtpuyq;Fyj;jpy; gpbj;jgb eLNtnjhl;lhy;  
xU tpuNyhby; thjKah; eLtpuypw;gpj;jk;  
jpUtpuy; %d;wpNyhby; Nrj;Jk ehbjhNd”.   –(mfj;jpaH ehb);;;  
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NAADI IN IYA SWASAKASAM 
1. KABA NAADI  
  “fgky;yhJ fhr Rthrk; tuhJ”  
  cw;wpLk; Iaehb Xq;fpNa Jbj;J epd;why;  
  gw;wpLk; <is gjwpNa ,iug;Gz;lhf;fp  
  nkj;jNt Nfhio tha; kpFjpg;gLk;”   
- (mfj;jpaH Fzthflk;); ;; ;; ;  
  “jhdKs;s Nrj;Jke; jhdpsfpy; ntg;G  
  rakPisapUky; ke;jhu fhrk;  
  <dKWQ;re;ep tplNjhlk; tpf;fy;  
  apUj;Nuhfq; fug;ghd; tpuzNjhlk;  
  khdidaPh; #iy jpus; tpahjp tPf;fk;  
  tUQ;rj;jp Rthrk; neQ;rilg;G> J}f;fk;  
  VdKWq; fhkhiy ghz;L Nrhig  
VORuq;fs; gyJf;fk; tplKz;lhNk”  (rjf ehb) 
 
2. VATHA KABAM  
 The level of vatha Naadi increased to two times  of its normal level, i.e..2 
mathirai and the level of kaba increased to two times, i.e. ½ mathirai. But it never 
goes beyond twice its normal level.  
“ghq;fhd thjj;jpy; Nrj;Jk ehbg;  
ghprpj;jhy; jpkph; NkT Kisr;ryhFk;  
jPq;fhd ,UkYld; rd;dp Njhlk;  
Nrh;e;j tplk;  ntb#iy ,Uj;Nuhfk;  
thq;fhj <is ke;jhufhrk;  
typAlNd GwtPr;RAs; tPr;R tPf;fk;  
xq;fhDQ; RuKlNd Rthrfhrk;  
cz;lhFk; ntF Neha;f;Fk; cWjpjhNd” (rjf ehb) 
 
3. KABA PITHAM  
 When the Naadi rhythm varies from normal to kaba pitham, it causes 
Swasakasam. The level of Vatha Naadi increased to two times of tis normal level i.e  
2 Mathirai and the level of pitham increased to two times i.e. 1  mathirai. But it never 
goes beyond twice its normal level. 
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“,lkhd Nrj;Jkj;jpy; gpj;jehb  
vOe;jZfpy; tplKlNd tPf;f Kz;lhk;  
jplkhd Fsph;fha;r;ry; kQ;rs; NehTe;  
Njfj;jpYisr;rypisg; gpUky; the;jp  
tplkhd neQ;rilg;G Rthrk; tpf;fy;  
ntF RuKk; ehtwl;rp ghz;L Nuhfk;  
mlkhd Ftis uj;jkjp rhue;jhd;  
mDfp ntFgy Neha;f;Fe; jlq;fz;lhNa”.    (rjf ehb) 
4. IYA VAYU  
 When Iyam combined with vayu then it leads  to Swasakasam. 
“njhe;jpj;j Nrj;Jkj;jpy; thA$bj; njhlh;e;j  
Fd;kk; neQ;rilg;G Rthrfhrk;  
te;jpj;j Fuy;jdpNy AWj;j yPis  
tOtOg;G ePUwy; kyj;jpy; rPjk;  
nte;jpj;jy; nfhOj;jy; Fj;Je; jpkph; tpahjp  
tPr;Rlnd typnal;Le; jpul;rp ghz;L  
me;jpj;j fpWfpWg;G kaf;fk; tpf;fy;  
Md gy gpzpfSNk te;jlUe; jhNd”.   (rjf ehb) 
5. IYA USHNAM  
When Iyam and ushnam are combined then leads to Swasakasam.  
“fjpg;ghd Nrj;Jkj;jpy; cl;bzq; $by;  
fye;j Fsph; rakpUky; Rthrfhrk;  
kjpg;ghd Nfhio uj;jk; tpg;GUjpAlNd  
tsh;ehrpfh gPlkpUj; Nuhfq;  
nfhjpg;ghd rpq;Fit ahf;fpuhz thA  
nfhl;lhtp tpf;fy; ke;jhufhrk;  
Jjpg;ghd tPuyj;jpf; fha;T uj;jk;  
Njhd;wkpF gpzp gyTe; njhe;jpg;ghNk”.   (rjf ehb) 
 
6. IYA SEETHAM  
 When Iyam combined with seetham then it leads to Swasakasam. 
“mlkhd Nrj;Jkj;jpy; rPjsk; gw;wpy;  
mZfpdhy; Rthrkilg;G apisg;G %h;r;ir  
jplkhd thahr kaf;fk; tpah;it  
Nrh;e;j tpf;fy; re;ep tplNjhlk; tPr;R  
,lkhd tapW nghUky; Fsph; eLf;fy;  
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apuj;j RuNkhq; fhuk; ngUj;j tPf;fk;  
flthd mtFwp te;jZF nkd;Nw  
rhh;e;j nghpNah Uiuj;j jaTjhNd”.   (rjf ehb)   
2. SPARISAM (PALAPTION)  
 By sparisam, the temperature of skin, (hot or cold) smoothness, sweet, 
dryness, hard patches, swelling, abnormal growth, tenderness, ulcers, enlargements, 
nourishment can be noted. In Swasakasam patient’s body is cold.  
 ‘Nrl;k rlk; tpah;it nfhz;NlapUf;Fk;’            (jpul;L ehb);;;   
 ‘Nrl;kj;jpd; Njfe;jhDk; rpf;nfd;W Fsph;e;jpUf;Fk;’(ehb epjhdk; nr.30);;;  
3. NAA (TONGUE)  
 In the examination of tongue, it’s colour, it’s coating, it’s dryness, it’s 
deviatioin and movement, variations in taste and the conditions of teeth and gums can 
be noted. During this examination if there are any ulceration, inflammations and 
malignant growth, they should also be carefully noted. most of the case Swasakasam 
tongue is white in colour.  
4. NIRAM (COLOUR OF SKIN)  
 By examining the niram the type of udal (body) whether vatha (black), pitha 
(red or yellow) and kaba (white) or mixed, cyanosis and pallor of the body can be 
noted. In Swasakasam  niram, conjunctiva and tongue is pale in nature.  
 ‘le<eqb!Osk<Kl!lQxqz<!ligibl<!ouTg<G!Oleq’)ngk<kqbI*<<< !
5. MOZHI (SPEECH OR VOICE)  
 In the examination of mozhi the pitch of the voice, (whether it is high or low) 
actions of laughing, crying, slurring, speech in hallucination, sadness, argument, 
breathlessness, wheezing and incompletences while talking may be noted. Speech will 
not usually affected in this disease. In severe condition (severe dyspnoea)  the patient 
will not able to speak well.  
6. VIZHI (EYES)  
 In the examination of vizhi the change of colour of the eye for vatha, pitha and 
kaba or mixed condition and other colours such as redness, yellowishness, pallor etc., 
may be noted. With these dryness, lacrimation, sharpness of vision, response of the 
pupil, falling of hair in eye lashes, inflammations and ulcerations may also be noted.  
 In the case of Swasakasam, the colour  of the conjunctiva pale in colour.  
 ‘NfhJw;w rpNyw;gdj;jhh;f;Ff; $h;tpop ntSj;jpUf;Fk;’ 
- (rpj;j kUj;Jthq;f RUf;fk;) ; ; ; ; ;; ; ; ; ;; ; ; ; ;  
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7. MALAM (STOOLS)  
 In the examination of malam its nature, (whether it is solid, semisolid or 
liquid), it’s colour, its quantity (increased or decreased) can be noted. other 
examinations like diarrohea, presence of blood, mucus, rice and indigested matter in 
the stools and odour should be studied. In Kabha disease it is white in colour.  
  ‘kd;DQ; Nrj;Jkj;Njhh;  kyk; tPo;Fop  
  ,d;dy; jPu tPOk; ntWg;gd;dNt’              - (NjiuaH) 
  ‘kykw rpf;fyhf ntWj;jpL ikaj;jpw;F’ - (Gypg;ghzp);;;  
8. MOOTHIRAM (URINE)  
 In the examination of urine the colour, odour, quantity of urine, the presence 
of froth, deposits, blood, pus, small stones, abnormal constituents such as sugar, 
proteins etc.  and the frequency of urination can be noted.  
 Neerkuri and Neikuri are the two methods also used to diagnose the disease. 
They are explained below, 
NEERKURI  
  ‘te;j ePH; fhpail kzk; Eiu vQ;rnyd;  
  iwe;jpa Ysit aiwFJ KiwNa” 
                           - rpj;j kUj;Jt Neha;ehly; ; ; ; ;; ; ; ;; ; ; ;  
      Neha;Kjdhly; jpul;L Kjy; ghfk; ; ; ; ; ;; ; ; ; ;; ; ; ; ;  
 According to this verse, the general features of urine, niram, edai, manam, 
nurai and enjal were analyzed.  
 Niram indicates the colour of the urine voided  
 Edai indicates the specific gravity of the urine  
 Manam indicates the smell of the urine voided  
 Nurai indicates the frothy nature of urine voided.  
 Enjal indicates the quantity (increased or Decreased)  
NEERKURI IN KABAM 
“tPONk Nrj;J kj;Njhh; ePH;f;Fzk; tpsk;gf; Nfsha;  
ehSNk ntSj;J iwe;J eyk; ngw tPOq; fz;lha;” 
-(rpj;j kUj;Jthq;f RUf;fk;); ; ; ; ;; ; ; ; ;; ; ; ; ;  
NEIKURI  
  Before urine testing, the patient was the patient was asked to take regular and 
quality diet without any derangements in amount  in correct time. The urine was 
collected in next day  early morning in a glass vessel. The same method was 
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employed for Neerkuri. A drop of gingelly oil was dropped and  the urine was kept 
without any movements . The spread of nei is noted, this is most diagnostic evidence 
for deranged humour. 
“mUe;JkhwpujKk; mtpNuhjkjha;  
m/fy; myh;jy;  mfhyt+d; jtpe;jow;  
Fw;wstUe;jp cwq;fp itfiw 
Mbf;fyrj; jhtpNa fhJ nga;  
njhU K$h;j;jf; fiyf;Fl;gL ePhpd;  
epwf;Fwp nea;f;Fwp epUkpj;jy; flNd” 
“muNtd ePz;bbd; m/Nj thjk;  
MopNghw; gutpd; m/Nj gpj;jk;  
Kj;njhj;J epw;fpd; nkhoptnjd; fgNk” 
      - rpj;j kUj;Jt Neha;ehly;; ; ; ;; ; ; ;; ; ; ; 
       Neha;;;; Kjdhly; jpul;L ; ;; ;; ; Kjy; ghfk;;; ;  
 
The oil spreading like a snake indicates vatha  
The oil spreading like a ring indicates pitha  
The oil remaining floating as a pearl means kaba  
So, in Swasakasam oil spreading like a pearl in the urine. 
 “Kj;njhj;J epw;fpd; nkhoptnjd; fgNk”  
      - rpj;j kUj;jthq;f RUf;fk;; ; ; ; ;; ; ; ; ;; ; ; ; ; 
PROGNOSIS  
 Swasakasam  was relieved by taking regular as well as proper treatment.  
2.3.9.LINE OF TREATMENT  
 The line of treatment of Swasakasam consists of  
 Kazhichal Maruthuvam  - To bring the kabha dhosha and udhanan to 
equilibrium  
 Internal Medicines  - Mainly expectorant drugs to expel the increased kabha  
 Diet  - To maintain tridhoshas and energy  
 Prevention methods - To strength the muscles of respiration  
1. KAZHICHAL MARUTHUVAM (LAXATIVE) 
 Each patients were given Nilavagai Chooranam 5 gms with hot water  
before the bed time on the first day before starting the main treatment. 
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2. ADMINISTRATION OF INTERNAL MEDICINE  
 For treatment the disease Swasakasam several remedies are suggested in 
ancient siddha literature. The Jaathipalathi Chooranam 30mg/kg/Bw three times a 
day with honey after meals for 30 days. 
The identification of Suvaigal were based on individual ingredients of these 
preparations.The trial medicine  Jaathipalathi chooranam has the tastes of Kaippu, 
Kaarppu, Thuvarppu. Jaathipalathi chooranam  has got the  Kaarppu  pirivu. The 
Karppu suvai which has potent to act as antagonist the excessive  Kabam . 
“Ia tpfhuk; mopj;jpLk;”       
       -rpj;j kUj;Jthq;fr; RUf;fk;; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ; 
All these drugs has got the thanmai veppam (presence of karppu taste). The 
thanmai veppam has go to action to decrease the vitiated  Kabam . After ingestion 
while the trial medicine reaches the gastric juice ,it will change into vibagam karpu. 
At this stage also, the medicine will acts as anti kaba medicine due to the vibagam 
karppu. 
  “NrjKwr; nra;AQ; rpiwak;- Xjf;Nfs;    
  fhuk; Jtu; frg;G fhl;LQ; Rit vy;yhk;    
  rhug; gupfhuQ; rhw;W”      
     -Neha; ehly; Neha; Kjy; ehly; jpul;L; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ;  
 fhu;g;G, ifg;G, Jtu;g;G Ritfs; Ia kpFjpia rkd; nra;Ak;. 
 The method of preparation and properties of this medicine is given in the 
Annexure I.  
4.DIET 
Vegeables to be added  
• kzj;jf;fhsp- Solanum nigrum 
• nghd;dhq;fhzp–Alternantherasessilis 
• KRKRf;if - Mukia scavrilla 
• Fg;igNkdp - Acalypha indica 
• J}Jtis - Solanum trilobatumn 
• miuf;fPiu  - Amaranthus tristis 
• rpWfPiu - Amaranthus gangeticus 
• ty;yhiu - Centella asiatica 
• KUq;if fPiu - Moringa olefera 
• fj;jhp  - Solanum melongena 
• fz;lq;fj;jphp-Solanum xanthocarpum 
• gPf;fk;gpQ;R - Luffa ocutaugula 
• mj;jp - Ficus glomavata 
• <Us;sp - Allium cepa  
• KUq;ifg; gpQ;R- Moringa olefera 
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PREVENTION MEHTODS  
 Intake of hot water and hot foods 
 Avoidance of chill weather 
 Avoidance of factors which cases digestive disturbances. 
 Avoidance of allergic factors. 
 Avoidance of smoking and snuff. 
 Taking bath strictly in hot water 
 Advised to take dinner before 8 p.m. 
 Avoidance of stress. 
 Avoid work in dust, cement and cotton mills. 
 Advice to practice  pranayamam and yogasanam.  
 Advice to sleep in the phoenix mat.  
PIRANAYAMAM (BREATHING PRACTICE)  
 Piranayamam (or) breathing mainly consists of inhalation of air by deep 
inspiration (Poorakam), holding of breath as it possible (Kumabakam) and exhalation 
of air by a expiration (Rasakkam). By this exercise, the duration of Kumbagam 
(retention of air in the lungs) is increased. So, that results in proper gaseous exchange 
which produces increased oxygen supply to all cells.  
 By the regular practice of pranayama, one can get a feeling of clamnes of 
mind and as a result of excess supply of oxygen to the brain cells. This state of mind 
ultimately helps in good concentration and mediation.This practice also given good 
appetite, great strength, enthusiasm, a high standard health, vigour and vitality. 
During breathing exercise, the lungs expand well and get proper supply of oxygen by 
proper expansion of chest. So, pranayama practice is one of the preventive methods 
for asthma.  
 
Diet Restritction 
Siddhars advice to avoid some certain food items in Swasakasam. They are 
• Ghee 
• Buttermilk  
• Chillies 
• Ice creams  
• Sweets 
• Cool drinks 
• Watery vegetables  
• Watery fruits 
• Sugar 
• Curd 
 
• Strong tea,Coffee 
• Alcoholic beverages 
• Pickles 
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2.3.10.NOI KANIPPU VIVATHAM (Differential diagnosis): 
ke;jhu fhrk;:; ;; ;; ;  
“jhdhd J}aNjhH ehrp jd;dpy;  
ryNeha;ePh; jhd; tpOe;J Jk;kYz;lhk; 
 khdhd khh;GneQ; rilj;J%r;R 
  tYthfg; ghk;GNghw; rPwyhFk; 
fhdhd fz;lnkhL KfKk; fhJq; 
  fhakJq; frpthfp tpau;itahFk; 
Vdhd ,UkNyhL Nfhio fk;ky; 
,iug;ghFk; ke;jhufhr khNk ”(A+fp itj;jpa rpe;jhkzp); ;; ;; ;  
Mandara kasam there is running nose, sneezing, tightness of chest, breath 
sound like hissing of snake, sweating all over the body, cough, expectoration, 
dyspnea, etc., In Swasa kasam there is no sweating all over the body. 
 
fz;l fpuhf thjk;; ;; ;; ; 
  “tifahd Fuy;jidg; gw;wp nehe;J 
   khh;NghL  gplhpapdpy; typAz; lhfp 
  Efuhd ruPunky;yhk; nehe;jo yhw;wp 
   EZf;fkha; RthrkJ Gwg;g lhky; 
  Kifahd ehthNy %r;R khwp 
   Kfj;jpNy tpah;thfp tpyhNeh Tz;lhk; 
  Gifahd td;dj;ij gUf;nfhl;lhJ 
  ghpafz;l fpuhfj;jpd; gz;G jhNd”(-A+fp itj;jpa rpe;jhkzp); ;; ;; ;  
 Kandakiragam, there is difficulty in speech, pain in the chest and occipit 
region, pain all over the body, breathlessness, mouth respiration, sweating in face, 
pain in the ribs, anorexia.  In Swasa kasam, there is no pain in the occipital region. 
 
Suis!hqk<kl<;< << << < !
“fUj;jhfr; RthrkJ kpfTz; lhFq;   
fdkhf tapWNk Cjpf; fhZk; 
cUj;jhf clyJjhd; kpf typf;F 
   %WNk NfzpNghy; tha;ePh; jhDk; 
  kUj;jhf kaq;fpNa fz;k iwf;Fk; 
   khh;gpNy typNahL ,Uk Yz;lhe; 
  JUj;jhf tapwjdpw; grpNah apy;iy 
Rthrkhk; gpj;jj;jpd; #l;re; jhNd” 
(A+fp itj;jpa rpe;jhkzp); ;; ;; ;  
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In Swasa Pitham, there is increased respiration, flatulence, pain all over the 
body, brashing, loss of consciousness, pain in the chest followed by cough, loss of 
appetite etc.,In Swasa kasam there is no loss of consciousness. 
 
%f;filg;G ,Uky; ;; ;; ; ;: 
“nrg;gNt apUknyhL Nfhio tPOk; 
Nrj;Jkkhkpisg; NghL ,iug;Gz;lhFk;> 
cg;gkha; tapwJT %jpf;nfhs;Sk;> 
CZwf;fkpy;yhkYyUe;Njfk;> 
Fg;gkha; kyryKq; fWfp tPOk;  
NfhioaplFze;jhd; kPd; ftpr;rbf;Fe;  
Jg;gkha;r; RUz;L tapW typAkhFk;  
RthrgPdrnkd;Nw #l;blhNa” (- A+fp itj;jpa rpe;jhkzp ; ;; ;; ; -) 
 Cough with expectorant, dyspnoea, wheezing, abdominal distention, anorexia, 
insomnia, oliguria, constipation, abdominal pain and sputum has fish like is odour.  
 
moy; I;;; ak;; ;; 
“gz;ghff; fz;kaq;fpf; fpWfpWf;Fk;  
gj;jpae;jhd; kpFjpah arjp ahFk; 
cz;ghf trdkpfj;jhDQ; nry;yh  
CwpNatha; ePh;jhd; kpfTz;lhFk;  
fz;ghff; fz;lj;jpw;Nfhiofl;Lq;  
fdf;fNtapUkNyhL %r;RkhF  
kpz;ghfNkdpANkhkQ;rspf;F  
kpf;f gpj;jrpNyl;Lkj;jpd; tptue;jhNd” 
- A+fp itj;jpa rpe;jhkzp; ;; ;; ;  
Fainting,giddiness, tiredness, anorexia, excessive salivation, accumulation of 
phlegm in the throat, cough with severe dyspnoea, yellowish discoloration of the 
body. 
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2.4.MODERN ASPECTS  - BRONCHIAL ASTHMA 
2.4.1.DEFINITION 
Bronchial Asthma (BA) is a bronchial hypersensitivity disorder characterized 
by reversible airway obstruction,produced by a combination of mucosal 
edema,constriction of the bronchial musculature and excessive  secretion of viscid 
mucus,causing mucous plugs. Asthma is characterized by recurrent attacks of 
Dyspnea, cough with expectoration of tenacious mucoid sputum and usually 
wheezing. Symptoms may be mild and may occur only in association with respiratory 
infection or they may occur in various degrees of severity to the point of being life –
threatening. 
2.4.2.EPIDEMIOLOGY 
Bronchial asthma is the most common chronic respiratory disease with a case 
burden of approximately 358.2 million in 2015. In 2015, about 0.40 million people died 
from asthma, a decrease of 26.7% from 1990, and the age- standardized prevalence 
decreased by 17.7 %.( GBD 2015). It has a higher prevalence in boys than in girls before 
puberty and a higher prevalence in women than in men in adultwood(Postma DS. 2007). 
According to the latest WHO estimates, released in December 2016, there were     
3,83,000 deaths due to asthma in 2015. World wide about 400 million people will be 
affected by asthma in 2025. 
2.4.3.ETIOLOGY  
Etiologicaly asthma is heterogeneous disease. It is useful for epidemiological and 
clinical purposes to classify asthma by the principle stimuli. There are two types of 
asthma and Rackemann first introduced the terms “extrinsic” and “intrinsic” asthma in 
1947 
 Early onset asthma (atopic, allergic, extrinsic) 
 Late onset asthma(Non-atopic, Idiosyncratic, Intrinsic) 
ATOPIC ASTHMA 
Atopic asthma is the most common type of asthma usually begins in 
childhood. This  disease has been thought to be result from sensitization of the 
bronchial mucosa by tissue specific antibodies .The antibodies produces a specific 
immunoglobulin IgE (type 1) class and the total Serum IgE levels are 
usually.Exposure to the environmental antigens, such as dust, pollens, animal’s 
dander, fungal spores and food result in an antigen antibody reaction. A positive 
family history of atopy is common, and asthmatic attacks are often preceded by 
allergic rhinitis, utricaria or eczema. A skin test with antigen results in an immediate 
wheal and flare reaction, a classic example of type I 
reaction. 
NON – ATOPIC ASTHMA (Idiosyncratic asthma)
A significant fraction of asthmatic patients present with no personal or family 
history of allergy, with negative skin tests, and with normal serum levels of IgE, and 
therefore have disease that 
mechanisms.  These patients are said to have idiosyncratic asthma. Many develop a 
typical symptom complex upon contracting an upper respiratory illness. The initial 
insult may be little more than a c
begins to develop paroxysms of wheezing and dyspnea that can last for days to 
months. 
2.4.4.PATHOGENESIS
 Atopic asthma is caused by aT
in genetically predisposed
increased local secretion of growth factors which induce mucous gland hypertrophy, 
smooth muscle proliferation, angiogenesis, fibrosis and nerve proliferation. The 
contributions of the immune respon
separately below although they are closely intertwined.
TH2 Responses, IgE and inflammation :
 
 
          Courtesy: Clinical science (2009)
Figure 2.4.3
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Pathogenesis of Bronchial Asthma 
tivity 
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A fundamental abnormality in asthma is an exaggerated the Th2 responses to 
normally harmless environmental antigens.Th2 cells secrete cytokines that promote 
inflammation and stimulate B cells to produce IgE and other antibodies. These 
cytokines include IL4 which is stimulates the production of IgE.Interleukin 5 which 
activates locally recruited eosinophils; and IL13 which stimulates mucous secretion 
from bronchial sub mucous glands and also promotes Ig E production by B cells. The 
T cells and epithelial cells secrete chemokines that recruit more T cells and eosinophil 
that exacerbating the reaction.As in other allergic reaction IgE binds to the FC 
receptors on sub mucosal mast cells and repeat exposure to the allergen triggers the 
mast cells to release granule contents and produce cytokines and other mediators 
which collectively induce the early phase (immediate hypersensitivity)reaction and 
the late phase reaction.The early reaction is dominated by bronchoconstriction, 
increased mucous production, variable degrees of vasodilation, and vascular 
permeability.  
Bronchoconstriction   is triggered by direct stimulation of sub epithelial vagal 
(parasympathetic) receptors through both central and local reflexes triggered by 
mediators produced by mast cells and other cells in the reaction. The late phase 
reaction is dominated by recruitment of leucocytes, notably eosinophils, neutrophils 
and more T cells. Although Th2 cells are the dominant T cell type involved in the 
disease, other T cells that contribute to the inflammation include TH17 (interleukin 17 
produce) cells which recruit neutrophils.Many mediators produced by leucocytes and 
epithelial cells have been implicated in the asthmatic response.Mediators whose role 
in bronchospasm is clearly supported by efficacy of pharmacologic intervention are: 
(1)Leukotriene’s C4, D4 and E4 which cause prolong bronchoconstriction, 
vascular permeability and mucous secretion (2) Acetylcholine - released from 
intrapulmonary parasympathetic nerves, which can cause airway smooth muscle 
constriction by directly stimulating muscarinic receptors.A second group includes (1) 
Histamine, a potent bronchoconstrictor (2) prostaglandin D2, which elicits 
bronchoconstriction and vasodilation (3) Platelet Activating Factor (PAF), which 
causes aggregation platelets and release of serotonin from their granules. These 
mediators might yet prove important in certain types of chronic or non allergic 
asthma. 
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Genetic susceptibility: 
One susceptibility  focus for asthma is located on chromosome 5q,near the 
gene cluster encoding the cytokines IL-3,IL-4,IL-5,IL-9 and IL -13 and the IL-4 
receptor. Among the genes in this cluster,polymorphisms in the interleukin 13 gene 
have the strongest and most consistent associations with asthma are allergic disease. 
Particular class II HLA alleles are linked to production of IgE antibodies 
against some antigens such as ragweed pollen.Polymorphisms in the gene encoding 
ADAM33,a metalloproteinase may be linked to increased proliferation of bronchial 
smooth muscle cells and fibroblasts, thus contributing to bronchial hyper reactivity 
and sub epithelial fibrosis.Beta 2-adrenergic receptor gene variants are associated 
with differential in vivo airway hyper-responsiveness and in vitro response to Beta 
agonists stimulation.IL-4 receptor gene variants are associated with atopy, elevated 
total serum IgE, and asthma. 
Environmental factors:  
 Over time, repeated   bouts of allergen exposure and immune reactions result 
in structural changes in the bronchial wall, refered towards “airway remodelling” 
include hypertrophy and hyperplasia of bronchial smooth muscle, epithelial injury, 
increased airway vascularity, increased sub epithelial mucus  gland hypertrophy, and 
deposition of sub epithelial collagen. 
Allergens 
Allergies with asthma are a common problem. Eighty percent of people with 
asthma have allergies to airborne substances such as tree, grass, and weed pollens, 
mold, animal dander, dust mites, and cockroach particles.Allergic asthma is 
dependent on IgE response controlled by T and B lymphocytes and activated by the 
interaction of antigen with mast cells-bound IgE molecule. 
Pharmacological stimuli 
  The drugs most commonly associated with the induction of acute episodes of 
asthma are aspirin, coloring agents – tartazine, b- adregenic antagonists, sulfating 
agent.Aspirin – sensitive syndrome affects adults through seen in childhood. The 
problem usually begins with perennial vasomotor rhinitis that is followed by a hyper 
plastic rhino sinusitis with nasal polyps, progressing to asthma. Indomethacin, 
fenoprofen, naprocen, zonepirae sodium, ibuprofen, mefanamic acid and 
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phenylbutazone are particularly important.B-Adrenergic antagonist regularly 
obstructs the airway in asthmatics. In fact, the local use of b- blockers in the eye for 
the treatment of glaucoma has been associated with worsening asthma. 
Environment and air pollution 
 Environmental caused of asthma are usually related to climate conditions that 
promote the concentration of atmospheric pollutants and antigens. The air pollutants 
known to have this effect are ozone, nitrogen dioxide & sulphur dioxide. 
Occupational factors 
Occupation related asthma is significant health problem and acute and chronic 
airway obstructions have been reported to follow exposure to a large number of 
compounds used in many types of industrial process.Broncho constriction can result 
from working with or being exposed to metal salts, wood and vegetable dust, husk of 
grains, flour, castor bean, gum acacia, karay gum, tragacanth, pharmaceutical agents 
e.g. antibiotics, piperazine and cimetidine, industrial chemicals and plastics, 
biological enzymes, laundry detergents and pancreatic enzymes, animal & insect 
dusts, serum and secretions.  
There seems to be three underlying mechanisms 
1. In some cases, the offending agent results in formation of significant IgE. 
2. Substances cause direct liberations of broncho constrictor substances. 
3. Substances cause direct or reflex stimulation of the airway of latent of frank 
asthmatics. 
Infections 
Cold, flu, bronchitis, and sinus infections can cause an asthma attack. These 
respiratory infections that trigger asthma can be viral or bacterial .This airway 
sensitivity that causes the airways to more easily narrow can last as long as two 
months after an upper respiratory infection. It's thought that anywhere from 20% to 
70% of asthmatic adults have coexisting sinus diseases. Conversely, 15% to 56% of 
those with allergic rhinitis (hay fever) or sinusitis have evidence of asthma. 
Exercise 
               In people, exercise is the main trigger for their asthma symptoms. In 
exercise-induced asthma, some patient feels chest tightness, coughing, and difficulty 
breathing within the first five to eight minutes of an aerobic workout. These 
symptoms usually subside in the next 20 to 30 minutes of exercise, but up to 50% of 
those with exercise-induced asthma may have another asthma attack six to 10 hours 
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later. It is important to warm up slowly and adequately prior to rigorous exercise. This 
may prevent an attack. 
Emotional stress 
 Psychological factors can interact with the asthmatic diasthesis to worsen or 
ameliorate disease process. Changes in airways caliber seem to be mediated through 
modification of nasal efferent activity, but endorphins also may play a role. 
Foods and drinks 
 Food allergies can cause mild to severe life-threatening reactions. Atopic 
asthmatics may occasionally notice that their symptoms are provoked by certain foods 
or drinks.The most common foods associated with allergic symptoms are: 
• Eggs 
• Cow's milk 
• Peanuts 
• Soya 
• Wheat 
• Fish 
• Shrimp and other shellfish 
• Salads & fresh fruits 
 
Food preservatives can also trigger asthma. Sulfite additives, such as sodium 
bisulfite, potassium bisulfite, sodium metabisulfite, potassium metabisulfite, and 
sodium sulfite, are commonly used in food processing or preparation and may trigger 
asthma in those people who are sensitive. 
Smoking  
 Smokers appear to be at greater risk of developing asthma and have a higher 
prevalence of hyper-reactivity.  
Heartburn  
Severe heartburn and asthma often go hand-in-hand. Recent studies show that 
up to 89% of asthma patient also suffer from severe heartburn, known as 
gastroesophageal reflux disease (GERD). GERD generally occurs at night when the 
sufferer is lying down. Normally a sphincter between the esophagus and stomach 
prevents stomach acids from backing up into the esophagus. In GERD, the sphincter 
does not function properly. The stomach acids reflux, or back up, into the esophagus; 
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if the acid reaches into the throat or airways the irritation and inflammation can 
trigger an asthma attack. 
 Certain clues that suggest reflux as the cause of asthma include the onset of 
asthma in adulthood, no family history of asthma, no history of allergies or bronchitis, 
difficult-to-control asthma, or coughing while lying down. 
2.4.5.CLINICAL FEATURES 
Typical symptoms include recurrent episodes of wheeze,chest tightness,breathlessness 
cough.Not uncommonly asthma is mistaken for a cold or chest infection that is failing 
to resolve. 
 
1. Acute Severe Asthma (Status Asthmaticus) 
1. It is a medical emergency;  
2. Patient is hypoxic and cyanosed due to severe bronchospasm. 
3. Severe dysphoea, unproductive cought, patient adopts an upright position  
fixing the shoulder gridle to assist the accessory muscles of respiration 
4. It is characterized by tachycardia (Pulse rate> 120) Tachyphoea (respiratory 
rate> 30/minute) sweating, pulsus paradoxus, altered level of consciousness 
and an inspiration, expiration ratio of 1:3 or 1:4. 
5. The presence of a silent chest and bradycardia in such patients is an ominous 
sign. 
 
Acute Severe Asthma-Grade 
Grade1A : Able to carry out house work or job with moderate difficulty. Sleep 
occasionally disturbed. 
Grade1B : Only able to carry out house work or job with great difficulty. Sleep 
frequently disturbed. 
Grade2A : Continued to chair (or) bed, but also to get up with moderate 
difficulty. Sleep disturbed, with little or no relief from inhaler. 
Grade2B : Confined to chair or bed and only able to get up with great difficulty 
Unable to sleep. Pulse over 120/min  
Grade 3 : Totally confined to chair or bed. No sleep. No relief from inhaler. 
Pulse over 120/min. 
Grade 4 : Immobilized and completely exhausted. 
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2.4.6.DIAGNOSIS AND INVESTIGATION 
An account of episode wheeze, breathlessness interpreted with period of 
normality is sufficient evidence to suspect asthma and further evidence comes from a 
history or marked variability, attacks in small hours of the night, provocation by 
strong exercise and allergens and paroxysmal cough, productive small amount of 
sticky sputum. 
CONFIRMATION OF THE DIAGNOSIS 
PULMONARY FUNCTION TESTS 
Pulmonary function tests are a broad range of tests that measure how well the 
lungs take in and exhale air and how efficiently they transfer oxygen into the 
blood.Pulmonary function tests (PFTs) are non invasive diagnostic tests that provide 
measurable feedback about the function of the lungs. By assessing lung volumes, 
capacities, rates of flow, and gas exchange, PFTs provide information that help to 
evaluated and diagnosis certain lung disorders. They may not be able to detect early 
stages of the diseases in which function has not been appreciably reduced.  
TESTING FOR VENTILATOR CAPACITY:  
The simplest test of dynamic ventilatory function is the tests of forced 
expiration. A spirometer is used for this test, and the procedure is called spirometery. 
Nowadays, computerized spirometery is available which gives a print out of the data, 
as well as the predicted value. 
LUNG VOLUMES AND CAPACITY 
 In normal quiet breathing there are about 15 complete respiratory cycles per 
minute. The lungs and air passages are never empty and as the exchange of gases take 
place only across the wall of the alveolar ducts and alveolar. The remaining capacity 
of the respiratory passages is called the anatomical dead space (about 150ml).  
TIDAL VOLUME 
The volume of air breathed in and out of lungs in a single  normal quite  
respiration.It signifies the normal depth of breathing .Normally it is about 500ml. 
INSPIRATORY RESERVE VOLUME 
It is an additional amout of air that can be inhaled into the lungs after the end 
of normal inspiration beyond the tidal volume.Normal value is 3300ml. 
EXPIRATORY RESERVE VOLUME 
Maximal volume of air which can be expired out forcefully after the expiration 
of a tidal volume or normal  breath. It is about 1000ml . 
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RESIDUAL VOLUME 
 The volume of air remaining in the lung seven after forced expiration.Itcannot 
be measured by spirometry.It is significant because it help to aerate the blood in 
between breathing and expiration.It is about 1200ml. 
LUNG CAPACITIES:  
 Four lung capacities are recognized and each includes two or more lung 
volume. 
INSPIRATORY CAPACITY (IC): 
It is the maximum volume of air that can be inspired by forced inspiration 
after a normal expiration. 
IC  =  TV+IRV                           (500+3300=3800ml) 
 VITAL CAPACITY (VC): 
It is the maximum amout of air that can be expelled by a forced expiration 
after a maximum inspiration. 
VC= IRV + TV + ERV (3300+500+1000=4800ml) 
FUNCTIONAL RESIDUAL CAPACITY (FRC):  
             It is the volume of air remaining in lung at the end of a normal expiration. The 
FRC is physiologically very important. If there is no FRC and the lung is completely 
emptied during each respiratory cycle, the alveolar PO2& PCO2 will vary widely 
during breathing and will interfere with diffusion of respiratory gases.  
FRC  = ERV + RV           ( 1000+1200=2200ml ) 
TOTAL LUNG CAPACITY (TLC): 
 The amount of air present in the lungs after a maximal(deep) inspiration. 
TLC=IRV+TV+ERV+RV       (3300+500+1000+1200 = 6000 ml) 
ALVEOLAR VENTILATION 
This is the volume of air that moves into and out of the alveoli per minute. It is the 
tidal volume minus the anatomical dead space, multiplied by the respiratory rate. 
   Alveolar ventilation = (TV-anatomical dead space) respiratory rate 
     = (500-150) ml x 15 per minute = 5.25liters / minute. 
Lungs function tests are carried out to determine respiratory function and are 
based on the parameters out lined above.  
Spirometry : 
There are many types of spirometry available and all record similar 
information.  A spirometry test measures the volume of air that you are able to expel 
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from the lungs after taking a full breath in.The normal forced vital capacity (FVC) is 
fully exhaled in less than 3 seconds more than three quarter is exhaled in the first 
second. In addition to measuring the vital capacity in liters, volume expired in first 
second of the first second or first expiratory volume at 1 second (FEV1) can be 
measured and the ratio of FEV1 : FVC can be calculated. The results are compared 
with predicated values based on age height and ethnic group. FEV1/FVC ratio is 
normally greater than 70%. 
 If diffuse airflow obstruction is present, the rate at which the air can be 
exhaled is diminished throughout expiration. The length of expiration is prolonged 
and FEV1 is much reduced. This is an obstruction pattern and is seen in as time, 
chronic bronchitis and emphysema. In patients with asthma this obstruction may be 
reversible with bronchodilators or even corticosteroids.In a restrictive pattern, there is 
a reduced lung volume, perhaps as a result of pulmonary fibrosis or that wall 
deformity but there is no obstruction to airflow and FEV1 in normal. 
Peak Expiratory Flow Meter 
It is a popular instrument for assessing airflow obstruction there is a cheap, 
simpler version called the mini peak flow meter which is suitable for use at home by 
individual patients. Those machines measure the maximal rate of flow which is 
achieved during a forced expiration and most healthy people will achieve values of 
greater than 400 liters/min. 
  Patients with lung fibrosis and restriction changes on the spirogram may also 
have normal expiratory flow rates so the meter is not suitable for assessment of their 
disability. Patients with airflow obstruction will have reduced flow rates, which 
values below 200 liters/min being very significant and those below 100 liters/min 
extremely severe. 
Flow Volume Curves : 
The plotting of flow versus volume during both maximal expiratory and 
inspiratory maneuvers is of major help in differentiating central airflow obstruction 
(leading to stridor)   from diffuse airflow obstruction as seen in COPD and Asthma. 
Lung Volumes : 
 Measurement of total lung capacity and residual volume is best performed 
using a whole body plethysmograph, but can be measured by a helium dilution 
method. In general, restrictive lead to reduced values, and obstructive defects to 
increased values. 
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Measurement Of Diffusing Capacity: 
The diffusing capacity (DLCO) is a measure of lung’s ability to transfer gas 
from alveoli to blood. The test utilized of carbon monoxide from a single breath of  
0.3 %  mixture in air, this gas is chosen because it combines rapidly with hemoglobin 
and provides a true estimate of diffusion across the alveolar capillary membrane. The 
diffusing capacity is reduced in patients with disease principally affecting alveoli such 
as fibrosing alveoli is or emphysema. The Transfer Coefficient (KCO) is a measure of 
diffusing capacity expressed per volume of ventilated lung during the single breath 
test and is useful to confirm that low DLCO is due to alveolar disease rather than 
misdistribution of ventilation. High values of DLCO may be seen in alveolar 
hemorrhage. 
Arterial Blood Gases and Oximetry: 
Measurement of hydrogen ion concentration PaO2 and PaCO2, derived 
bicarbonate of arterial blood are essential in assessing the degree and type of 
respiratory failure and for measuring overall acid-base status. Use of a pulse oximeter 
allows a non-invasive continuous method of assessing oxygen saturation in patients 
who require continuous method of assessing oxygen saturation in patients who 
required continuous monitoring in order to assess hypoxemia and its response to 
therapy, including supplemental oxygen. 
Exercise Tests: 
Formal exercise testing with measurement of metabolic gas exchange and 
respiratory and cardiac response using cycle aerometry or treadmill exercise is useful 
in providing a detailed analysis of both pulmonary and cardiac function in the 
breathless patients. Exercise challenge with measurement of spirometry before and 
after can also be helpful in demonstrating exercise – include asthma. Finally, the 6 
minute walk test or‘shuttle’ test can provide a simple but adjective assessment of 
disability and response to treatment. 
Skin Hypersensitivity Test 
A prick is made in the skin with a fine needle through a drop of an aqueous 
extract of the substance to be tested. A positive reaction is indicated by the 
development of a wheal and flare, which begins to appear within few minutes. Tests 
are usually performed with a group of common allergens knows to cause bronchial 
asthma. It is seldom possible with these tests to identify the one particular allergens as 
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the causes of asthma are an individual patient and their chief value is to distinguish 
atopic from non-atopic subjects. 
Physical signs of the chest : 
During an attack of asthma, the following signs are detectable. Respiratory 
rate is increased with the use of accessory muscles of respiration. Hyper – resonant 
percussion note over the lungs. Breath sounds are vesicular in character with 
prolonged respiration. Numerous high pitched polyphonic expiratory and inspiratory 
rhonchi are audible.During very severe attacks the airflow may be insufficient to 
produce rhonchi. This results in a ‘Silent Chest’ which is an ominous sign. In between 
attacks the chest is clear and no abnormal physical signs may be detectable. Chronic 
asthmatics usually have some scattered rhonchi persisting always in their chest. 
Radiology Examination 
In an acute attack of asthma, the lungs appear hyper inflate. Between episodes 
the chest x-ray is usually normal. In long standing case, the appearance may be 
indistinguishable from hyper-inflation caused by emphysema and a lateral view may 
demonstrate a ‘pigeon chest’ deformity. Occasionally when a large bronchus is 
obstructed by tenacious mucus, there is opacity caused by lobar of segmental 
collapse.A chest x-ray should be performed if possible in all patients with severe 
acute asthma to exclude pneumothorax a rate but potentially fatal complication of the 
pulmonary hyper – inflation produced by severe airflow obstruction in asthma. The 
chest x-ray show meditational and subcutaneous emphysema in very severe disease. 
Sputum Examination 
Sputum eosinophilia is useful indication of an asthmatic type of airway 
reaction. Stained section of sputum fixed in alcohol or formalin is probably severe 
indication of asthma than a sputum eosinophil count. This is useful for the 
demonstration of aspergillums fumigates. Eosinohhils are a prominent feature of the 
inflammatory exudates within the airway lumen lies a thick tenacious mucus which 
under the microscope is seen to contain strips of desquamated epithelial cells 
(Curschman’s spirals) eosinophils, isolated metaplastic epithelial cels (Creola 
bodies) & crystalline materials consisting largely of major basic protein derived from 
eosinophilic granules. (charcot – leydon crystals). 
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2.4.7. COMPLICATIONS 
Mortality is uncommon in asthma but a severe attack may result in respiratory 
failure and death.This is more in 'status asthmaticus'. Other complications include 
frequent respiratory infection, pulmonary collapse due to obstruction by viscid 
secretions, pneumothorax, and emphysema and cough fracture (fracture of ribs due to 
violent coughing), children with asthma may show retardation of growth, especially if 
toiled with corticosteroid on a long term basic. Long standing bronchial asthma, 
punctured with frequent expiratory infections may lead to emphysema and chronic 
corpulmonale. 
 
2.4.8.DIFFERENTIAL DIAGNOSIS 
1.Vocal Cord Dysfunction : 
           Vocal cord dysfunction may exist alone or with asthma, it is caused by 
paradoxical adduction of the vocal cords during inspiration, and may disappear with 
panting, speech, or laughing. Patients with chronic symptoms suggestive of asthma, 
normal spirometry, poor response to asthma medications, and frequent evaluations 
should be evaluated for vocal cord dysfunction. Usually, the diagnosis can be made 
using direct laryngoscopy, but only during symptomatic periods or after exercise. The 
presence of flattening of the inspiratory limb of the flow-volume loop may also 
suggest vocal cord dysfunction, but this is only seen in 28% of patients at baseline. 
2.Tracheal and Bronchial Lesions  
A variety of airway tumors are reported to manifest with symptoms similar to 
those of asthma. These tumors include endobronchial carcinoid and mucoepidermoid 
tumors and other tracheal lesions can include bronchocentric granulomatosis, 
subglottic stenosis, subglottic web, tracheal hamartoma, bronchogenic cysts, 
leiomyoma, and tracheobronchopathia osteoplastica. All these types of tracheal 
lesions have been reported with symptoms similar to asthma.  
Persistent wheeze localized to one area on the chest in associated with paroxysms of 
coughing indicates the bronchial diseases, such as foreign body aspiration  
3. Congestive Heart Failure  
 Congestive heart failure causes engorged pulmonary vessels and interstitial 
pulmonary edema, which reduce lung compliance and contribute to the sensation of 
dyspnea and wheezing. Cardiac asthma is characterized by wheezing secondary to 
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bronchospasm in congestive heart failure, and it is related to paroxysmal nocturnal 
dyspnea and nocturnal coughing. 
4. Pulmonary Migraine  
 Pulmonary migraine consists of combined recurrent asthma; cough with thick 
mucoid sputum; lower back pain radiating to the shoulder; subtotal or total atelectasis 
of a segment or lobe; and, occasionally, nausea with vomitingThe symptoms are often 
accompanied closely in time by focal headache. Spastic narrowing of the bronchi is 
postulated—along with retained mucous secretions, smooth muscle hypertrophy, and 
thickened bronchial walls—to cause expiratory collapse of selected airways. Cerebral 
and abdominal vascular migraine episodes are believed to accompany pulmonary 
migraine. 
5. Chronic Bronchitis  
In chronic bronchitis, there are no true symptom –free periods and one can 
usually obtain a history of chronic cough and sputum production as a background 
upon which acute attack wheezing are superimposed. Frequently patients with this 
condition will present the episode of breathlessness particularly on exertion and they 
sometimes wheeze. 
6. Pulmonary Tuberculosis 
 Pulmonary tuberculosis affects generally all age group.It may be precipated by 
infection of Mycobacterium tuberculosis.Symptoms of tuberculosis coughing that 
lasts three or more weeks, haemoptysis,hard, thick, tenacious sputum, chest pain or 
pain with breathing, loss of weight, fatigue ,fever( evening rise of temperature),night 
sweats and chills.On inspection affected side of  the chest flattened and displaced, 
apical  impulse deviated in  the side of lesion, clubbing of fingers also present. On 
palpation movement of chest is diminished in affected side, vocal fermitus  is 
diminished but increased in consolidation, lymphadenopathy is  also noted. On 
percussion dull note is noted in the apex, other areas may have impaired note. On 
auscultation breath sounds are bronchial in nature with early wheezing, late crackling 
rales, diminished vocal resonance in early  stage and it is increased in later conditions. 
7. COPD:  
Chronic Obstructive Pulmonary Disease affects the most of the older people 
Patients with known history of smoking, exposure to pollution and no history of 
allergy and corpulmonale. Symptoms of COPD - Cough can be dry or with phlegm, 
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shortness of breath or wheezing present.Patients may be fatigue or inability to 
exercise.  
2.4.9.PROGNOSIS 
The prognosis of the individual attack is good, except in severe acute asthma, 
when there is occasionally a fatal outcome, especially if treatment is inadequate of 
delayed. Spontaneous remission is fairly common in episodic asthma, particularly in 
children, but rare in chronic asthma, which can lead to irreversible airflow 
obstruction. Seasonal fluctuation can occur in both types of asthma. Atomic subject 
with episodic asthma are usually worse in the summer, when they are more heavily 
exposed to antigens, while chronic asthmatics are usually worse in winter months, 
because of the increased frequency of viral infections. 
2.4.10. PREVENTION 
Avoidance of allergens 
There are few instances, in which a single agent can be identified as the cause 
for attacks of asthma. These allergens include grass pollens, mites, animal dander, 
drugs, industrial chemicals such as isocyanates and certain articles of diet. The 
majority of patients are hypersensitive to a wide range of allergens and attempts to 
avoid all of them are impracticable. 
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CHAPTER-III 
MATERIALS AND METHODS 
3.1 STUDY AREA AND SETTING   
The study period was covered from June 2017 to July 2019 at the Govt. 
Siddha Medical College and Hospital, Palayamkottai- 627 002, Tirunelveli, Tamil 
Nadu. All procedures were carried out after getting the permission from Institutional 
Ethical Committee(GSMC-IV-IEC/2017/Br.-I/09/29.05.2017).  
3.2 STUDY DESIGN 
 The study design is a prospective open labelled Phase-II  non- randomized  
clinical trial . The selected subjects were newly diagnosed or already diagnosed as 
bronchial asthma patients  with or without taking treatment.  A written informed 
consent form was recruited in the study. The purpose of the study was explained to 
the patients before administration of trial drug.  The patients information, life style, 
anthropometric measurements and siddha parameters were recorded before starting 
the treatment.   
 The total number 40 patients of either sex and aged between 20 to 60 were 
taken for  this study. The selected patients were treated with the trial drug for the 
entire study period (30 days).  
3.3 SELECTION OF PATIENTS 
Patients who reported with symptoms of inclusion criteria in P.G Dept of 
Pothu Maruthuvam, GSMC, Palayamkottai was subjected to screening test and 
documented using screening proforma. Details like personal history, family history, 
occupation, habits, clinical symptoms, medical history, and the duration of illness 
were recorded in all patients (Proforma annexed).  
3.3.1 Inclusion Criteria 
1)   Age 20 to 60 yrs. 
2)   Sex: Both male and female . 
3)  Patient with the symptoms of  
• Difficulty in breathing, 
• Tightness of chest, 
• Wheeze - Added sound  (Rhonchi),  
• Cough with or without expectoration. 
4)  H/o allergy, sneezing. 
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5) Patients who are willing to take radiological investigation and provide  
      blood for lab investigation. 
6) Patients who are willing to estimate volume of air forcibly expired after a 
deep inspiration by using Mini-Peak flow meter and PEFR below normal 
range from 250L/min to 150 l/min for men, from 200L/min to 100 L/min 
for women,for those patients are included.   
 [Normal range of PEFR: 
     Male: young adult: 400-650 L/min; Above 40 yr: 300-500L/min 
 Female: young adult: 250-450L/min; Above 40 yr: 200-400L/min] 
7) Patients who are willing to take spirometer study to estimate Lung Function 
Test (LFT) to confirm the major airway diseases. 
3.3.2.Exclusion Criteria 
01. Cardiac disease 
02. Renal disease 
03. Tuberculosis 
04. COPD 
05. Status asthmaticus 
06. Diabetes mellitus 
07. Hypertension  
08. Pregnancy 
09. Lactating Mothers 
 10.Autoimmunediseases 
WITHDRAWAL CRITERIA 
 Intolerance to the drug & development of adverse reactions during drug trial     
 Poor patient compliance & defaulters 
 Patient turned unwilling to continue in thecourse of clinical trial 
 Occurrence of any serious illness 
3.3.3 DIAGNOSIS 
The Siddha diagnostic procedures included in this study were,               
• Poriyalarithal 
• Pulanalarithal 
• Vinathal 
• Mukkutra nilaigal 
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• Envagai thervugal 
• Nilam 
• Kaalam & Udal kattugal 
TESTS AND ASSESSMENT  
A. Clinical assessment 
B. Routine investigations 
C. Specific investigations 
D. Siddha investigations  
A. CLINICAL ASSESSMENT  
 Dry or protective Cough 
 Dyspnoea 
 Wheezing 
 Tightness of chest 
 Sneezing ,Rhinorrhoea 
 Hoarseness of voice 
Evaluation visits made at baseline and 1st, 10th, 15th, 20th and 30thdays. Effect 
of treatment was evaluated on the basis of changes in the signs and symptoms after 
the treatment.  
3.3.4.INVESTIGATION 
Following investigations was carried out before treatment and on 30th day after 
commencement of treatment. 
BLOOD  
 Hb (gm/dl )            
 Total WBC Count (Cells/cumm)      
 DC-  Polymorphs(%)        
 Lymphocytes(%)         
 Eosinophils(%)          
 Monocytes(%)      
 Basophils (%)      
 Total RBC count(Million cells / cumm)  
 ESR(mm/hr)       
 Blood glucose( mg/dl):  (Fasting)&(Post – prandial)  
 Blood urea(mg/dl)     
 AEC (Absolute Eosinophil Count)  
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URINE 
 Urine sugar (F)&(PP) 
 Albumin 
 Deposits 
MOTION 
 Ova  
 Cyst 
 Occult blood 
SPUTUM - AFB 
OTHER INVESTIGATION 
 X Ray Chest (PA view) 
 ECG 
SPECIFIC INVESTGATIONS 
 PEFR (Peak Expiratory Flow Rate) [L/min] 
 Spirometry Study 
3.4. Preparation of Trial Medicine (Annexure-I) 
All the patients were treated with the following medicine,  
• Jaathipalathi chooranam – 30mg/kg/bw thrice day with honey after food 
(internally) was given for 30 days till the end of the course.  
• Reference book -Sarabendhra  Vaithiya  Muraikal- Kasa Swasa Roga Sikicha, 
Vasudevasasthri,  and Venkadarajan,2006.page no:131,132. 
• All the patients were adviced to follow dietary regimen. 
3.5. Collection and authentication of TrialMedicine Annexure-VI (A) & VI (B) 
The raw drugs for Jaathipalathi Chooranam were purchased from Nagercoil 
based   Siddha medical shop and the herbal drugs were authenticated by medicinal 
botanist & Gunapadam experts at Govt. Siddha Medical College, Palayamkottai-
627002.  Mineral drug was authenticated by head and professor, Dept. of Chemistry,  
Sadakathullah Appa College, Rahmath nager, Tirunelveli-627011. 
3.6. Preclinical Analysis of Trial Medicine 
                All the preclinical studies of the trial drug including bio-
chemical,phytochemical, anti-microbial,   pharmacological  and toxicological studies 
were done and results were cross checked before starting the treatment. The 
biochemical analysis was carried out in Dept. of Biochemistry, GSMCH, 
Palyamkottai.  
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  Relevant pharmacological activities (anti-histamine, bronchodilator, anti-
inflammatory actions) phytochemical and toxicological analysis  were studied in this 
study. Studies were executed in  K.M. College of Pharmacy, Madurai -625107.  
3.7. Ethical Review 
The study was conducted in accordance with the ethical principles that are 
consistent with Good Clinical Practice guidelines and prior approval was obtained 
from the Institutional Ethics Committee of GSMCH, Palayamkottai (GSMC-IV-
IEC/2017/Br.-I/09/29.05.2017) (Annexure- IV) and Institutional animal ethical 
committee (IEAC) of K.M. College of Pharmacy, Madurai 
(TNMGRMU/KMCP/IEAC/28/2018) (Annexure- V)  before starting the trial. The trial 
was submitted and got enrolled in Clinical Trial Registry of India with the allotment 
number as CTRI/2018/03/012772 registered on: 22/03/2018 (Annexure- VII). Trial 
was registered prospectively as per the norms. 
3.8. Study Enrollment   
Participants were informed in Tamil language, regarding the trial, the expected 
benefits and their right to opt-out of trial at any time without prejudice.  Informed 
written consent was obtained from each participant, prior to his/her inclusion into the 
trial. In this clinical trial, patients who reported at the Pothu Maruthuvam, Govt 
siddha medical college and Hospital, Palayamkottai with clinical symptoms of rhinitis 
for short period, difficulty in breathing due to chest tightness, cough, sneezing was 
examined clinically for enrolling in the study based on the inclusion and exclusion 
criteria. 
           The subjects with history of serious adverse effects or hypersensitivity 
reactions to the medication such as rashes, diarrhoea, vomiting etc., and history of 
treatment with other anti-hyperglycaemic drugs, active liver disease or hepatic 
dysfunctions, higher serum creatinine (> 2.5 mg/dl) and serious or unstable medical or 
psychological condition were excluded from the study.   
           During the visit body weight, blood pressure, cardiovascular, neurological and 
respiratory system were clinically recorded. In case of any adverse reaction or side 
effects of patients, it would be informed to pharmacovigilence committee 
immediately. At the end of the study period, all the patients were instructed to follow 
diet control, regular exercise,  meditation and to monitor relevant parameters.They 
were also advised to pursue the further treatment in the PG, Pothu Maruthuvam OP 
for the follow up study. 
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3.9. Statistical Analysis  
All data were analysed using the SPSS 20.0 (IBM). Data were expressed as 
means and standard deviation. The significance of the difference between the means 
of the baseline and the final examinations was tested using the paired “t” test. A 
probability value of <0.05 was considered to be statistically significant. 
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CHAPTER - IV 
OBSERVATION AND RESULTS 
4.1.PRECLINICAL  STUDY : 
4.1.1.BIO-CHEMICAL ANALYSIS OF “JAATHIPALATHI CHOORANAM” 
Preparation of the extract:  
 5gm of the drug was weighed accurately and placed in a 250ml clean beaker 
then 50ml of distilled water was added and dissolved well followed by boiling for 
about 10 minutes. It was cooled and filtered in a 100ml volumetric flask and  made 
into 100ml with distilled water.  This fluid was taken for analysis. 
Table.4.1.1.BIO-CHEMICAL ANALYSIS OF “JAATHIPALATHI 
CHOORANAM” 
S.No EXPERIMENT OBSERVATION INFERENCE 
01 
TEST FOR CALCIUM 
2ml of the above prepared extract is 
taken in a clean test tube. To this add 
2ml of 4% Ammonium oxalate solution 
A white 
precipitate was 
formed 
presence of 
Calcium 
02 
TEST FOR SULPHATE 
2ml of the extract is added to 5% 
Barium chloride solution. 
No white 
precipitate was 
formed 
Absence of 
Sulphate 
03 
TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution 
No white 
precipitate was 
formed 
Absence of 
Chloride 
04 
TEST FOR CARBONATE 
The substance is treated with 
concentrated Hcl. 
No brisk 
effervescence was 
formed 
Absence of 
Carbanate 
05 
TEST FOR STARCH 
The extract is added with weak iodine 
solution 
Blue colour was 
formed 
presence of 
Starch 
06 
TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro cyanide. 
No blue colour 
was formed 
Absence of 
ferric Iron 
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07 
TEST FOR FERROUS IRON  
The extract is treated with concentrated 
Nitric acid and Ammonium thiocyanate 
solution 
Blood red colour 
was formed 
presence of 
ferrous Iron 
08 
TEST FOR PHOSPHATE 
The extract is treated with Ammonium 
Molybdate and concentrated nitric acid 
No yellow 
precipitate  was 
formed 
Absence of 
Phosphate 
09 
TEST FOR ALBUMIN 
The extract is treated with Esbach’s 
reagent 
No yellow 
precipitate  was 
formed 
Absence of 
Albumin 
10 
TEST FOR TANNIC ACID 
The extract is treated with ferric 
chloride. 
Blue black 
precipitate was 
formed 
presence of 
Tannic acid 
11 
TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract 
It gets 
decolourised 
presence of 
unsaturated 
compound 
12 
TEST FOR THE REDUCING 
SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil 
for 2 minutes and add 8-10 drops of the 
extract and again boil it for 2 minutes. 
Colour change 
occurs 
presence of 
Reducing 
Sugar 
13 
TEST FOR AMINO ACID 
One or two drops of the extract is placed 
on a filter paper and dried well. After 
drying, 1% Ninhydrin is sprayed over 
the same and dried it well. 
Violet colour was 
formed 
presence of 
Amino acid 
14 
TEST FOR ZINC 
The extract is treated with Potassium 
Ferro cyanide. 
No white 
precipitate was 
formed 
Absence of 
Zinc 
 
Inference:  
Biochemical analysis of Jaathipalathi Chooranam revealed the presence of 
Calcium,  Starch, Ferrous Iron, Tannic acid, Unsaturated compounds, Reducing sugar  
and amino acids, No toxic chemicals was found in this analysis. 
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4.1.2PHYTOCHEMICAL  ANALYSIS  FOR  JAATHIPALATHI  CHOORANAM(Tab.4.1.2) 
S.No PHYTO CHEMICALS TESTS INFERENCE 
I ALKALOIDS 
  1.Mayer’s test Positive 
2.Dragendroff’s test Positive 
3.Hager’s test Positive 
II CARBOHYDRATES & GLYCOSIDES 
 
 1.Molisch test Positive 
2.Legal’s test Positive 
3.Borntrager’s test Positive 
III PHYTOSTEROLS 
 1.Liebermann-Burchard test Positive 
2.Salkowski test Positive 
IV FLAVANOIDS 
 
 
 
 
1.Shinoda test Positive 
2.Magnesium turnings &HCL Positive 
3.Fluorescence test Positive 
V TANNINS 
  1.Ferric chloride test Positive 
2.Potassium dichromate test Positive 
3.Lead acetate test Positive 
VI PROTEINS 
  1.Millon’s test Positive 
2.Biuret test Positive 
3.Ninhydrin test Positive 
VII FIXED OILS AND FATS 
  1.Spot test Positive 
2.Saponification test Positive 
VIII LIGNIN 
  1. Phloroglucinol test Positive 
IX SAPONINS 
  1.Frothing test Negative 
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The phytochemical screening of poly herbal formulation JPC  showed the 
presence of alkaloids, carbohydrates, glycosides, phytosterols, flavonoids ,tannins,   
protein, fixed oil & fat  and lignin, which has medicinal value and can be used for 
various diseases. 
4.1.3.ANTI –MICROBIAL ANALYSIS  OF JAATHIPALATHI CHOORANAM 
Table.4.1.3. Anti –Microbial Analysis  of Jaathipalathi Chooranam 
Sample 
Code 
Bacteria  Strains Name 
Staphylococcus 
aureus (G+) 
Streptococcus 
mutans (G+) 
Bacillus 
subtilis(G+) 
Klebsillae 
pneumonia 
E – coli  
(G-) 
AC 7 11 8 10 10 
PC 27 17 14 28 18 
NC - - - - - 
 
Keys 
PC        -     Positive Control (Streptomycin) 
NC      -    Negative Control 
- -       No Zone 
Mm     -    Millimetre 
G+      -   Gram Positive Organism 
G-       -   Gram Negative Organism 
Trial drug showed the anti microbial activity against both Gram 
positive(Staphylococcus aureus , Streptococcus mutans, Bacillus subtilis) and Gram 
negative bacteria ( Klebsiella pneumonia, and E.coli) 
4.1.4. ANTIHISTAMINIC AND ANTIANAPHYLACTIC ACTIVITY: 
1.Mast cell stabilizing activity 
Inbred Wistar rats (175–200 g) and guinea pigs (400–600g) of either sex 
housed in standard conditions (temperature22 ± 2° C, relative humidity 60 ± 5% and 
12 h light/dark cycle) were used. They were fed with standard pellet diet and water ad 
libitum. The Institutional Animal Ethics Committee approved the experimental 
protocol. 
 
 
 
                       FIGURES :4.1.3. ANTI –MICROBIAL ANALYSIS  OF  
 JAATHIPALATHI CHOORANAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
      Figure 4.1.3.a. Staphylococcus aureus 
      Figure 4.1.3.b.   Streptococcus mutans 
      Figure 4.1.3.c.  Bacillus subtilis 
      Figure 4.1.3.d.  Klebsiella pneumoniae 
      Figure 4.1.3.e.  E.coli 
 
 
 
Figure 4.1.3.a. 
   Figure 4.1.3.b 
Figure 4.1.3.c    Figure 4.1.3.d
   Figure 4.1.3.e 
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Treatment protocol  
 Twenty-four rats were divided into four groups of six animals in each group.  
Group I served as control and received vehicle (water). 
Group II sensitized control group 
GroupIII served as the treatment control, which was treated with Jaathipalathi  
chooranam at a dose of 100mg/kg body weight, in oral route. 
Group IV served as the treatment control, which was treated with Jaathipalathi 
chooranam at a dose of 200 mg/kg body weight, in oral route. 
  In group II to group 1V were sensitized by injecting 0.5 ml of horse 
serum subcutaneously along with 0.5 ml of triple antigen containing 20,000 million 
Bordetella pertussis organisms (Serum Institute of India Ltd.,Pune), Once a day for 14 
days.  
On day 14, the rats were sacrificed 2 h after the treatment and the intestinal 
mesentry was taken out for the study on mast cells. Mesentries along with intestinal 
pieces were excised and kept in Ringer Locke solution (NaCl 154, KCl 5.6, CaCl 2 .2, 
NaHCO3 6.0, Glucose 5.55 mM/L of distilled water) at 370C. The mesenteric pieces 
were challenged with 5% horse serum for 10 min after which the mast cells were 
stained with 1.0% toluidine blue and examined microscopically for the number of 
intact and degranulated mast cells. 
TABLE NO:4.1.4.1.EFFECT OF  JAATHIPALATHI CHOORANAM ON 
MAST CELL STABILIZATION IN SENSITIZED RATS 
• Values are expressed as Mean±S.E.M        
 
*a significantly different from sensitized control at p<0.01 
 
 
GROUPS 
                     MAST CELLS 
INTACT DISRUPTED 
Normal control 84.65±3.52 14.10±0.85 
Sensitized rats 13.10±0.90 86.58±2.66 
Jaathipalathi chooranam  100mg/kg 66.15±2.90*a 35.22±1.38*a 
Jaathipalathi chooranam  200mg/kg 63.60±2.55*a 35.90±1.45*a 
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Statistical analysis 
The results of various studies were expressed as mean ± SEM and analyzed 
statistically using one-way ANOVA, followed by Newmann keul’s multiple range 
tests. P<0.05 was considered statistically significant.The analysis was performed 
using Graphpad Prism software package (Version 4.0). 
RESULTS 
 Mast cell stabilizing potential of  antigen challenge resulted in significant 
degranulation of the mesentric mast cells. Pretreatment of sensitized animals with 
Jaathipalathi chooranam at a dose of 100mg/kg and 200mg/kg, p.o., for 2 weeks 
resulted in a significant reduction in the number of disrupted mast cells (P <0.001) 
when challenged with horse serum. 
2.Histamine-induced bronchospasm in guinea pigs 
 
Bronchospasm was induced in guinea pigs by exposing them to 1% histamine 
aerosol under constant pressure (1 kg/cm2) in an aerosol chamber (24 × 14 × 24 cm) 
made of perplex Glass,of the three groups of six animals each. 
 
Group I       - served as control. 
GroupII      - served as the treatment control, which was treated with Jaathipalathi 
 chooranam at a dose of 100 mg/kg body weight, in oral route. 
Group III   - served as the treatment control, which was treated with Jaathipalathi   
 chooranam at a dose of 200 mg/kg body weight, in oral route. 
 The animals were exposed to 1% histamine aerosol under constant pressure (1 
kg/cm2) in an aerosol chamber on day 0 without any treatment. The end point,         
Pre Convulsive Dyspnea (PCD) was determined from the time of aerosol exposure to 
the onset of dyspnoea leading to the appearance of convulsions .As soon as PCD 
commenced, the animals were removed from the chamber and exposed to fresh air. 
This PCD was taken as day 0 value. On days 1 and 5,2 h after the administration of 
the drug, the time for the onset of PCD was recorded as on day 0. 
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Table 4.1.4.2.Effect of  Jaathipalathi chooranam   on histamine induced 
bronchospasm in guinea pigs. 
 
GROUPS 
 PRE-CONVULSION DYSPNEA (PCD)(SEC) 
DAY 0 DAY 1 DAY 5 
GP 1 176.45±7.35 263.20±9.4 220.38±9.4
 
GP 2 ( JPC -100mg/kg) 183.22±6.38 220.35±6.2 415.28±13.2*a 
GP3 (JPC- 200mg/kg) 184.15±6.46 223.28±8.0 410.20±12.8*a 
 
Values are expressed as Mean ±S.E.M 
*a significantly different from control on day 5 at p<0.001 
Effect on histamine-induced bronchospasm 
Jaathipalathi chooranam at a dose of 100mg/kg and 200mg/kg p.o., 
significantly prolonged the latent period of PCD (P <0.001) as compared to control, 
following exposure to histamine aerosols on day 5 [Table no.4.1.4. 2]. 
This antianaphylactic and antihistaminic effect may be caused by the 
stabilization of the mast cell membrane, suppression of IgE, and inhibition of 
pathological effects induced by the release of inflammatory mediators in Jaathipalathi 
chooranam treated animals. All the above findings lend credence to the beneficial use 
of Jaathipalathi chooranam in the treatment of asthma and related conditions. 
4.1.5.BRONCHODILATOR ACTIVITY  
1.Egg albumin induced anaphylaxis in guinea pigs 
Guinea pigs were sensitized by two intraperitoneal injections of 0.5 ml and 
10% w/v solution of egg albumin at a 48-h interval. After sensitization, the animals 
were divided into two groups. Animals of group I received 0.5% CMC and served as 
control group. Animals of Group II received jathipalathi chooranam (200 mg/kg, p.o, 
once daily) dissolved in distilled water for 14 days. On day 14, two hours after 
treatment, the animals were challenged with 0.5 ml of 2% w/v solution of egg 
albumin into the saphenous vein. Guinea pigs were observed for the onset of 
symptoms such as dyspnoea and cyanosis, duration of persistence of symptoms (min.) 
and mortality. 
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Table No 4.1.5.1 : Effect of Jathipalathi chooranam on egg albumin induced 
anaphylaxis in rats. 
 
GROUPS 
PRE 
CONVULSION 
TIMEONSET 
 (MIN) 
DURATION  
 (MIN)  
 
 
SEVERITY 
(SCORE) 
PERCENT 
PROTECTION 
MORTALITY 
GROUP-1  
Normal Control 
 
1.212 ± 0.048  
 
 
9.4 ± 0.306 
 
22.15± 0.322                                           
 
70% 
GROUP-2 
Treatment Control 
JPC -200mg/Kg P.O 
 
2.905±0.090* 
 
7.048±0.118* 
 
2.9 ± 0.608* 
 
0% 
 Values are expressed as Mean± S.E.M. 
Values are significantly different from normal control at P<0.05 
2.Bronchodilator effect 
Guinea pigs of either sex weighing 350 - 500 g were selected and randomly 
divided into four groups each containing four animals. The drugs were dissolved in 
distilled water and administered orally through intubation canula. The single dose 
treatments were given one and half an hour before the study. Group I was 
administered 0.5% CMC (control), Group II: Mepyramine melate (10 mg/kg= 0.1% 
Soln.) (standard),Group III: Jaathipalathi chooranam (100 mg/kg), Group IV: 
Jaathipalathi chooranam (200 mg/kg). 
  One and half hour later the animals were exposed to 0.2% histamine aerosol 
and time for Pre Convulsion Dyspnoea state(PCD) was noted for each animal. The 
end point for PCD was determined from the time of aerosol exposure to the onset of 
dyspnea leading to the appearance of convulsions. As soon as PCD commenced, the 
animals were removed from chamber and placed in fresh air to recover. This time for 
PCD was taken as day 0 value. After 15 days of wash out period, the animal of group 
III,&  IV, were again given same schedule of drug and exposed to histamine aerosol 
and the time for PCD was noted. The % increase in time of PCD was calculated using 
the following formula. Percentage increase in time of PCD = 1 – T1/T2 X 100 Where: 
T1= time for PCD onset on day 0, T2 = time for PCD onset on day 15. 
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Table No 4.1.5.2 : Effect of Jaathipalathi chooranam on histamine-aerosol in 
guinea pigs 
TREATMENT DOSE  
(mg/kg BW) 
ONSET OF 
CONVULSION 
IN SEC. 
PROTECTION 
(%) 
INCREASE IN  
PRE 
CONVULSION  
TIME (%) 
Control Saline,10 
ml/kg 
91.52+0.098 0 0 
Mepyramine 10mg/Kg 1030.0 + 4.525 90*** 33.90+ 3.15 
 
JPC 
 
100mg/kg 
 
805 + 0.390 
 
80** 
 
27.80+ 3.92*** 
 
JPC 
 
100mg/kg 
 
855 +0.670 
 
86*** 
 
36.20+ 3.75*** 
 
n=6 in each group; **P < 0.01, ***P < 0.001 vs. control 
3.Assessment of Anti-histaminic activity of Jaathipalathi chooranam on Isolated 
Guinea Pig ileum 
 Overnight fasted guinea pigs of either sex weighing 400 - 600 g were 
sacrificed using cervical dislocation method. The lower most 10cm of ileum was 
removed from the abdomen and placed in a shallow dish containing warm Tyrode 
solution. Ileum lumen was cleaned by passing through warm 0.9% saline and then 
segments about one inch in length, were made. The mesentric attachment and blood 
etc. were carefully cleaned and the tissues was mounted in a thermostatically 
controlled Dale’s organ bath (temp. 37+ 0.50 C) containing 20 ml Tyrode’s solution 
under basal tension of 500mg.  
 The composition of solution in mm was NaCl, 137; CaCl2, 1.8; KCl, 2.7; 
glucose, 5.55; NaHCO3, 11.9; MgCl2, 1; NaH2PO4, 0.4. The solution was 
continuously bubbled with air. The responses to drug were recorded on a Student 
physiograph (Bio Devices) using isotonic transducer, which exerted a basal tension 
equivalent to 500 mg load on tissue. The issue was allowed to equilibrate for 30 min, 
during which, the bathing solution was changed at every 10 min. Increasing 
concentration of histamine were added to the bath and the control cumulative 
concentration- response curve was constructed. 
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Table No 4.1.5.3 :Assessment of Anti-histaminic activity of Jaathipalathi 
chooranam on   Isolated Guinea Pig ileum. 
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0.1ml  
 
7.10  
 
32.59 + 1.020  12.60 + 1.562    
 
0.5mg   
 
20.92+ 2.30  
0.2ml 6.80 51.90±1.480 24.18 + 2.058 1.0mg 31.40±2.05 
0.4ml 6.50 78.30±2.028 36.25 + 1.022 10mg 43.10±1.28 
0.8ml 6.20 92.95±2.545 43.64 + 1.650 20mg 65.80±1.22 
1.6ml 5.90 99.60±1.048 52.30 + 1.240 50mg 83.80±1.45 
 
Values are expressed as mean±SEM (n=6). *p<0.05 when compared to control group, 
**p<0.05 when compared to standard group. 
Disscussion  
Pharmacodynamic Screening of Drug 
Screening the activity of drug on antiasthmatic parameters such as anti-
histaminic,  bronchodilator, effect to assess probable mode of action of drug shows 
that the drug possess anti-histaminic property. Brochodilation produced against 
histamine induced bronchoconstriction confirm the anti-histaminic activity of drugs.
 Egg induced anaphylactic response was significantly prohibited by the 
polyherbal drug and there is 0.00% mortality in group treated with siddha formulation 
Jaathipalathi chooranam drug against 70% mortality in control group (untreated 
group). The findings reveal protection against egg albumin induced anaphylactic 
shock characterized by decrease in intensity and delay in the development of 
symptoms of dyspnoea, asphyxia and collapse. In line with this notion, anti-
anaphylactic effect of Jaathipalathi chooranam may be due to inhibition of 
phenomenon of sensitization or non-availability of antibodies on the mast cell surface.  
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Conclusion: 
It can be concluded that siddha formulation Jaathipalathi Chooranam has 
potent antiasthmatic activity. It can be further concluded that these siddha formulation 
Jaathipalathi chooranam can be used as 'Therapeutic Agent' in the management of 
acute attack of Asthma as well as chronic persistent Asthma.  
4.1.6.Anti-inflammatory activity: 
1. Carrageenan induced paw edema assay  
Paw swelling or footpad edema, is a convenient method for assessing 
inflammatory responses to antigenic challenges and irritants.The Albino Wister rats 
(180 + 5g) were used. The rats were divided into 5 groups of 5 animals each. 
• Rats of group I were given normal saline and treated as negative control.  
• Rats of group II were treated with carrageenan (1%w/v) in saline in 
the sub-plantar region of the right hind paw.  
• Rats in group III were administered Indomethacin( 10 mg/kg, bw) and  
considered as standard.  
• Rats from group IV and V were given two doses siddha formulation 
 (100 and 200 mg/kg bw) respectively.  
Method: 
Acute paw edema was induced by injecting 0.1 ml of 1% (w/ Carrageenan 
solution, prepared in normal saline. After 1 h, 0.1 ml, 1 % Carrageenan suspension in 
0.9% NaCl solution was injected into the sub-plantar tissue of the right hind paw.The 
linear paw circumference will be measured at hourly interval for 4h.The perimeter of 
paw was measured by using vernier callipers.Measurements were taken at 0-4 h after 
the administration ofcarrageenan. 
The anti-inflammatory activity was calculated by using the relation 
  
 % inhibition of edema =  T-T0 x 100 
     T 
T= Thickness of paw in control group 
T0= Thickness of paw edema inthe test compound treated group. 
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Table 4.1.6.1. 
Effect of siddha formulation Jaathipalathi chooranamon Carrageenan Induced 
Rat Paw Edema. 
Treatment  
 
Dose (mg/kg, p.o.) 
 
Mean increase 
in paw volume 
(ml) 
% Decrease 
in Paw 
volume 
Normal control 10ml/kg saline 1.18 ± 0.14  
Toxic control 0.1 ml, 1% Carrageenan 3.62 ± 0.34*a  
Standard control 10mg/kg Indomethacin 1.24 ± 0.16*b 65.74% 
Treatment control 100mg/kg 
Jaathipalathi  chooranam 
1.38 ± 0.20*b 
 
61.87% 
Treatment control 200mg/kg 
 Jaathipalathi chooranam 
1.29 ± 0.18*b 
 
64.36% 
• Values are expressed as mean ± SEM. 
• Values were compared by using analysis of variance (ANOVA) followed 
by Newman-Keul's multiple range tests.   
• * (a) Values are significantly different from normal control G1 at P<0.01. 
* (b) Values are significantly different from Toxic  control G2 at  P<0.01. 
Results 
The results obtained indicate that the Jaathipalathi chooranam had significant 
anti-inflammatory activity in rats. The chooranam reduced  carrageenan  induced 
edema by 61.87% and 64.36% on oral administration of 100 and 200 mg/kg, as 
compared to the untreated control group.Indomethacin at 10 mg/kg inhibited the 
edema volume by 65.74%. 
2. Carrageenan Induced Pleurisy In Rats 
The animals were divided into five groups of five rats each as described in the 
carrageenan induced paw edema model and each were pretreated with siddha 
formulation (100 and 200 mg/kg. p.o.), Indomethacin (10 mg/kg, p.o.) or normal 
saline (0.1 ml).One hour laterall the animals were received 0.25 ml of an intra-pleural 
injection of carrageenan on the right side of the thorax.  
The animals were sacrificed 3 h after carrageenan injection by ether 
inhalation. One ml of heparinized Hank's solution was injected into the pleural cavity 
and gently massaged to mix its contents. The fluid was aspirated out of the cavity and 
the exudates were collected. The number of migrating leukocytes in the exudates was 
68 
 
determined with Neubauer chamber . The values of each experimental group were 
expressed as mean SEM and compared with the control group. 
 
Table 4.1.6.2. Effect of siddha formulation Jaathipalathi chooranam on 
Carrageenan Induced Pleurisy in Rats. 
Treatment  
 
Dose 
(mg/kg, p.o.) 
Pleural  
  Exudates  (ml) 
Leukocytes 
(×103 cells/ml) 
Normal control 10ml/kg saline 0.11±0.06 0.42±0.07 
Toxic control 0.1 ml, 1% carrageenan 0.50±0.21*a 4.26±0.40*a 
Standard control 10mg/kg Indomethacin 0.17±0.11*b 0.46±0.09*b 
Treatment 
control 
100mg/kg  
Jaathipalathi chooranam 
0.23±0.14*b 0.57±0.12*b 
Treatment 
control 
200mg/kg 
 Jaathipalathi chooranam 
0.19±0.12*b 0.51±0.10*b 
• Values are expressed as mean ± SEM. 
• Values were compared by using analysis of variance (ANOVA) followed 
by Newman-Keul's multiple range tests.   
• * (a) Values are significantly different from normal control G1 at P<0.01. 
  * (b) Values are significantly different from Toxic  control G2 at  P<0.01. 
Results 
The volume of pleural exudates in the toxic control group was 0.50+0.21 ml. 
Animals treated with the  Jaathipalathi chooranam (100 and 200 mg/kg, p.o.) 
decreased the pleural exudates to 0.23 ±0.10 ml and 0.19 ±0.12ml.Treatment with 
Indomethacin(10 mg/kg,p.o.) produced the exudates of 0.17+0.11 ml. The leukocyte 
count for the control group was found to be 4.26+0.40x103 cells/ml. Animals treated 
with the Jaathipalathi chooranam  and standard produced a leukocyte migration of 
0.57+0.12x103,0.51+0.10X103and 0.46+0.09X103cells/ml, respectively. 
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4.1.7.TOXICITY STUDY OF JAATHIPALATHI CHOORANAM 
Acute toxicity 
Female Wister albino rats weighing 180 ± 20 g were used in acute toxicity study. The 
total no of 18 animals were divided into three groups of six animals in this study. 
 The Group I animals were administered with a single daily dose of 0.5 ml of 
Tween 80 orally for 15 days. 
 In Group II are administered with (300 mg.kg-1b.w. JPC)  a day for 15 days.  
 The Group III are fed 2000 mg.kg-1b.w. once daily for 15 days for acute 
toxicity studies. 
HPE revealed no acute toxic symptoms were observed after 15 th day All test animals 
were subjected to gross necropsy. 
Table.4.1.7.1. Acute toxicity study of Jaathipalathi chooranam: 
Treatment Dose 
(mg.kg-1) 
Sign of Toxicity 
(ST.NB-1) 
Mortality 
(D.S-1) 
Group I 0 0/3 0/3 
Group II 300 0/3 0/3 
Group III 2000 0/3 0/3 
From the above table of Jaathipalathi chooranam on experimental rats were tested 
using OECD -423 guidelines, where ST-sign of toxicity ,NB- normal behaviour, D- 
died, S-survive. Values are expressed as number of animals (n=3).  
RESULTS 
• The acute toxicity of Jaathipalathi Chooranam  has showed no mortality and 
morbidity in animals through the 15-days period following single oral 
administration at all selected dose levels of the JPC (Table- 1). 
• The morphological characteristics and physical appearance of all animals 
seems to normal. The physical appearance and motor nervous system was 
normal.  
• On comparison,  Group I ,II and III showed no toxic effects for the doses upto 
2000/kg/bw. 
Sub-acute toxicity 
 The sub acute toxicity were performed in Male and female Wistar rats 
weighing 180 ± 10 g. The animals were divided into five groups of six animals each. 
The administration of dose is calculated based on the body weight of the animal. 
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 The animals in Group I were administered with a single daily dose of 0.5 ml of 
Tween 80 orally for 20 days.  
 The animals in Group II were administered with 50 mg.kg-1 b.w. of the JPC 
once in daily for 20 days. 
 The animals in Group III were administered with 100 mg.kg-1 b.w. of the JPC 
orally once daily for 20 days. 
 The animals in Group IV and V were administered 200 and 400 mg.kg-1 b.w. 
once in daily for 20 days. 
The animals were weighed during every five days starting from commencement of 
the study to record the weight variations. At the end of the treatment, blood samples 
were taken for biochemical analysis. The serum plasma was analyzed for 
 Total cholesterol 
 Total triglyceride 
 HDL-cholesterol levels 
 LDL-cholesterol 
 Plasma glucose 
 Alanine aminotransferase (ALT)  
 Aspartate aminotransferase (AST) 
 Creatinine and urea level. 
Effect of Jaathipalathi chooranam  (JPC) on internal organs 
 According table no 4.1.7.2.no toxic effects found in kidney, heart, liver and 
brain of the rats were observed. From the study it was clear that, significant (p<0.01) 
changes in the weights of various organs of the animals with higher doses of JPC (400 
mg.kg-1 bwt). The group I was compared with other group II, III, IV, and V.  
 
Table: 4.1.7.2. The effects of JPC on kidney, heart, liver and brain of the rats 
Treatment Heart (gms) Kidney (gms) Liver (gms) Brain (gms)   
Control 0.340± 0.05 0.60± 0.03 3.32± 0.05 0.67± 0.05 
JPC 50 mg.kg-1 0.31± 0.02 0.74± 0.03 3.44± 0.03 0.70± 0.3 
JPC 100 mg.kg-1 0.32± 0.06 0.82± 0.04 3.36±0.02 0.68± 0.2 
JPC 200 mg.kg-1 0.31± 0.04 0.77± 0.02 3.34± 0.02 0.75± 0.05 
JPC 400 mg.kg-1 0.30± 0.03 0.78± 0.03 3.37± 0.03 0.77± 0.05 
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The values are expressed as mean ± S.E.M. n=6. The results of group I were 
compared with other groups such as II, III, IV, and V. The statistical analysis was 
carried out using one way ANOVA  method, where **P<0.01. 
Effect of biochemical profiles of rats 
Table no 4.1.7.3.. Shows that Jaathipalathi chooranam  has significantly 
decreased (p<0.05)  the plasma glucose level in treated rats especially at higher dose 
(400 mg.kg-1) compared with control groups. **P<0.01 *P<0.05. Significant 
decrease (p<0.05) in the plasma total cholesterol (TC), triglyceride (TG) and LDL-
cholesterol levels were also noted. There was no evidence of severe toxicity 
associated with the administration of higher concentration of JPC . 
 
Table no 4.1.7.3.The effect of Jaathipalathi chooranam (JPC) on biochemical 
parameters 
Treatment 
Glucose 
(mg.dl-1) 
Cholesterol 
(mg.dl-1) 
Triglyceride 
(mg.dl-1) 
HDL 
(mg.dl-1) 
LDL 
(mg.dl-1) 
Control 94.65± 0.62 40.62± 0.56 25.25± 0.45 135.25± 0.55 84.15±1.72 
JPC 50  
mg.kg-1 
92.50± 0.56 26.85± 0.25* 10.22± 0.23* 175.28± 
0.65* 
71.59±1.28 
JPC 100 
mg.kg-1 
89.45± 0.47 27.74± 0.26* 12.42± 0.28* 165.18±0.78* 69.84±1.10 
JPC  200 
mg.kg-1 
90.25± 
0.55** 
34.18± 0.30 14.84± 0.38* 184.30± 
0.84* 
48.60±1.30 
JPC 400 
mg.kg-1 
86.25± 
0.45** 
33.78± 0.28 16.28± 0.34* 182.2± 0.85* 46.50±0.84 
 
Change noted in the hepatic enzymes. 
In table.4.comparison of AST, ALT, ALP, TP and Albuminvalues  between Group I 
and  groups II, III, IV, and V were demonstrated.  
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Table.4.1.7.4.The effect  of  Jaathipalathi chooranam on hepatic enzymes in rats. 
 
Treatment 
AST 
(IU.l-1) 
ALT 
(IU.l-1) 
ALP 
(IU.l-1) 
TP 
(g.l-1) 
ALBUMIN 
(g.l-1) 
Control 331.5±12.40 67.5± 3.18 246.58± 8.80 69.85± 3.32 39.15±2.35 
JPC 50  
mg.kg-1 
320.0±9.50** 65.5± 2.20** 259.10± 2.75** 70.30± 2.32 36.30±2.65 
JPC 100 
 mg.kg-1 
321.3±7.20** 63.1± 3.15** 253.18± 6.70** 80.15± 2.82 38.30±3.05 
JPC 200  
mg.kg-1 
316.4±7.95 58.4± 2.90 258.00± 5.20 69.25± 3.32 40.20±2.75 
JPC 400  
mg.kg-1 
326.2± 8.20 60.3± 3.52 262.40± 4.40 74.05± 2.58 39.48±2.70 
 
Effect of Jaathipalathi chooranam on haematological parameters in rats 
 From the study it was evident that, a significant increase (p<0.01) were 
observed in the hemoglobin contents and RBC count in the group treated with 200 
mg.kg-1 / body weight. There was no significant change in the calcium level in all the 
treated animals compared to the control. 
 
Table.4.1.7.5.The effect of Jaathipalathi chooranam on haematological 
parameters&Calcium in rats  
Treatment Hb(mg.dl-1) RBC(106 /mm3) WBC(106 /mm3) Calcium(mg.dl-1) 
Control 11.3± 0.25 9.15± 0.02 11.45± 0.05  9.45 ±0.02 
JPC 50 mg.kg-1 12.5± 0.26* 9.45± 0.04*  10.01± 0.01*  9.16 ±0.02 
JPC 100 mg.kg-1 12.3± 0.15* 9.55± 0.02*   8.35± 0.32*  9.27 ±0.20 
JPC 200 mg.kg-1 10.7± 0.20* 8.33± 0.12* 11.45± 0.03*  9.61 ±0.13 
JPC 400 mg.kg-1 11.5± 0.35* 8.51± 0.45*   10.55±0.13  9.75±0.02 
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Effect of Jaathipalathi chooranam on body weight in rats 
The effect of JPC was observed for their effect on the body weight changes 
was observed ,significant increased (p<0.05) in body weight. The results are described 
in Table.6. The values are expressed as Mean ± S.E.M. n=6. The results of group I 
were compared with other group II, III, IV, and V ( **P<0.01 *P<0.05). 
 
Table.4.1.7.6.The effects of  Jaathipalathi chooranam   
on body weight changes in rats 
Treatment Day 1 Day 5 Day 10 Day 20 
Control 184.15±6.8  184.45  ±6.20 196.15 ±6.35 197.7±6.58 
JPC 50 
mg.kg-1 
191.30 ±6.4 190.30  ±6.30 198.25 ±6.70 199.30±6.72* 
JPC 100 
mg.kg-1 
183.35 ±5.7 186.30  ±6.40 196.55  ±7.10 198.36±6.30* 
JPC 200 
mg.kg-1 
192.30  
±7.2 
195.15±6.50 198.90  
±7.20** 
207.45±7.26** 
JPC 400 
mg.kg-1 
184.65  
±6.05 
189.15 ±5.60 195.60  
±6.35** 
208.66±7.38** 
 
DISCUSSION : 
 In acute toxicity, the limit dose of 2000 mg/ kg (JPC) did not result in 
mortality or any clinical sign of acute toxicity in animals in the short-term (48 hours) 
and long term (14 days) observatory periods, suggesting that no toxic effects upto 
2000 mg/kg in rats.  
 Sub acute toxicity study showed that the extract did not affect the normal 
growth of the animals as evidenced by comparing the body weight gain in both 
control and treated animals over the 28-day treatment periods. There were no 
significant changes in liver enzymes (ALT,AST,ALP and TP) .The significantly 
increased in the level of RBC,WBC  and hemoglobin was found in treatment with 
Jaathipalathi chooranam (400 mg.kg-1).. The extract caused no undesirable effect on 
the all organ of the animals making it safe for consumption by human health and it 
was non hemotoxic. 
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4.2.CLINICAL STUDY : 
For the clinical study 20 In patients and 20 Out patients were selected, treated in 
PG-I Department of PothuMaruthuvam G.S.M.C Palayamkottai. Results were 
observed with respect to following criteria. 
01. Age Distribution 
02. Sex  Distribution 
03. Religion 
04. Educational status 
05. Occupational Status 
06. Socio- Economical Status 
07. Diet 
08. Personal habit  
09. Type of the Patient 
10. Triggering factors  
11. Distribution of family history 
12. Clinical Manifestation  
13. Kaalam  
14. Thegi  
15. Gunam 
16. Thinai 
17. Paruva  kaalam 
18. Gnanendrium 
19. Kanmendrium 
20. Conditions of Mukkutram (Vatham,Piththam,Kabham) 
21. Udal Kattukal 
22. Envagai Thervugal 
23. Neikuri 
24. Case summary Out Patients 
25. PFT report 
26. Laboratory investigation in OP patients 
27. Respiratory rate – OP patient  
28. PEFR in OP patients 
29. Case summary IP 
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30. Laboratory investigation IP patients 
31. Respiratory rate – IP patients 
32. PEFR in IP patients 
33. Clinical manifestation after treatment 
34. Grading of Asthma 
35. Assessment of Outcome 
 
 
 
4.2.1. AGE DISTRIBUTION
 
TABLE – 4.2.1 - Illustrates the age distributions and its relative Percentage.
S.No 
Age 
Group in 
Year 
Out Patients 
No of Cases
01 18 – 30 
02 31 – 40 
03 41 – 50 
04 51 – 60 
 
Among the 20 Outpatients:
35% were in the age group between 18 
between 31 - 40yrs,  20% were in the age group between 41
age group between 51-60 yrs. 
Among the 20 Inpatients
35% were in the age group between 41
between 51-60 yrs.  
0
2
4
6
8
10
12
14
No of Cases
7
6
4
3
18 - 30
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 In Patients  
 Percentage % No of Cases Percentage %
07 35 0 
06 30 0 
04 20 07 
03 15 13 
Figure  4.2.1. Age Distribution 
 
 
- 30 yrs. 30% were in the age group 
- 50yrs, 15% were in the 
 
: 
- 50yrs, 65% were in the age group 
No of Cases
0 0
7
13
31 – 40 41 – 50 51 - 60
 
 
0 
0 
35 
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4.2.2. SEX DISTRIBUTION
 
TABLE 
 
S.No Sex 
No of Cases
01 Male 
02 Female 
 
 
Among 20 Outpatients 
11 Patients were males 
 
Among 20 Inpatients 
11 Patients were males 
 
 
 
0
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4
6
8
10
12
No of Cases
Out Patients (OP)
11
9
77 
 
-4.2.2. SEX DISTRIBUTION 
Out Patients In Patients
 Percentage % No of Cases Percentage %
11 55 11 
09 45 09 
Figure –4.2.2. Sex Distribution 
 
– 55%  and  09 Patients were females -45%.
– 55%  and  09 Patients were females -45%.
No of Cases
In Patients (IP)
11
9
Male Female
 
 
55 
45 
 
 
 
4.2.3. RELIGION DISTRIBUTION
 
   TABLE 4.2.3. Religion 
 
S.No 
 
Religion
01 Hindu 
02 Christian 
03 Muslim 
 
Figure 
 
Among 20 Outpatients: 
 70% of cases were Hindus, 25% are
Among 20 Inpatients: 
 75% of cases were Hindus, 20%  are Christians, 5% were Muslims.
0
2
4
6
8
10
12
14
16
No of Cases
Out Patients (OP)
14
5
1
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Distribution 
 
Out Patients In Patients
No of Cases % No of Cases
14 70 15 
05 25 04 
01 05 01 
-4.2.3. Religion Distribution 
 
 
 Christians,5% were Muslims.
No of Cases
In Patients (IP)
15
4
1
Hindu Christian Muslim
 
 % 
75 
20 
05 
 
 
 
4.2.4.DISTRIBUTION OFEDUCATIONAL STATUS
 
TABLE 
 
S.No Educational status
01 Illiterate 
02 Read and write
03 Primary 
04 Middle School
05 High School 
06 College 
 
Figure 
Among 20 Outpatients: 
 10% Illiterate, Read and write 25%, Primary school  15%, Middle School 10% 
High School 20%, 20% College cases were observed.
Among 20 In patients: 
 35% Illiterate, Read and write 15%, Primary school  25%, Middle School 25% 
cases were observed.. 
0
1
2
3
4
5
6
7
Illiterate Read and 
write
2
5
7
Out Patients (OP) No of Cases
79 
 
– 4.2.4. Distribution of Educational Status 
 
Out Patients In Patients
No of Cases % No of Cases
02 10 07 
 05 25 03 
03 15 05 
 02 10 05 
04 20 0 
04 20 0 
- 4.2.4.Distribution of Educational Status 
 
 
Primary Middle 
School
High 
School
College
3
2
4 4
3
5 5
0
In Patients (IP) No of Cases
 
 % 
35 
15 
25 
25 
0 
0 
 
0
4.2.5. OCCUPATION 
 
    
 
S.No Occupation
01 Hotel server 
02 Agricultural labourer
03 House wife 
04 Painter  
05 Mason  
06 Carpenter  
07 Beedi maker 
08 Labourer 
09 College student
10 Office work  
11 Auto driver 
 
 
0
1
2
3
4
5
6
1
5
3
1
6
Out Patients (OP) No of Cases
80 
TABLE - 4.2.5. Occupation 
 
Out Patients In Patients
No of Cases % No of Cases
1 5 1 
 5 25 6 
3 15 4 
0 0 1 
1 5 1 
1 5 2 
1 5 2 
2 10 3 
 2 10 0 
3 15 0 
1 5 0 
Figure –4.2.5. Occupation 
 
0
1 1 1
2 2
3
4
1 1
2 2
3
0 0
In Patients (IP) No of Cases
 
 % 
5 
30 
20 
5 
5 
10 
10 
15 
0 
0 
0 
 
1
0
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Among 20 Outpatients: 
 
 Among 20 patients, 1 case was hotel server, (5%). 5 cases were agricultural 
labourer (25%), 3 cases were housewife (15%), 1 case was mason (5%), 1 cases was  
carpenter (5%), 1 case was beedi maker (5%), 2 cases were  labourer (10%),                       
2 cases were  college student (10% ),   3 cases were office work (15%), 1 case was 
auto driver (5%).                            
 
Among 20 In patients: 
 
Among 20 patients, 1 case was hotel server, (5%). 6 cases were agricultural 
labourer (30%), 4 cases were housewife (20%), 1 case was painter (5%), 1 case was 
mason(5%), 2 cases were carpenter (10%), 2 cases were beedi maker (10%), 3 cases 
were  labourer (15%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.6. DISTRIBUTION OF SOCIO
 
  TABLE – 
 
S.No Socio Economic Status
01 Rich Income cases 
02 Middle Income cases
03 Poor Income cases
 
 
Figure –4.2.6
 
Among 20 Outpatients: 
 20% Rich Income
were observed. 
 
Among 20 In patients: 
 55% Middle Income cases, 45% Poor Income cases were observed.
 
 
 
0
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10
15
No of Cases
Out Patients (OP)
4
15
1
Rich Income cases 
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-ECONOMIC STATUS: 
4.2.6  .Distribution of socio-economic status 
 
Out Patients In Patients
No of Cases % No of Cases
 04 20 0 
 15 75 11 
 01 5 09 
 .Distribution of socio-economic status 
 
 cases, 75% Middle Income cases, 5% Poor Income cases 
No of Cases
In Patients (IP)
0
11
9
Middle Income cases Poor Income cases
 
 % 
0 
55 
45 
 
 
4.2.7. DIET 
 
  TABLE -4.2.7 
 
S.No Diet
01 Vegetarian 
02 Non- Vegetarian
 
Figure 
 
Among 20 Outpatients: 
 15% vegetarian and 85% Non
 
Among 20 In patients: 
 25% vegetarian and 75% Non
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- Illustrates the Diet and relative percentage.
 
Out Patients In Patients
No of Cases % No of Cases
03 15 05 
 17 85 15 
–4.2.7 - Illustrates the Diet of patients 
 
-vegetarian were observed. 
-Vegetarian  were observed 
No of Cases
In Patients (IP)
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4.2.8. PERSONAL HABIT 
 
TABLE – 4.2.8– Illustrates the Personal habit
 
S.No Habit
01 Smoking 
02 Alcohol 
03 Tobacco 
 
Figure –4.2.8.
 
Among 20 Outpatients: 
15% of cases were Smokers, 40% of cases were Alcoholics
 
Among 20 In patients: 
50% of cases were Smokers, 45% of cases 
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s of  patients and  relative percentage.
 
Out Patients In Patients
No of Cases % No of Cases
03 15 10 
08 40 09 
0 0 0 
Illustrates the Personal habit of patients 
 
. 
were Alcoholics. 
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In Patients 
(IP)
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4.2.9. TYPE OF THE PATIENT
 
 TABLE – 4.2.9 - Illustrates the type of the patients and relative percentage.
 
S.No Occupation
01 Acute Patients
02 Chronic Patients
 
Figure –
 
Among 20 Outpatients: 
 05% Acute and 95% Chronic cases were observed.
 
Among 20 In patients: 
 10% Acute and 90% Chronic cases were observed.
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4.2.9 - Illustrates the type of the patients. 
 
 
 
No of Cases
In Patients (IP)
2
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 % 
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4.2.10. TRIGGERING FACTORS 
 TABLE – 4.2.10. 
 
S.No Clinical manifestation
01 Dust 
02 Smoke exposure
03 Passive Smoking
04 Cold exposure
05 Exercise 
06 Emotion 
07 Occupation 
08 Food additive
09 Fumes of paints and petrol.
10 Detergents 
11 Chemicals 
12 Husks, Grass, Pollans
13 Others 
Figure –4.2.10.Illustrates the triggering factorsof patients.
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Illustrates the triggering factors and relative percentage.
 
Out Patients In Patients
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Among 20 Out cpatients: 
 
 70% of cases Dust, 25% of cases Smoke exposure, 10% of cases Passive 
Smoking,60% of cases Cold exposure, 05% of Exercise, 45% of cases Emotion, 25% 
of casesOccupation,  10% of cases Food additive, 05% of cases Fumes of paints and 
petrol, 10% of cases Detergents, 15% of cases Chemicals, 25% of cases Husks, Grass, 
Pollans. 
 
Among 20 Inpatients: 
 
 70% of cases Dust, 60% of cases Smoke exposure, 10% of cases Passive 
Smoking,45% of cases Cold exposure, 05% of Exercise, 35% of cases Emotion, 40% 
of casesOccupation,  05% of cases Detergents, 20% of cases Chemicals, 15% of cases 
Husks, Grass, Pollans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.11. DISTRIBUTION OF FAMILY HISTORY
 
  Table-4.2.11, Illustrates the distribution of family history
S.No 
Family 
History No Of 
Cases
1 YES 3
2 NO 17
 
Figure 4.2.11
 
 
Among 20 out patients 
3 cases had positiv
 
Among 20 In patients 
2 cases had positiv
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OP Cases IP Cases 
 
 
Percentage (%) No Of 
Cases 
Percentage (%)
 15 2 10%
 85 18 90%
, Illustrates the distribution of family history
 
e family history and 17 cases didn’t have. 
e family history and 18 cases did n’t have. 
NO OF CASES
IP CASES
2
18
 
 
 
 
 
4.2.12. CLINICAL MANIFESTATION
 
TABLE – 4.2.12  Illustrates the Clinical Manifestation and relative percentage.
S.No Clinical manifestation
01 Difficulty in breathing
02 Tightness of chest
03 Wheeze - Added sound
04 Dry cough 
05 Sneezing 
06 Hoarseness of voice
07 Sleep disturbance
08 Nocturnal wheezing
09 Associated symptoms
 
Figure –4.2.12, 
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Out Patients In Patients
No of Cases % No of Cases
 20 100 20 
 15 75 20 
 20 100 20 
20 100 20 
18 90 19 
 05 25 08 
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 0 0 0 
 03 15 0 
Illustrates the Clinical Manifestation of patients.
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Among 20 Outpatients: 
 
 100% of cases Difficulty in breathing, 75% of cases Tightness of chest, 100% 
of cases Wheeze - Added sound,100% of cases Dry cough, 90% of cases Sneezing, 
25% of cases Hoarseness of voice, 35% of casesSleep disturbance,  15% of cases 
Associated symptoms 
 
Among 20 In patients: 
 
 100% of cases Difficulty in breathing, 100% of cases Tightness of chest, 
100% of cases Wheeze - Added sound,100% of cases Dry cough, 95% of cases 
Sneezing, 40% of cases Hoarseness of voice, 55% of casesSleep disturbance.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.13. KAALAM 
 
  TABLE–4.2.13 
 
S.No Kalam
01 
Vadha Kaalam 
(first 33yrs and   4months)
02 
Pitha Kaalam  
(second 33yrs and 4 months)
03 
Kabha Kaalam 
(Third 33yrs and 4months)
 
Figure 
 
Among 20 Outpatients: 
 35% Patients under Vatha
 
Among 20 Inpatients: 
100% Patients under Piththakaalam 
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 Illustrates Kaalam and relative percentage
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–4.2.13  Distribution of Kaalam. 
 
 Kaalam, 65% Patient under Piththakaalam 
 
Pitha 
Kaalam 
Kabha 
Kaalam 
13
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 % 
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4.2.14. CONSTITUTION OF THE BODY
TABLE -4.2. 14 Illustrate constitution of the body and its relative Percentage.
S.No 
Constitutions of
the body
01 Vatha thegi 
02 Pitha thegi 
03 Kabha thegi 
04 Vatha Pitham 
05 Vatha Kabham
06 Pitha Vatham 
07 Pitha Kabham
08 Kabha Vatham
09 Kabha Pitham
 
Figure -
Among 20 Out patients:
 10%- vatha pitha thegi, 65%
pitha kabha thegi, 5% kaba vatha thegi,5% kaba pitha thegi.
Among 20 Inpatients: 
 5%- vatha pitha thegi, 65%
kabha thegi, 5% kaba vatha thegi,5% kaba pitha thegi.
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No of Cases % No of Cases
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4.2.14– Illustrate constitution of the body 
 
-vatha kabha thegi,10 % pitha vatha thegi, 5% 
 
-vatha kabha thegi,5 % pitha vatha thegi,15% pitha 
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4.2.15. GUNAM 
 
  TABLE –4.2. 15
S.No Gunam
01 Sathuvagunam
02 Rajogunam 
03 Thamogunam
 
Figure 
 
Among  20 Out patients:
 40% under Sathuva gunam,60% under Rajogunam 
 
Among 20 In patients: 
 45% are Sathuva gunam, 35% are Rajogunam, 20% thamogunam
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 - Shows Gunam and its relative percentage
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–4.2.15, Distribution of Gunam 
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4.2.16. THINAI 
TABLE -4.2.16 
S.No Thinai
01 Kurinji 
02 Mullai 
03 Marutham
04 Neithal 
05 Palai 
 
Figure 
 
Among 20 Outpatients: 
90% cases were in Marutham and 10% cases were in Neithal.
 
Among 20 Inpatients: 
 90% cases were in Marutham and 10% cases 
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- Illustrates the Thinai and relative percentage.
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–4.2.16. - Distribution of Thinai . 
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4.2.17. PARUVA KAALAM
 
TABLE -4.2.17 - Illustrates the paruvakaalam and its relative percentage.
S. 
No 
Paruva Kaalam
01 Kar Kaalam 
02 Koothir Kaalam
03 Munpani Kaalam
04 Pinpani Kaalam
05 Elavenil Kaalam
06 Muthuvenil Kaalam
 
Figure 
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 Months 
Out Patients In Patients
No of  
Cases 
% 
No of 
Cases
Aavani – Purattasi 01 05 04
 Iyppasi – Karthigai 04 20 03
 Markazhi - Thai 08 40 08
 Masi - Panguni 02 10 02
 Chithirai-Vaikasi 01 05 01
 Aani - Aadi 04 20 02
–4.2.17. Distribution of paruvakalam 
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Among 20 Out Patients:  
 5% cases were observed in Kar Kaalam, 20% cases were observed in Koothir 
Kaalam, 40% cases were observed in Munpani Kaalam, 10% cases were observed in 
Pinpani Kaalam, 05% cases were observed in Elavenil Kaalam,20% cases were 
observed in Muthuvenil Kaalam 
 
Among 20 In Patients:  
 20% cases were observed in Kar Kaalam, 15% cases were observed in Koothir 
Kaalam, 40% cases were observed in Munpani Kaalam, 10% cases were observed in 
Pinpani Kaalam, 05% cases were observed in Elavenil Kaalam, 10% cases were 
observed in Muthuvenil Kaalam 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.18. GNANENDRIUM
TABLE –4.2.18 -
S.No Gnanendrium
01 Mei 
02 Vai 
03 Kan 
04 Mookku 
05 Sevi 
 
Figure 
 
Among  20 Out patients:
 Kan  was  affected in 15%  cases, Mokku  was  affected in 80%  
was  affected in 15%  cases.
Among 20 In patients: 
Kan  was  affected in 20%  cases, Mokku  was  affected in 65%  cases,Sevi 
was  affected in 15%  cases.
 
 
 
0
2
4
6
8
10
12
14
16
Mei
0 0
Out Patients (OP) No of Cases
In Patients (IP) No of Cases
97 
 
 
 Illustrates the Gnanendrium and relative percentage.
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–4.2.18, Condition of Gnanendrium. 
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4.2.19. KANMENDRIUM
 
TABLE –4.2. 19 -
S.No Kanmendrium
01 Kai 
02 Kaal 
03 Vaai 
04 Eruvai 
05 Karuvai 
 
Figure 
 
Among 20 Out Patients: 
Kai was  affected in 10%  cases, Eruvai  was  affected in 15%  cases.
 
Among 20 In Patients: 
Kai was  affected in 40%  cases, Kaal was  affected in 50%  cases,
affected in 30%  cases. 
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 Illustrates the Kanmendrium and relative percentag
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–4.2.19 - Condition of Kanmendrium. 
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4.2.20. CONDITIONS OF MUKKUTRAM
4.2.20.1 – Condition of Vatham
TABLE 
S.No Vatham
01 Piranan 
02 Abanan 
03 Viyanan 
04 Udhanan 
05 Samanan 
06 Naagan 
07 Koorman 
08 Kirukaran 
09 Dhevathathan
10 Dhananjeyan 
  
Figure 
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–4.2. 20.1 -Condition of Vatham 
 
Out Patients In Patients
No of Cases % No of Cases
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–4.2.20.1 - Condition of Vatham 
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Among 20 Out Patients:  
100% cases were observed in Piranan affected, 35% cases were observed in 
Abanan affected, 10% cases were observed in Viyanan affected, 100% cases were 
observed in udhanan affected, 100% cases were observed in Samanan affected, 20% 
cases were observed in Koorman affected, 85% cases were observed in Kirukaran 
affected,100% cases were observed in Dhevathathan affected. 
 
Among 20 In Patients: 
100% cases were observed in Piranan affected, 05% cases were observed in 
Abanan affected, 100% cases were observed in Uthanan affected, 100% cases were 
observed in Samanan affected, 25% cases were observed in Koorman affected, 50% 
cases were observed in Kirukaran affected,100% cases were observed in 
Dhevathathan affected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.20.2 – Condition of Piththam
TABLE 
S.No Pitham
01 Analpitham
02 Ranjagam 
03 Prasagam 
04 Alosagam 
05 Sathagam 
 
Figure 
 
Among 20 Out Patients: 
75% cases were Analapitham affected. 
 
Among 20 In Patients: 
100% cases were observed in Analapitham affected, 15% cases were observed 
in Ranjagam affected.  
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– 4.2.20.2 -– Condition of Piththam 
 
Out Patients In Patients
No of 
Cases 
% 
No of 
Cases 
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–4.2.20.2-  Condition of Piththam 
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4.2.20.3 –  Condition of Kabham
 
TABLE 
S.No Kabham
01 Avalambagam
02 Kilethagam 
03 Pothagam 
04 Tharpagam 
05 Santhigam 
 
Figure 
 
Among 20 Out Patients: 
100% cases were observed in Avalambagam affected, 35% cases were 
observed in Kilethagam affected, 20% cases were observed in Pothagam affected.
 
Among 20 In Patients: 
100% cases were observed in Avalambagam affected, 35% cases were 
observed in Kilethagam affected, 10
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–4.2.20.3Condition of Kabham 
 
Out Patients In Patients
No of Cases % No of Cases
 20 100 20 
07 35 07 
04 20 02 
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–4.2.20.3 - Condition of Kabham 
 
% cases were observed in Pothagam affected.
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4.2.21. Involvement of Udal Kattukal:
Table 4.2.21 – Involvement of udal Kattukal and relative percentage.
S.NO Udal Kattukal
1 Saaram 
2 Senneer 
3 Oon 
4 Kozhuppu 
5 Enbu 
6 Moolai 
7 Sukkilam/Suronittham
 
Figure 
 
In  OP study: 
Saaram was affected in 75% of cases, Senneer was 
Enbu was affected in 10% of cases
In  IP study: 
Saaram was affected in 95% of cases, Senneer was affected in 15% of 
cases,Enbu was affected in 20% of cases
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–4.2.21 – Involvement of udal Kattukal 
affected in 25% of cases, 
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4.2.22. Conditions of Envagai thervugal:
Table -4.2.22 - Illustrates the 
S.NO Envagai thervugal
1 
Naadi 
(Thontha Naadi)
2 Sparisam 
3 Naa 
4 Niram 
5 Mozhi 
6 Vizhi 
7 Maalam 
8 Moothiram 
 
Figure –
 
In  OP study: 
Naa was affected in 20% of cases, Niram  was affected in 10% of cases, Vizhi 
was affected in 25% of cases.
In  IP study: 
Niram  was affected in 10% of cases, Vizhi was affected in 15% of cases.
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conditions of Envagai thervugal and relative percentage.
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4.2.22 - Conditions of Envagai thervugal 
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4.2.22.1 NAADI  
Table –4.2.22.1 - Illustrates the conditions of Naadi and relative percentage.
S.NO Naadi
01 Vatha Piththam
02 Vatha Kabham
03 Piththa Vatham
04 Piththa Kapam
05 Kabha Vatham
06 Kabha Piththam
 
Figure –4.2.22.1
 
Among 20 Op Patients: 
In OP 10% Vatha 
05% Piththa Kabham, 05% Kabha Vatham, 05% Kabha Piththam.
Among 20 In Patients: 
In OP 05% Vatha Piththam, 65% of Vatha Kabham, 05% Piththa Vatham, 
15% Piththa Kabham, 05% Kabha Vatham, 5% Kabha Piththam.
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Out Patients In Patients
No of Cases % No of  Cases 
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 - Illustrates the conditions of Naadi 
Piththam, 65% of Vatha Kabham, 10% Piththa Vatham, 
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4.2.23- NEIKURI 
Table –4.2.23. Neikuri Condition and relative percentage.
S.NO Neikuri 
1 Vatha neer 
2 Pitha neer 
3 Kabha neer
 
Figure 
 
Out of 20 Out patients: 
 10% had vathaneer, 10% had pithaneer, 80% had kabhaneer.
 
Out of 20 In patients: 
 10% had vathaneer, 05% had pithaneer, 85% had kabhaneer.
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–4.2.23 - Neikuri Condition 
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4.2.25. PFT  REPORT 
TABLE –4.2.25   PFT Report 
 
S.No OP.No 
Age / 
Sex 
PFT 
BEFORE TREATMENT AFTER TREATMENT 
FVC FEV1 
FEV1/ 
FVC 
EF – 25- 
75 
PEFR FVC FEV1 
FEV1/ 
FVC 
EF – 25- 
75 
PEFR 
01 34453 20/M 69 62 90 41 54 130 133 103 86 115 
02 100982 30/F 43 54 126 45 21 74 84 135 78 88 
03 101045 30/F 65 50 77 26 44 83 103 125 104 60 
04 14887 21/F 92 02 03 86 54 107 108 101 68 52 
05 18300 30/F 46 57 124 108 77 76 86 131 64 103 
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Figure –4.2.25 PFT  report 
 
EF – 25- 75 PEFR FVC FEV1 FEV1/ FVC
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EF – 25- 75 PEFR
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4.2.26. LABORATORY INVESTIGATION (OP PATIENTS) 
TABLE –4.2.26 LABORATORY INVESTIGATION OF OP PATIENTS 
S. 
No 
OP.  
No 
HAEMATOLOGICAL INVESTIGAION URINE ANALYSIS 
Before Treatment After Treatment Before Treatment After Treatment 
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01 34453 6300 64 30 6 20 11.7 6400 66 32 2 14 12.0 Nil Nil 2-3 Nil Nil Nil 
02 64239 7300 62 26 12 65 11.2 7600 63 26 11 59 11.6 Nil Nil Nil Nil Nil Nil 
03 68834 9900 64 27 9 32 11.0 10200 67 30 3 12 11 Nil Nil Nil Nil Nil Nil 
04 65582 8900 67 24 9 30 12 8900 70 26 4 23 12.2 Nil Nil Nil Nil Nil Nil 
05 67535 7300 68 22 10 79 9.6 7600 70 21 9 68 10.4 Nil Nil 2-3 Nil Nil 1-2 
06 78244 9900 63 27 10 32 12.0 10100 67 28 5 14 12.0 Nil Nil Nil Nil Nil Nil 
07 99022 6000 60 29 11 55 10.5 6400 62 29 9 47 11.0 Nil Nil Nil Nil Nil Nil 
08 100204 6300 63 33 4 30 12.0 7000 64 33 3 16 12.2 Nil Nil Nil Nil Nil Nil 
09 100982 8400 66 28 6 30 13.6 9000 66 31 3 10 11.5 Nil Nil Nil Nil Nil Nil 
10 101045 9800 54 36 10 65 11.2 9800 65 26 9 15 11.6 Nil Nil Nil Nil Nil Nil 
11 106012 8000 57 27 16 55 11.5 8000 59 28 13 44 12.0 Nil Nil 2-3 Nil Nil 1-2 
12 107838 9900 64 30 6 36 12 10000 64 32 4 26 12.4 Nil Nil Nil Nil Nil Nil 
13 107839 6800 62 32 6 50 11.6 6900 64 32 4 42 11.6 Nil Nil Nil Nil Nil Nil 
14 108698 6400 67 27 6 24 11.6 6800 67 30 3 18 12.0 Nil Nil 1-2 Nil Nil Nil 
15 8297 7300 68 26 6 27 12.6 7900 70 27 3 20 12.6 Nil Nil Nil Nil Nil Nil 
16 9136 6400 62 30 8 50 12.5 6700 64 29 7 45 13.0 Nil Nil Nil Nil Nil Nil 
17 14887 6800 66 25 9 32 12.6 6800 70 25 5 26 12.4 Nil Nil Nil Nil Nil Nil 
18 15345 9700 54 33 13 20 12.2 9800 66 24 10 14 12.6 Nil Nil 1-2 Nil Nil Nil 
19 18300 8300 67 26 7 40 9.0 8400 68 28 4 29 10.0 Nil Nil Nil Nil Nil Nil 
20 30170 9300 58 25 17 35 11.0 10000 59 26 15 30 11.0 Nil Nil 2-3 Nil Nil Nil 
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Figure –4.2.26.1 ESR (OP) 
 
 
Figure –4.2.26.2EOSINOPHILS COUNT (OP) 
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4.2.27. Respiratory Rate in OP Patient 
TABLE –4.2. 27. Respiratory Rate in OP Patient before and after treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure –4.2.27.Respiratory Rate in OP Patient before and after treatment. 
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Before Treatment
After Treatment
Changes in Respiratory Rate
S.No O.P No Before Treatment 
After 
Treatment 
1. 34453 19 18 
2. 64239 23 20 
3. 68834 21 18 
4. 65582 20 17 
5. 67535 22 21 
6. 78244 18 17 
7. 99022 22 18 
8. 100204 21 18 
9. 100982 24 18 
10. 101045 26 24 
11. 106012 23 19 
12. 107838 20 17 
13. 107839 23 18 
14. 108698 24 18 
15. 8297 19 18 
16. 9136 24 20 
17. 14887 21 18 
18. 15345 24 22 
19. 18300 20 18 
20. 30170 24 21 
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4.2.28. PEFR in OP Patient 
TABLE –4.2.28  PEFR in OP Patient before and after treatment. 
 
Good         – PEFR value increased 100 and above 100 
Moderate  – PEFR value increased 50 - below100. 
Poor          – No change and below 50 in PEFR value. 
 
Figure –4.2.28  PEFR in OP Patient before and after treatment. 
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Before Treatment  PEFR (lit/min After Treatment PEFR (lit/min
S. 
No 
O.P 
No Age Sex 
PEFR  (lit/min) 
Before Treatment 
PEFR (lit/min) 
After Treatment Result 
1. 34453 20 M 210 360 Good 
2. 64239 56 F 210 280 Moderate 
3. 68834 32 M 280 390 Good 
4. 65582 48 M 230 360 Good 
5. 67535 40 F 180 210 Poor 
6. 78244 25 M 250 380 Good 
7. 99022 45 M 210 300 Moderate 
8. 100204 37 M 220 340 Good 
9. 100982 30 F 210 320 Good 
10. 101045 30 F 180 360 Good 
11. 106012 53 F 190 210 Poor 
12. 107838 43 M 210 380 Good 
13. 107839 39 F 170 290 Good 
14. 108698 28 F 190 330 Good 
15. 8297 40 M 170 320 Good 
16. 9136 36 M 230 310 Moderate 
17. 14887 21 F 180 290 Good 
18. 15345 55 M 220 310 Moderate 
19. 18300 30 F 160 290 Good 
20. 30170 44 M 210 300 Moderate 
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4.2.29. CASE REPORT IP 20 PATIENTS TREATED FOR SWASAKASAM 
TABLE -4.2. 29. CASE REPORT OF IP PATIENTS 
S.No OP NO IP NO Name Age Sex Date Of Admission 
Date Of 
Discharge 
Number  of 
days with 
Follow  Up 
Total  
No. of  
Days 
Result 
IP OP 
01 44013 1333 RAJAGOPAL 43 M 19.05.2018 08.06.2018 21 9 30 Moderate 
02 60092 1827 MAATHAVAN 50 F 19.07.2018 13.08.2018 26 5 31 Good 
03 66343 2046 AAVUDAIAMMAL 50 F 10.08.2018 11.09.2018 33 - 33 Good 
04 70005 2159 MALLIGA 49 F 23.08.2018 24.09.2018 33 - 33 Good 
05 70129 2163 POOTHATHAN 60 M 23.08.2018 11.09.2018 20 10 30 Moderate 
06 70108 2166 VELLAIAMMAL 57 F 23.08.2018 25.09.2018 34 - 34 Good 
07 72239 2228 AAVUDAIAMMAL 55 F 30.08.2018 02.10.2018 34 - 34 Good 
08 97112 2874 SRIRANGAM 50 F 24.11.2018 21.12.2018 28 4 32 Good 
09 98860 2922 GANAPATHI 60 M 29.11.2018 19.12.2018 21 9 30 Poor 
10 103591 3080 SHANMUGAVEL 60 M 14.12.2018 08.01.2019 26 5 31 Good 
11 105774 3125 ESSAKIAMMAL 60 F 22.12.2018 23.01.2019 33 - 33 Good 
12 106816 3145 SUBBAIAH 55 M 25.12.2018 19.01.2019 26 5 31 Good 
13 360 4 MANONMANI 59 F 02.01.2019 27.01.2019 26 4 30 Good 
14 6277 64 MOHAMMED ASAN 47 M 17.01.2019 16.02.2019 31 - 31 Poor 
15 8465 131 TAMILKODI 52 F 23.01.2019 17.02.2019 26 4 30 Good 
16 10354 175 SORNAM 60 M 28.01.2019 21.02.2019 25 5 30 Good 
17 14511 288 AROKKIYAM 60 M 08.02.2019 07.03.2019 28 2 30 Good 
18 14594 299 LAKSHIMI 45 F 08.02.2019 09.03.2019 30 - 30 Good 
19 18241 413 PATTAN 60 M 19.02.2019 20.03.2019 30 - 30 Moderate 
20 23669 592 KAILASAM 60 M 07.03.2019 06.04.2019 31 - 31 Good 
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4.2.30. LABORATORY INVESTIGATION (IP PATIENTS) 
TABLE -4.2. 30 LABORATORY INVESTIGATION OF IP PATIENTS 
S
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HAEMATOLOGICAL INVESTIGAION URINE ANALYSIS 
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01 44013 1333 9000 64 27 9 47 11.9 9900 65 28 7 25 12.0 Nil Nil 2-3 Nil Nil Nil 
02 60092 1827 7300 65 28 7 35 11.2 7700 67 29 4 18 11.4 Nil Nil Nil Nil Nil Nil 
03 66343 2046 8900 67 24 9 40 12.2 9800 69 27 4 17 12.3 Nil Nil Nil Nil Nil Nil 
04 70005 2159 9900 63 31 6 42 12.0 10200 67 30 3 19 12.7 Nil Nil Nil Nil Nil Nil 
05 70129 2163 6300 64 28 8 50 11.7 6400 66 27 7 26 11.7 Nil Nil 2-3 Nil Nil 1-2 
06 70108 2166 8500 67 27 6 30 13.6 8600 70 28 2 15 13.6 Nil Nil Nil Nil Nil Nil 
07 72239 2228 6800 62 32 6 40 12.5 7000 64 32 4 20 12 Nil Nil Nil Nil Nil Nil 
08 97112 2874 7000 66 31 3 20 9.2 7100 66 32 2 15 10.0 Nil Nil Nil Nil Nil Nil 
09 98860 2922 10900 50 38 12 56 13.3 10900 60 29 11 30 14.2 Nil Nil Nil Nil Nil Nil 
10 103591 3080 7600 63 33 4 26 15.3 7400 64 33 3 15 15.3 Nil Nil Nil Nil Nil Nil 
11 105774 3125 7500 68 29 3 18 12.0 7600 70 28 2 8 12 Nil Nil 2-3 Nil Nil 1-2 
12 106816 3145 6700 67 30 3 50 9.7 6900 68 30 2 20 10.3 Nil Nil Nil Nil Nil Nil 
13 360 4 8900 64 27 9 32 11 9200 70 27 3 14 11.4 Nil Nil Nil Nil Nil Nil 
14 6277 64 7300 65 25 10 55 11.2 7400 69 22 9 29 11.4 Nil Nil 1-2 Nil Nil Nil 
15 8465 131 6100 67 30 3 32 10.6 6200 68 30 2 24 10.9 Nil Nil Nil Nil Nil Nil 
16 10354 175 6200 66 30 4 32 15.5 7400 66 32 2 22 15.0 Nil Nil Nil Nil Nil Nil 
17 14511 288 10500 70 20 10 40 8.4 10500 70 26 4 18 9.0 Nil Nil Nil Nil Nil Nil 
18 14594 299 9200 70 27 3 26 12.0 9700 71 27 2 20 12.0 Nil Nil 1-2 Nil Nil Nil 
19 18241 413 8200 51 38 11 75 10.3 8200 57 34 9 26 10.3 Nil Nil Nil Nil Nil Nil 
20 23669 592 6300 68 28 4 5 10.7 6300 70 28 2 4 11.0 Nil Nil 2-3 Nil Nil Nil 
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Fig. 4.2.30.1.  ESR Variation in IP Patients 
 
 
 
Fig. 4.2. 30.2  Eosinophils countvariation in IP Patients 
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4.2.31. Respiratory Rate in IP Patient 
TABLE –4.2. 31 Respiratory Rate in IP Patient before and after treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure –4.2.31.Respiratory Rate in IP Patient before and after treatment 
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Before Treatment 
After Treatment
Variation in Respiratory Rate / Minute 
S.No I.P No. Before Treatment After Treatment 
1. 1333 25 20 
2. 1827 24 18 
3. 2046 23 17 
4. 2159 22 18 
5. 2163 23 20 
6. 2166 19 17 
7. 2228 25 17 
8. 2874 23 18 
9. 2922 26 24 
10. 3080 21 17 
11. 3125 24 17 
12. 3145 19 18 
13. 4 24 18 
14. 64 24 22 
15. 131 20 18 
16. 175 23 17 
17. 288 23 18 
18. 299 22 17 
19. 413 24 20 
20. 592 22 17 
 118 
 
4.2.32. PEFR in IP Patient 
TABLE – 4.2.32. PEFR in IP Patient before and after treatment. 
 
 
Good         – PEFR value increased 100 and above 100 
Moderate  – PEFR value increased 50 - below100. 
Poor          – No change and below 50 in PEFR value. 
 
Figure –4.2.32. PEFR in IP Patient before and after treatment 
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S.No I.P No Age Sex PEFR(lit/min) B.Treatment 
PEFR (lit/min) 
A.Treatment Result 
1. 1333 43 M 150 250 Moderate 
2. 1827 50 F 180 380 Good 
3. 2046 50 F 190 390 Good 
4. 2159 49 F 140 370 Good 
5. 2163 60 M 170 250 Moderate 
6. 2166 57 F 190 360 Good 
7. 2228 55 F 180 380 Good 
8. 2874 50 F 160 270 Moderate 
9. 2922 60 M 200 240 Poor 
10. 3080 60 M 160 470 Good 
11. 3125 60 F 170 350 Good 
12. 3145 55 M 170 420 Good 
13. 4 59 F 190 360 Good 
14. 64 47 M 190 230 Poor 
15. 131 52 F 180 300 Good 
16. 175 60 M 230 470 Good 
17. 288 60 M 160 450 Good 
18. 299 45 F 170 350 Good 
19. 413 60 M 190 280 Moderate 
20. 592 60 M 210 430 Good 
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4.2.33. CLINICAL MANIFESTATION – AFTER TREATMENT 
 
TABLE –4.2.33 - Illustrates the Clinical Manifestation  
After treatment and relative percentage. 
 
S.No 
Clinical 
manifestation 
Out Patients (OP) In Patients (IP) 
No of Cases % No of Cases % 
01 Difficulty in 
breathing 
2 10 3 15 
02 Tightness of  
chest 
4 20 5 25 
03 Wheeze - Added 
sound 
3 15 4 20 
04 Dry cough 2 10 3 15 
05 Sneezing 0 0 1 5 
06 Hoarseness of 
voice 
0 0 0 0 
07 Sleep  
disturbance 
2 10 3 15 
08 Nocturnal 
wheezing 
0 0 0 0 
09 Associated 
symptoms 
0 0 0 0 
 
 
 
 Figure –4.2.33
 
Among 20 out Patients 
After treatment 10 %  cases were persisted with the symptom of difficulty in 
breathing, 20 % cases were persisted with the symptom of
cases were persisted with the symptom of
persisted with the symptom of
symptom of sleep disturbances.
 
Among 20 In Patients 
After treatment 15 %  cases were persisted with the symptom of difficulty in 
breathing, 25% cases were persisted with t
cases were persisted with the symptom of
persisted with the symptom of
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-  Clinical Manifestation after treatment. 
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 4.2.34.GRADING OF ASTHMA:
Grade 
 
BEFORE TREATMENT
OP CASES
No of 
Cases 
(%)
Grade -4 0 0
Grade -3 3 15
Grade -2 7 35
Grade -1 10 50
Grade -0 0 0
 
 
Grade -4  : Severe Persistent Asthma
Grade -3 : Moderate Persistent Asthma
Grade - 2 : Mild  Persistent Asthma
Grade -1 : Mild Intermittent Asthma
Grade -0 : Normal
0
20
40
60
80
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OP CASES 
BEFORE TREATMENT
15
35
50
0
Grade -4 Grade -3
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Table 4.2.34. Grading of Asthma: 
 AFTER TREATMENT
 IP CASES OP CASES IP CASES
 
No of 
Cases 
(%) 
No of 
Cases 
(%) 
No of 
Cases
 0 0 0 0 0 
 8 40 2 10 2 
 5 25 1 5 2 
 7 35 4 20 2 
 0 0 13 65 14 
Figure-4.2.34 Grading of Results 
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Before treatment: 
Among 20 OP patients 
50% cases were in  Grade I ,  35% cases were  in Grade II, 15%  cases were in 
Grade III. 
Among 20 IP Patients 
35% cases were in Grade I, 25%  cases were in Grade II, 40%  cases were in 
Grade III 
After treatment: 
Among 20 OP patients 
65%  cases were in Grade 0 , 20%  cases were in Grade I,  5%  cases were in 
Grade II , 10% cases were in Grade III. 
Among 20 IP Patients 
 70%  cases were in Grade 0,  10%  cases were in Grade I ,10 %  cases were in 
Grade- II, 10 %  Grade -III 
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4.2.35.Assessment of Outcome 
 
TABLE –4.2.35. Assessment of Outcome 
S. 
No 
Result 
Out Patient (OP) In Patient (IP) 
No of 
Cases 
% 
No of 
Cases 
% 
1 Good Response 13 65 14 70 
2 Moderate  Response 05 25 04 20 
3 Poor Response 02 10 02 10 
 
Figure-4.2.35. Assessment of Outcome 
 
 
 
Among 20 Out Patients: 
65% had good prognosis, 25% had Moderate prognosis, 10% had Poor 
prognosis. 
 
Among 20 In Patients: 
70% had good prognosis, 20% had Moderate prognosis, 10% had Poor 
prognosis. 
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4.3.STATISTICAL ANALYSIS 
From the below table no.4.3  the paired  ‘ t ’ Test of these values shows that  
all the clinical assessment and parameters were with  siginicaficant P value. 
 
Table.4.3.Statistical Analysis 
 
  MEAN 
STANDARD 
DEVIATION 
t 
VALUE 
P  
VALUE 
PEFR 
BT 192.250 28.5089 
-13.063 < 0.01 
AT 333.250 66.4633 
EOSINOPHIL 
COUNT 
BT 7.775 3.4751 
10.075 < 0.01 
AT 5.250 3.4770 
ESR 
BT 38.590 15.9421 
8.704 < 0.01 
AT 23.925 13.4248 
ASTHMA 
GRADE 
BT 1.850 0.834 
11.180 < 0.01 
AT 0.60 1.008 
CLINICAL 
MANIFESTATIONS 
BT 51.545 8.150 
1.03 < 0.01 
AT 5.060 0.800 
 
BT – Before TreatmentAT – After Treatment 
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V. DISCUSSION 
 The present study is entitled as “A Prospective, Open labeled, Non- 
randomized, Phase – II clinical trial on  SWASAKASAM (Bronchial Asthma) with 
evaluation of the trial drug JAATHIPALATHI CHOORANAM. 40 patients (20 
outpatients and 20  in patients) were selected based on clinical features.Modern 
investigations and siddha diagnostic methods (envagai thervugal) were carried out for 
the diagnosis. The trial drug was prepared and given to the patients. The reports of 
urine, blood and general details were collected from the patients before and after 
treatment. The PEFR measurement of each patient during the treatment were 
compared to assess the therapeutic value of the trail drug JAATHIPALATHI 
CHOORANAM . 
AGE 
In OP cases, the maximum age distribution of Swasakasam was in 18-30  age 
group- 7 cases ( 35%). In IP cases, the maximum age distribution of Swasakasam was 
in 51-60 age group- 13 cases (65%). 
SEX 
Among the 20 outpatients and 20 in patients, 55% were male and 45% were 
female.  
 So in the current study Swasakasam is common in both sex. 
RELIGION 
 By analyzing both outpatients and inpatients, Hindus accounts for 75% and 
70% respectively, Christians 25%  and 20% respectively, Muslims 0% and 
10%respectively. 
 So, in the current study Swasa kasam was commonly affected in hindus. 
EDUCATIONAL STATUS 
 From the data collected during the enrolment of patients it was learnt that 
• 10% of outpatients and 35% of inpatients were illiterate, 
• 25 % of out patients and 15% of inpatients had the ability to read and write.   
• 15% of the op cases and 25% of the ip cases were studied upto primary school 
level.  
• 10% of the outpatients and 25% of the inpatients were studied upto middle 
school level. 
• 20% of the outpatients were  studied upto high school . 
•  20% of the outpatients obtained degree education.  
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OCCUPATION  
From the data collected during the enrolment of patients it was learnt that  
• 25% of out patients and 30% of in patients were Agricultural labourers.  
• 15% of out patients and 20% of inpatients were house wives.  
• 15% of out patients were office workers 
• 10% of out patients and 15% of inpatients were labourer. 
• 10% of out patients were college student. 
• 5% of the outpatients and 5% of the Inpatients were hotel server.  
• 5% of out patients and 5% of In patients were Masons. 
• 5% of inpatients were painter. 
• 5% of Out patients and 10% of In patients were carpenter. 
• 5% of Out patients and 10% of In patients were Beedi makers. 
• 5% of Out patients were Driver. 
 So, more incidence in Swasakasam was commonly  affected  agricultural 
labourers. 
SOCIO-ECONOMIC STATUS 
The present study revealed that of (75% OPD and 55% IPD) were hailing 
from the Middle class. The second majority were from Poor income class (45% of in 
patients and 5% of out patients). Patients from rich sector were only 20% who visited 
OP to receive treatment. 
 So, Swasa Kaasam was found to have  increased prevalances in middle 
income cases.  
DIET 
Out of the 40 cases,15% of outpatients and 25% of in patients were taking 
Vegitarian diet.Out of the 40 cases,85% of outpatients and 75% of in patients were 
taking Non- Vegitarian diet. 
So, Swasa Kaasam was commonly present in Non vegitarian patients. 
PERSONAL HABITS 
 It was noted that 15% of outpatients and50% inpatients had smoking habit.  
40% of outpatients and 45% inpatients had alcoholism. 
 So, Swasa Kaasam was more prevalent in persons with abusive habits. 
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TYPE OF THE PATIENTS 
 Out of the 40 cases whowere recruited for the study majority of them 
• 05% of out patients and 10% of in patients were acute patients. 
• 95% of outpatients and 90% in patients were chronic patients. 
 So, most of the  treated cases in the trial were chronic patients.  
TRIGGER FACTOR 
• 70% of out patients and 70% of in patients exposed to dust. 
• 25% of outpatients and 65% inpatients exposed to smoke. 
• 10% of outpatients and 10% of inpatients exposed to passive smoking. 
• 60% of out patients and 45% of in patients hadcold exposure. 
• 05% of out patients and 5% of in patients were affected during exercise. 
• 45% of out patients and 35% of in patients were affected due to emotion. 
• 25% of outpatients and 40% of inpatients were affected because of occupation 
nature. 
• 10% of out patients exposed to food additive. 
• 05% of out patients exposed to fumes of paints and petrol 
• 10% of Out patients and 5% of In patients exposed to detergents 
• 15% of out patients and 15% of In patients were exposed to chemicals 
• 25% of out patients and 20% of In patients were  exposed to husks, grass, 
pollans.  
 So, Swasa Kaasam can be triggered as a commonly dust, cold exposer, 
emotionand occupation and exposure to husk, grass pollens.  
DISTRIBUTION OF FAMILY HISTORY 
15% of Out Patients and 10% of In patients had positive family history. 85% 
of Out patients and 95% of Inpatients had no relative family history.So, Swasa 
Kaasam shows no relations with Family history in the current study. 
CLINICAL MANIFESTATION 
• 100% of out patients and in patients difficulty in breathing 
• 75% of out patients and 100% in patients had tightness of chest 
• 100% of out patients and 100% of in patients had wheeze 
• 100% of out patients and in patients had dry cough 
• 90% of out patients and 95% of in patients had sneezing 
• 25% of outpatients and 40% of inpatients had hoarseness of voice,  
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• 35% of out patients and 55% of in patients had sleep disturbance 
• Associated symptoms of Bronchial asthma were showed in 15% of Out 
patients. 
 So, Swasa Kaasam was commonly presented with wheezing, defaulting 
breathing, dry cough and tightness of chest.  
KAALAM  
 Among the patients   
 35% of the out patients were admitted in vatha kaalam 
 65% of the out patients and 100% of the in patients were admitted in piththa 
kaalam. 
 So, the prevalence of disease is during Piththa kaalam in this trial study. 
THEGI (CONSTITUTION OF BODY) 
Among 20 Out patients: 
 10%- vatha pitha thegi, 65%-vatha kabha thegi,10 % pitha vatha thegi, 5% 
pitha kabha thegi, 5% kaba vatha thegi,5% kaba pitha thegi. 
Among 20 Inpatients: 
 5%- vatha pitha thegi, 65%-vatha kabha thegi,5 % pitha vatha thegi,15% pitha 
kabha thegi, 5% kaba vatha thegi,5% kaba pitha thegi. 
 So in the current study Swasakasam is common in Vatha kaba thegi. 
GUNAM 
Among the 40 patients 
• 60% of the out patients and 35% of the in patients had Rajogunam 
• 40% of the out patients and 45% of the inpatients had Sathuvagunam 
• 20% of In patients had Thamogunam.  
So, most of the patients affected were subjects with Rajogunam. 
THINAI 
Among the patients who were selected for the trial  
• 90% of the out patients and 90% of the in patients were from Marutha nilam.  
• 10% of Out patients and 10% of in patients were from Neithal nilam. 
So, most of the cases were determined in Marutha nilam. 
PARUVAKAALAM 
In general, Swasa Kaasam occurs in all the seasons. But in the present study, 
it was found to be  
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• More during Munpani kalam (40% out patients and 40% of in patients). 
• 10% of out patient and 10% of in patients during Pinpani kaalam 
• 5% of out patients 5% of in patients during illavenil kaalam 
• 20% of out patients 10% of in patients during muthuvenil kaalam 
• 20% of out patients 15% of in patients during Koothir kaalam 
• 5% of outpatients and 20 % of In patients during Kar Kaalam. 
So, prevalence of disease is common during Munpani kaalam. 
GNANENDRIUM 
 In 80% of the outpatients and 65% of the inpatients Mookku was affected. 
 15% of the outpatients and 40% of the inpatients Sevi was affected.  
 15% of the out patients and 20% of the in patients Kan was affected.  
KANMENDRIUM 
• In 15% of the outpatients and 35% of the inpatients  eruvai was affected. 
• In 10% of the outpatients and 40% of the in patients  Kai was affected.  
• In 50% of the in patients  Kaal was affected. 
CONDITIONS OF MUKKUTRAM 
A. DISTURBANCE OF VATHAM 
In OP cases, derangement in vayus were noted as follows 
Piranan 100%, Abanan 35%, Viyanan 10%, Udhanan 100%,  Samanan 100%, 
Koorman 20%,  Kirukaran 85% and  Dhevathathan 100%. 
In IP cases,derangement in vayus were noted as follows  
Piranan 100%, Abanan 05%, Udhanan 100%, Samanan 100%, Koorman 25%, 
Kirukaran 50% and 100% Dhevathathan.  
• Affected Pranan can produce shortness of breath. 
• Affected Abanan can produce constipation. 
• Affected Viyanan can produce malaise, fatigue, neuralgic pain etc. 
• Affected Uthanan can producenausea and vomiting. 
• Affected Samanan can produce head ache, giddiness and all system affected. 
• Affected Naagan can produce loss of appetite and taste disturbance. 
• Affected Koorman can produce altered sensorium, horipliation and bluring of 
vision. 
• Affected Kirukaran can produce body pain and tiredness. 
• Affected Dhevathathan can produce malaise, fatigue, sleeplessness. 
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B. DERANGEMENT OF PITHAM 
In OP cases,  derangement in pitham  noted was Analapitham 75% & In IP 
cases were Analapitham 60% and Ranjagam 15% .  
• Affected Anal piththam can produce loss of appetite.  
• Affected Ranjaga piththam can produce pallor of nailbed, skin and 
conjunctiva, reduced haemoglobin 
• Affected Prasaga piththam can produce pallor of skin.  
• Affected Alosaga piththam can produce blurring of vision. 
• Affected Sathaga piththam can produce mental confusion and difficulty in 
concentration. 
C. DERANGEMENT OF KABHAM 
In OP and IP cases  derangement  were noted in Avalambagam 100%, 
Kilethagam 35%. In 20% Op cases & 10% IP cases, pothagam was affected.  
• Affected Avalambagam can produced derangement of other kabham. 
• Affected Kilethagam can produced loss of appetite. 
• Affected Pothagam can produced cough and respiratory discomfort. 
• Affected Santhigam can produced difficulty in join movements. 
UDAL KATTUKKAL 
Saaram was affected in 75% of out patients and 75% of in patients. 
Senneer was affected in 25% of outpatients and 15% of inpatients. 
Enbu was affected in 10% of outpatients and 20% of In patients.  
• Affected Saaram can produces weakness of the body and mind, fear and 
anxiety. 
• Affected Senneer can produces  derangement in piththam. 
• Affected Enbu can produces difficulty in range of movement, joint pain. 
ENVAGAI THAERVUGAL 
Naa  was affected in 20% of the Out Patients. 
Niram  was affected in 10% of the Out Patients and 10% of  the In Patients . 
Vizhi was affected in 25% of the Out Patients and 15% of  the In Patients. 
• Affected Naa and niram can produced paleness. 
• Affected Vizhi can produced blurring of vision, redness of eyes. 
• Affected Malam can produced constipation. 
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NAADI 
In OP, 65% of the cases had Vadha Kabha Naadi, 10% cases had Vatha Pitha 
Naadi, 10% cases had Pitha Vatha Naadi, 5% cases had Pitha  Kabha Naadi,5% cases 
had Kabha  Vatha Naadi and  5% cases had  Kabha Pitha  Naadi. 
In IP, 65% of the cases had Vadha Kabha Naadi, 5% cases had Vatha Pitha 
Naadi,    5% cases had Pitha Vatha Naadi, 15% cases had Pitha  Kabha Naadi,5% 
cases had Kabha  Vatha Naadi and 5% cases had  Kabha Pitha  Naadi. 
NEIKURI 
80% of outpatients and 85% of in patients were found to hadKabha neer 
10% of outpatients and 10% of inpatients hadVathaneer. 
10% of out patient and 5% of in patients were found Pitha neer. 
So, most of the cases were found Kabha neer. 
LAB INVESTIGATION   
 Routine investigation of blood and urine were done during the time of 
admission, between the treatment and at the time of discharge for all cases. 
LABORATORY INVESTIGATIONS  
Routine investigations of blood and urine were done before and after treatment 
in every case. Before treatment blood investigations of the patientsshowed  that  the 
Eosinophils count was in increased level range from 6- 15% cells and after treatment 
it was decreased to the range of  5 – 6%.   
 Before treatment blood investigations of the patients showed  that  the ESR 
was in increased level range from 20 -50 mm/hr and after treatment it was decreased 
to the range of 10 -20 mm/hr 
Blood Urea, Creatinine, Bilirubin and serum cholesterol were found to be in 
normal range before and after treatment.  
Sputum examination (AFB) was found to be negative for all thecases  of both 
Out and  In patients. 
SPECIAL INVESTIGATION: 
 Among the 18 Female (45%)patients, before treatment the peak flow meter 
reading were ranged from 100 lit/min to 180 lit/min and after treatment it got 
improvement and attained  the range  190lit/min to 360 lit/min. 
Among the 22 Male (55%)patients, before treatment the peak flow meter 
reading were ranged from 170 lit/min to 230 lit/min and after treatment it got 
improvement and attained  the range  250 lit/min to 470 lit/min. 
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PRIMARY OUTCOME 
As per objective parameters (PEFR ) 
 Among 20 cases of Out patients, 65% of cases had good improvement, 25% of 
cases had moderate improvement and 10% of cases had mild improvement. 
 Among 20 cases of In patients, 70% of cases had clinically good 
improvement, 20% of cases had clinically moderate improvement and 10% of cases 
had clinically mild improvement. 
SECONDARY OUTCOME  
As per subjective parameters (Clinical symptoms) 
 Among 20 cases of out patients, 90% of cases were relieved from difficulty in 
breathing,  90% of cases were relieved from dry cough, 85% of cases were relieved 
from wheezing, 80% of cases were relieved from tightness of chest, 100% of cases 
were relieved from sneezing and 90% of cases  were relieved from Sleep disturbance. 
Among 20 cases of In patients, 85% of cases were relieved from difficulty in 
breathing, 85% of cases were relieved from dry cough, 80% of cases relieved from 
wheezing, 75% of cases were relieved from tightness of chest, 95% of cases relieved 
from sneezing and 85% of cases were relieved from Sleep disturbance. 
STATISTICAL ANALYSIS 
Paired ‘t’ test was used to test the significance of treatment using before and 
after treatment data on PEFR, Gradation of asthma, Clinical Manifestations, 
Eosinophil and ESR.  
The level of significance probability 0.05 was used to test the treatment 
difference and the values are statistically significant. 
STATISTICAL ANALYSIS OF  PEAK EXPIRATORY FLOW RATE  
 The mean value ofPEFRbefore treatment is 192.250 and after treatment is 
333.250 and  t value is -13.063 which is statistically significant (p<0.01). It is 
classical evidence that  clinical trial drug  has  high  potential in Swasakasam. 
STASTITICAL ANALYSIS OF EOSINOPHILCOUNT : 
 The mean value of Eosinophil count  before treatment is 7.775 and after 
treatment is 5.250   and t value is 10.075 which is statistically significant (p<0.01) 
STATISTICAL  ANALYSIS  OF  ERYTHROCYTE SEDIMENTATION RATE  
(mm / 1 hr) 
The mean value of ESR (mm/ 1 hr)before treatment is 38.950 and after 
treatment  is 23.925 and t  value is 8.704 which is statistically significant (p<0.01). 
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STATISTICAL ANALYSIS  OF GRADING OF ASTHMA  
Grading of Asthma before treatment is 1.85 and after treatment is 0.60 and t 
value is 11.180 which is statistically significant (p<0.01). 
STATISTICAL ANALYSIS OF CLINICAL MANIFESTATIONS 
The mean value of clinical symptomsbefore treatment is 3.55 and after 
treatment is 0.55  and t value is 1.03 which is statistically significant (p<0.01). 
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VI. SUMMARY 
 Swasa kasam (Bronchial Asthma) now becomes a very common disease in the 
society due to increasing the air pollution and climate changes. It is common in both 
sex. Jaathipalathi Chooranam 30mg/kg/Bw with honey for 30 days was 
administered to subjects for the management of   swasa kasam in this clinical study. 
 The etiology, pathology, pathophysiology, classification, clinical features, 
complications, prognosis, diagnosis, treatment and prevention of the disease were 
collected from various literatures in Siddha and modern system of medicine. 
 Pharmacological & Toxicological studies were carried out in the 
pharmacological laboratory of K.M.Collage of Pharmacy, Madurai. 
 Biochemical analysis was performed in the Biochemistry lab of GSMC, 
Palayamkottai. 
 Based on the inclusion and exclusion criterias  totally 40 cases were selected. 
Out of this, 20 cases were treated in OPD and 20 cases in IPD. 
 The trial medicine showed the presence of calcium, starch, ferrous iron, tannic 
acid, unsaturated compounds, reducing sugar and amino acids in bio-chemical 
analysis. 
 The trial medicine showed the presence of Alkaloids, Carbohydrates and 
glycosides, Phytosterols, Flavanoids,  Tannins, proteins,Lignin ,Fixed oil and 
fats in phytochemical analysis. 
 In pharmacological analysis, the trial medicine has shown significant anti 
histaminic, anti-anaphylactic, bronchodilator  and anti- inflammatory activity 
 Trial drug showed  the anti microbial acivity against both Gram 
positive(Staphylococcus aureus , Streptococcus mutans, Bacillus subtilis)   
and Gram negative bacteria  
( Klebsiella pneumonia, and E.coli) 
 Toxicity study reveals that the trial drug is safe even in higher dosage of 
2gm/kg in albino rats.  
 During the study period,  no adverse reactions were reported. 
 The trial medicine  Jaathipalathi chooranam has the tastes of Kaippu, 
Kaarppu, Thuvarppu. Jaathipalathi chooranam  has got the  Kaarppu  pirivu. 
The Karppu suvai which has potent to act as antagonist the excessive  Kabam . 
 All these drugs has got the thanmai veppam (presence ofkarppu taste). The 
thanmai veppam has go to action to decrease the vitiated  Kabam . 
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 After ingestion while the trial medicine reaches the gastric juice ,it will change 
into vibagam karppu. At this stage also, the medicine will acts as anti kaba 
medicine due to the vibagam karppu. 
 The trial drug was found to play the major role in the correction of 
• the deranged vayus such as pranan, abanan, udhanan, kirugaran, 
devathathan 
• pitham such as anal pitham and the vitiated kabam. 
 Blood and urine Investigations were carried out before and after treatment and 
data was recorded in the proforma. 
 Among 20 Out patients cases,  65%  had clinically good improvement, 25% 
had clinically moderate improvement and 10%  had clinically poor response. 
 Among 20In patients cases,  70% had clinically good improvement, 20%  had 
clinically moderate improvement and 10%  had clinically poor response. 
 As per objective parameters (PEFR)inOut patients cases, 65% had good 
improvement, 25% had moderate improvement and 10% had poor.Among In 
patients  cases,  70%  had good improvement, 20%  had moderate 
improvement and 10%  had poor response. 
 Paired ‘t’ test was used to test the significance ( before and after treatment 
data) on PEFR gradation of asthma , clinical Manifestations, eosinophil and 
ESR. The values were  found to be statistically significant (p<0.01) 
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VII.CONCLUSION 
 The pharmacological analysis of  Jaathipalathi chooranam  showed the 
following findings. 
• Mast cell stabilizing potential of JPC resulted in significant 
degranulation of mesenteric mast cells,JPC prolonged the latent period of 
preconvulsion dyspnea as compared to control ,following exposure to 
histamine aerosols. 
• The anti anaphylactic effect of JPC was demonstrated and it may be due 
to inhibition of phenomenon of sensitization or non-availability of 
antibodies on the mast cell surface. 
• JPC reduced  the Carrageenan induced edema considerably on oral 
administration of 100&200 mg/kg and decreased the pleural exudates,this 
revealed the anti inflammatory action of JPC. 
 Trial drug showed the anti microbial acivity against both Gram 
positive(Staphylococcus aureus , Streptococcus mutans, Bacillus subtilis)  and 
Gram negative bacteria ( Klebsiella pneumonia, and E.coli) 
 The toxicity study of trial medicine was done and found to be non toxic and 
safe to use for longer duration.No evidence of  Chronic toxicity was  seen on 
the administration  of JPC at higher concentration. 
 Statistical analysis of PEFR,Eosinophil, ESR, Gradation of asthma and clinical 
manifestation was statistically significant. 
 The clinical efficacy of JPC in the treatment of Swasakasam were noted in the 
following manner:- 
• 67.5% got good improvement 
• 22.5% showed the moderate result 
• 10%showed  poor results. 
 After the trial drug administration, the clinical symptoms like difficulty in 
breathing,tightness of chest,dry cough and sneezing were reduced. 
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    ANNEXURE - I 
PREPARATION OF TRIAL MEDICINE 
JAATHIPALATHI CHOORANAM 
mf;fpdp ke;jk;>; ; ;; ; ;; ; ;  Rthrfhrk;;;;> twl;rp;> Fd;kk;> cs;nsupT; ; ; ; ;; ; ; ; ;; ; ; ; ; > <uy;FiynaupT> ;;;
gPypif> Nrj;Jk gpj;j tpfhuq;fSf;Fr; #uzk;P ; ; ; ; ; ;P ; ; ; ; ; ;P ; ; ; ; ; ; 
rhjpf;fh Ak;nts;sp Nyhj;jpuK 
kpytq;fe; jf;Nfhyj;Njh 
NlhJnrt; tpakpsFq; fw;G+uQ; 
ru;(f;) fiuap Dldhfg;G+ 
thjpae;j khnahd;gJ tifkUe; 
JQ;rupaha iuj;Jj;Njdpy; 
Ngjkpyh nea;apuz;b nyhd;wjpNy 
fye;JFog; gpAq;nfhs;thNa (228) 
 
nfhd;syf; fpdpapd;ke;jq; fhrRth 
rk;twl;rp Fd;kj;NjhNl 
cs;nsuptp DldPuy; FiynaupTk; 
gPypifap DlNdNrj;Jk 
Ks;stpfh uq;fs;Nrj;Jk tpfhuq;fs; 
fz;lj;jp Yw;w Neha;fs; 
js;spA+h;tpl; Lf;fjph; fz;lgdp 
nadNthLQ; rfj;jpw;whNd (229) 
 
rhjpf;fha;> fpuhk;G> nrt;tpak;> fw;G+uk;> rpW ehfg;G+> 
nts;spNyhj;jpug;gl;il> jf;Nfhyk;> kpsF> ru;f;fiu- ,e;j xd;gJ tifr; 
ruf;FfisAk; rkndil vLj;Jr; #uzpj;J> t];jpufhak; nra;J nfhz;L> 
NjdpNyh my;yJ nea;apNyh Fioj;Jr; rhg;gplTk;. ,jdhy; mf;fpdp ke;jk;> 
fhrRthrk;> twl;rp> Fd;kk;> cs;nsupT (Njfj;jpd; mdj;jy;)><uy;Fiy vupT> 
gPypff; fl;b> fgj;jpdhYz;lhd tpfhuq;fs;> fOj;J tpahjpfs; Kjypad jPUk;. 
INGREDIENTS 
01. Jaathikkai   -   rhjpf;fha; 
02. Kirambu   -  fpuhk;G 
03. Cheviyam   -  nrt;tpak; 
04. Sirunagapoo   -  rpWehfg;G+ 
05. Vellilothrappattai   -  nts;spNyhj;jpug;gl;il 
06. Thakkolam   -   jf;Nfhyk; 
07. Milagu   -  kpsF 
08. Karpporam   -  fw;G+uk; 
09. Nattu sarkarai  -  ehl;L ru;f;fiu 
   PURIFICATION OF RAW DRUGS. 
1. Jathikkai: 
 Peeled  off the outer layer and cut into small pieces allowed it to dried on the 
shade light. 
2. Kirambu: 
 Removed the adulterant & the flower bud and made it dried on the shade light. 
3. Cheviyam: 
 Peeled off the outer layer and cut into small pieces allowed it to dried on the 
shade light. 
4. Karpporam: 
 Soaked in Senkazhuneer flower juice for 1 nazhigai (24mins) then allowed  it 
to dried on the sun light. 
5. Sirunagappu: 
 Removed  the adulterant and made it dried on the shade light. 
6. Vellilothirapattai: 
 Removed the adulterant and made it dried on the shade light. 
7. Thakkolam: 
 Removed the adulterant and made it dried on the shade light. 
8. Milagu: 
 Soaked in butter milk for 3 days then fried in  the clay plate. 
  METHOD OF PREPARATION AND DISPENSING 
 Each purified raw drugs  was taken in equal quantity and powdered separately. 
Then the powders of all the drugs were mixed homogenously and taken as a 
compound powder. 
 The chooranam was stored in air tight clean container and labelled as JPC  and  
it was issued to patients in packets.  
 Each packet contains 6g of the compound powder. 
 For OP patients, 2 packets were given twice a day. 
 In case of  IP patients, the medicine packet was directly issued by me every 
time. 
 
 
01.JAATHIKKAI 
 Botanical  name :  Myristica  fragrans  Houtt. 
 Family : Myristicaceae 
 Part used : seed 
 Other name : Gzg<gib< 
 Sju!;!Kui<h<H?!gii<h<H!
 ke<jl!;!ouh<hl<!
 hqiqU!;!gii<h<H!
 Phytochemicals : neolignins,licarin A, Licarin B,Odoratisol A, B-Sitosterol 
 Action : Stimulant, Carminative, Narcotic,Aromatic, Aprodisiac,Tonic 
 G{l<;!
“kiK!fm<ml<!Ohkq!sVuisq!bR<sqv!Ofib<!
YKSui!sr<gisl<!dm<gqv{q!–OuOki!
czg<gib<!uVl<hq{qOhil<!Wx<xlbz<!hqk<kr<!
Gzg<gib<!bVf<Kuv<g<Gg<!%X/”!
!
-keiz<! uqf<K! GjxU?! ohVr<gpqs<sz<?! uiBuqeiz<! d{<miGl<! Ofib<?!
kjzuzq?! -jvh<H! )Suisl<*?! -Vlz<! )gisl<*?! fim<hm<m! gpqs<sz<?! ouh<hk<jk!
Le<eqm<M!uVl<!hq{qgt<!-jugt<!OhiGl</!Neiz<?!lbg<gk<jkk<!kVl</!OlZl<!
-K!ubqx<Xuzq?!ubqx<Xh<ohiVlz<?!ng<gqeq!lf<kl<!-jugjtBl<!Ohig<Gl</!
02. gqvil<H!<<< - Kirambu 
 Botanical Name : Syzygiumaromaticum.Linn 
 Family   : Myrtaceae 
 Part used  : Flowerbud 
 Other name   : -zur<gl<?!nR<Sgl<?!dx<gml<?!Osigl<?!!
kqvtq?!uvir<gl<!
 Sju   :  givl<!
 ke<jl!  :  ouh<hl<!
 hqvqU!   :  gii<h<H!
 Phytochemicals :  Alkaloids, Sapanin, Flavonoids , Tanin ,  
Terpenoids   
 Action  : Antispasmodic ,Carminative ,Stomachic 
  Antibacterial ,Stimulant  
 
 G{l<<<< : 
  “hqk<k!lbg<gl<!OhkqobiM!uif<kqBl<Ohil<!
Sk<kuqvk<!kg<gMh<Hf<!Okie<XOli!–!olk<k!
-zur<gr<!ogi{<muVg<!Okie<XOli!–!olk<k!
lzlr<Og!gm<Mole!uip<f<K”!
 
“Sg<gqzfm<!mr<gI{!$Iuqbr<g!ziR<sef<kim<!
sqg<gzuqmis<!sIui!sqbh<hq{qB!–!lg<gqg<Gm<!
mr<gh<!H,OuiM!kvqhmVf<!Okie<xqzqz<!
ur<gh<H,!OuiMjvk<K!ui”!
! -K?! lbg<gl<?! Ohkq?! uif<kq?! GVkqg<gpqs<sz<?! fim<hm<m! gpqs<sz<?!
wVuib<g<gMh<H?! osuqOfib<?! squf<kls<sl<?! gXk<k! ls<sl<?! g{<{qz<! H,?! hjmgt<!
Ngqbux<jx!fQg<Gl</!!!
4/!osu<uqbl<< << << <- Cheveyam 
 Botanical Name :  Piper nigram.Linn 
 Family   :  Piperaceae 
 Part used  :  Root 
 Other name    : g{<Cjv?!suqjg?!suqbl<!
 Phytochemicals :  Piperin ,Piperidine,Chavicin 
 Action   :  Expectorant , Bronchodilator, Antidote ,  
Carminative 
 G{l<<<< : 
 “$jz!nVgqse<eq!okiz<zqVlz<!=jthqk<kl<!
! Oljzg<!Gvx<gl<lz<!our<gtOfib<!.!&zSvl<!
! gu<uqbr<gk<!OkX!gtki!uvuqmLR<!
! osu<uq{r<!ogit<tuqMf<!OkI”!
$jz?!Sjubqe<jl?!Lh<hq{q?!fim<hm<m!Svl<?!fQck<k!-Vlz<?=jt?!ouxq?!
Gvx<gl<lz<?! oki{<jm?! Ofib<?Svl<?! wZl<jhh<hx<xq! WXgqe<x! fR<S! Ngqbju!
Ohil</!
 
04.sqXfigh<H,< <<  - Sirunakapoo 
 Botanical Name :  Mesua naggesarium .Linn 
 Family   :  Clusiaceace 
 Part used  :  Flower 
 Other name  : figl<?!figHm<hl<?!figOgsvl<?!Ogsvl<?!!
sil<Ohbhl<!
 Sju! ! ! ;! sqXjgh<H!
 ke<jl! ! ;!! km<hl<!
 hqvqU! ! ! ;!! giIh<H!
 Phytochemicals : Flavanoids , Triterpennoids ,Coumarins 
 Action   :  Astringent ,Carminative 
 G{l<!<<< : 
  “sqXfigh<!H,uqeK!osb<jgkje!osiz<Ouil<!
GxqbiGl<!Olgk<jkg<!ogiz<Zl<!.!ofxquqm<Mk<!
kQkib<s<!osz<uiBjuBf<!kQi<g<GlqV!lx<Ohig<Gl<!
Ogikib<!-jkbxqf<K!ogit<”!
! ! out<jt?!-Vlz<?!gpqs<sz<!-jugjth<!Ohig<Gl</!
5.VELLILOTHRAPPATTAI 
 Botanical Name : Symplocos racemosa Roxb. 
 Family   : Symplocaceae 
 Part used  : stem bark  
 OuX!ohbi<! ! ;! gis!sr<jg?!gib!uqjz?!kqz<zgl<?!!
ozik<Kgk<!Okiz<!?!out<tzk<kqh<!hm<jm!
 Sju! ! ! ;! Kui<h<H!
 ke<jl! ! ;! km<hl<!
 hqvqU! ! ! ;! -eqh<H!
 Phytochemicals : Benzolsalireposide, Symploracemoside,   
Alkaloids, Loutrine, Colloturine, ash having 
carbonate of soda.  
 Actions   : Mild astringent, Refrigerant, Antidote. 
 !G{l<! ! ;! !
“kiuvfR<!ose<HVg<gq!kipi!lOgikv!Ofib<!
%uouim<mik!Gvx<sikl<.!H,Uzgqz<!
ouz<zuiq!kib!uqbr<gLki!uik<kLl<Ohil<!
fz<z!out<tq!Ozik<kqvk<kqeiz<”!
-keiz<! gpqs<sz<?! sQkg<gpqs<sz<?! uQg<gl<?! g{<Ofib<?Svl<?! H{<gt<?=vjzh<!
hx<xqb!hq{qgt<?!ohVl<hiM?!$kgk<!kjm!-ju!fQr<Gl</!
!
!6.THAKKOLAM 
 Botanical Name :  Illium verum Hook. 
 Family   :  Illicium 
 Part used  : fruit  
 OuX!ohbi<! ! ;! ne<eisqh<!H,!
 Sju! ! ! ;!! -eqh<H?!uqXuqXh<H!
 ke<jl! ! ;!! ouh<hl<!
 hqvqU! ! ! ;! gii<h<H!
 Phytochemicals  : Tannins,Linoleic Acid , Foeniculin,  
Palmittic Acid. 
 Actions  : Spasmodic, Stimulant, Tonic. 
 G{l<<<< 
“hi{<MSvl<!OhiGl<!hgvqx<!hzR<OsVlm 
kQ{<MLh!bisqbLf<!kQVr<gi{<!.!fQ{<mokiV!
kiKuqv<k<kq!biGf<!ktv<f<klz!Lr<gm<Ml<!
OgikgZf<!kg<Ogizr<!ogit<”!
-keiz<! hi{<M?! Svl<?! uijbh<hx<xqb! utq! ofib<gt<! OhiGl</! dmz<!
ue<jl!ohXl</!N{<jl!ohXl</!
 
7. lqtG!. Milagu 
 Botanical Name : Piper nigrum.Linn 
 Family   : Piperaceae 
 Part used  : Fruit  
 Other name  : gzqje?!gxq?gibl<?!Ogitgl<?!kqvr<gz<?!!
sVlhf<kl<?! ut<tqsl<?! lisl<?! GXlqtG?!
ljzbitq!
 Sju! ! ! ;! jgh<H!
 ke<jl! ! ;! ouh<hl<!
 hqvqU! ! ! ;! giIh<H!
 Phytochemicals : Piperin, Piperlonguminine  
 Action   : Carminative, Rubefacient ,Stimulant 
Resolvent , Antivatha ,Antidode 
 
  G{l<;!! ! !
“sQkSvl<!hi{<M!sqOzk<Klr<!gqvi{qGe<ll<!
uikl<!nVsqhqk<kl<!li&zl<!.!YKse<eq!
! bislh^<!livl<!nme<Olgl<!gislqju!
! fisr<!gxqlqtgqeiz<”!
! !
“Ogi[gqe<x!hg<guzq!Gb<bUOvi!gl<uik!
! Osi{qkr<g!Pk<kqx<Gt<!Okie<XOfib<!.!gi{vqb!
! giKOfib<!likIGe<lr<!gilijz!lf<fole<xQI!
! WKOfib<!gibqVg<gqz<!=r<G”!
! GtqISvl<?! hi{<M?! Ogijp?!gpqs<sz<?!Ge<ll<?!uiB?!Sjubqe<jl?!ouxq?!
&zl<?! se<eqbisl<?! nh^<livl<?! hqvOlgl<?! -Vlz<?! osvqbijl?! hg<guikl<?!
Gb<bOvigl<?Osi{qkuikl<?! ghOfib<?! osuquzq?! -vk<kGe<ll<?! gilijz! -ju!
OhiGl</!
8.KARPOORAM (gx<H,vl<*< << << <  
 Botanical Name  : Cinnamomum camphora Linn 
 Family   : Lauraceae 
 Part used  :  A white crystalline ketone 
 OuX!ohbi<! ! ;! gVh<H,vl<?Smv<g<ogicObie<?!H,vl<?kQhl<! !
 Sju! ! ! ;! uqXuqXh<Hme<!%cb!jgh<H?!giv<h<H!
 ke<jl! ;! ouh<hl<!
 uqhigl<! ! ;! giv<h<H/!
 Phytochemicals  : Cinnamic acid,  Cinnacassiol, Kaempferol,  
Cinnamtannin B-1 
 Actions   : Expectorant, Carminative,Sedative. 
G{l<;<<< !
“gqVlqszOkimr<!gqjtuzqh<H!sf<fq!
ohiVLlf<kl<!nr<gqhm<m!H{<O{i.omvqSvr<gt<!
uif<kqhqk<kR<!sQkLX!uikR<!osuqLg!Ofib<!
gif<kqgVh<!H,volie<xix<!six<X”!
-keiz<!gqVlq?! fQOvx<xl<?!-sqU?! sf<fqhikl<?!uik!nzsl<?!kQs<Sm<m!H{<?!
OgivSvl<?! uif<kq?! hqk<kl<?! ghuikl<?! gijkBl<! Lgk<jkBl<! hx<xqb! hq{qgt<!
Lkzqbe!fQr<Gl</!!
 
 9.Nattu sarkkarai )fim<M!sv<g<gjv*< < << < << < <  
 Botanical Name : Sacharum  officinarum.Linn 
 Family   : Poaceae 
 Part used  : Stem juice 
 Other name  : Hex<H,sl<?!-g<G?!Oub<!
 Sju! ! ! ;! -eqh<H!
 ke<jl! ! ;! sQkl<!
 hqvqU! ! ! ;! -eqh<H!
 Phytochemicals : Phenolic acid,Terpenoids,Flavonoids 
 Action   :  Demulcent, Anti septic, Laxative, Diuretic,  
Nutrient 
 G{l<;<<< !! ! ! !
“nVf<K!lVf<kqx<!gEhie!ligh<!
! ohiVk<Klmz<!uif<kqhqk<kl<!Ohig<Gl<!.!nVf<kVsq!
! fQg<G!lkqghk<jk!fQx<Xlgqp<s<sqB{<!
! mig<G!fXR<sIg<g!jv”!
lVf<kqe<! nEhieliBt<tK?! uif<kq! hqk<kl<?! Sjubqe<jl! -ux<jx!
Ohig<Gl</!ogm<chm<m!ghk<jk!-tg<gq!lgqp<s<sqjbk<!kVl</!
!
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Figure 2.1.1 Myristica  fragrans
Figure 2.1.3  Piper nigrum
Figure 2.1.5  Mesua naggesarium
 
 
 
 Figure 2.1.2Syzygium aromaticum
 - seed Figure 2.1.4 Piper nigrum
   Figure 2.1.6 Symplocos  racemosa
 
-root 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.7 . Illicium  verum
Figure 2.1
Figure 2.1
         
 
 Figure 2.1.8.Cinnamomum  camphora
.9Sacharum officinarum 
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